COMPOSITION OF CATIONIC EMULSION OF OIL IN WATER AND ITS USE

专利摘要:
cationic oil-in-water emulsions the present invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. the emulsion particles comprise an oily core and a cationic lipid. the cationic lipid can interact with the negatively charged molecule, thus anchoring the molecule to the emulsion particles. the cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antidene) to cells and formulating nucleic acid-based vaccines.
公开号:BR112013000391B1
申请号:R112013000391-0
申请日:2011-07-06
公开日:2020-12-15
发明作者:Luis Brito；Andrew Geall；Derek O'Hagan；Manmohan Singh
申请人:Novartis Ag；
IPC主号:

专利说明:

RELATED REQUESTS
This application claims the benefit of U.S. Provisional Application No. 61 / 361,892, filed on July 6, 2010, all teachings of which are hereby incorporated by reference. BACKGROUND OF THE INVENTION
Nucleic acid therapies hold promise for the treatment of diseases ranging from acquired hereditary diseases to conditions such as cancer, infectious disorders (AIDS), heart disease, arthritis and neurodegenerative disorders (for example, Parkinson's and Alzheimer's). Functional genes can not only be distributed to repair a genetic deficiency or induce expression of exogenous gene products, but nucleic acids can also be distributed to inhibit expression of the endogenous gene to provide a therapeutic effect. Inhibition of gene expression can be mediated by, for example, antisense oligonucleotides, double-stranded RNAs (for example, siRNAs, miRNAs), or ribozymes.
A key step in this therapy is the distribution of nucleic acid molecules to cells in vivo. However, the in vivo distribution of nucleic acid molecules, in specific RNA molecules, faces a number of technical obstacles. First, due to cell and serum nucleases, the half-life of RNA injected in vivo is only about 70 seconds (see, for example, Kurreck, Eur. J. Bioch 270: 1628-1644 (2003)). Efforts have been made to increase the stability of the injected RNA through the use of chemical modifications; however, there are several cases in which chemical changes have led to an increase in cytotoxic effects or a loss of function or decreased function. In a specific example, the cells were intolerant to doses of an RNAi duplex in which each phosphate sequence was replaced by phosphorothioate (Harborth, et al., Antisense Nucleic Acid Drugs Rev. 13 (2): 83-105 (2003)) . As such, there is a need to develop delivery systems that can deliver sufficient amounts of nucleic acid molecules (in certain RNA molecules) in vivo to induce a therapeutic response, but which are not toxic to the host.
Nucleic acid-based vaccines are an attractive approach to vaccination. For example, intramuscular (IM) immunization of plasmid DNA encoding the antigen can induce humoral cellular and immune responses and protect against challenge. DNA vaccines offer some advantages over traditional vaccines that use protein antigens, or attenuated pathogens. For example, compared to protein vaccines, DNA vaccines may be more effective in producing a properly folded antigen in its native conformation, and in generating a cellular immune response. DNA vaccines also lack some of the safety problems associated with dead or attenuated pathogens. For example, a dead viral preparation can contain residual live viruses, and an attenuated virus can mutate and revert to a pathogenic phenotype.
Another limitation of nucleic acid-based vaccines is that large doses of nucleic acid are generally necessary to obtain potent immune responses in non-human and human primates. Therefore, delivery systems and adjuvants are needed to increase the potency of vaccines based on nucleic acids. Several methods have been developed for the introduction of nucleic acid molecules into cells, such as transfection with calcium phosphate, transfection with polyprene, protoplast fusion, electroporation, microinjection, and lipofection.
Cationic lipids have been widely formulated as liposomes to distribute genes in cells. However, even a small amount of serum (-10%) can significantly reduce the transfection activity of liposome / DNA complexes, because the serum contains anionic materials. Recently, the cationic lipid emulsion was developed to supply DNA molecules in cells. See, for example, Kim, et al., International Journal of Pharmaceutics, 295, 35-45 (2005).
U.S. Pat. 6,753,015 and 6,855,492 describe a method of delivering nucleic acid molecules to a vertebrate in question using cationic microparticles. The microparticles comprise a polymer, such as a poly (α-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyiortoester, a polyanhydride, and the like, and are formed with cationic surfactants. The nucleic acid molecules are adsorbed on the surfaces of the microparticles.
Kim et al. (Pharmaceutical Research, vol. 18, pages 54-60, 2001), and Chung et al. (Journal of Controlled Release, Volume 71, pages 339-350, 2001) describe several oil-in-water emulsion formulations that are used to enhance the efficiency of in vitro transfection of DNA molecules in vivo.
Ott et al. (Journal of Controlled Release, volume 79, pages 1-5, 2002) describes an approach involving a cationic submicron emulsion as a DNA delivery system / adjuvant. The submicron emulsion approach is based on MF59, a potent squalene in water adjuvant that has been manufactured on a large scale and has been used in a commercially approved product (Fluad®). 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) was used to facilitate the intracellular distribution of plasmid DNA.
Although DNA-based vaccines hold great promise for disease prevention and treatment, general concerns have been raised about their safety. The introduced DNA molecules could potentially integrate into the host's genome or, due to their distribution to various tissues, could lead to the undesirable sustained expression of antigens. In addition, certain DNA viruses have also been used as a vehicle to distribute DNA molecules. Due to their infectious properties, such viruses achieve a high transfection rate. The viruses used are genetically modified so that no functional infectious particles are formed in the transfected cell. Despite these precautions, however, it is not possible to exclude the risk of uncontrolled spread of the introduced gene and viral genes, for example, due to potential recombination events. This also implies the risk of DNA being inserted into an intact gene in the host cell genome, for example, recombination, with the consequence that this gene can be mutated and therefore completely or partially inactivated or can give rise to wrong information. In other words, the synthesis of a gene product that is essential for the cell can be completely suppressed or, alternatively, a modified or incorrect gene product is expressed. In addition, it is generally difficult to increase the production and purification of clinical-grade viral vectors.
A particular risk occurs if the DNA is integrated into a gene that is involved in the regulation of cell growth. In this case, the host cell can be degenerated and lead to the formation of tumors or cancer. In addition, if the DNA introduced into the cell is to be expressed, the corresponding DNA vehicle must contain a strong promoter, such as the viral CMV promoter. The integration of such promoters into the genome of the treated cell can result in undesirable changes in the regulation of gene expression in the cell. Another risk of using DNA as an agent to induce an immune response (for example, as a vaccine) is the induction of anti-pathogenic DNA antibodies from the patient into whom the foreign DNA has been introduced, thereby eliciting an undesirable immune response.
RNA molecules that encode an antigen or a derivative of it can also be used as vaccines. RNA vaccines offer certain advantages compared to DNA vaccines. First, RNA cannot integrate into the host's genome, thus abolishing the risk of malignant diseases. Second, due to the rapid degradation of RNA, expression of the foreign transgene is often short-lived, avoiding uncontrolled long-term expression of the antigen. Third, RNA molecules need only be distributed to the cytoplasm to express the encoded antigen, whereas DNA molecules must penetrate through the nuclear membrane.
However, compared to DNA-based vaccines, relatively less attention has been paid to RNA-based vaccines. RNAs and oligonucleotides are hydrophilic. ! icos, negatively charged molecules that are highly susceptible to degradation by nucleases, when administered as a therapeutic agent or vaccine. In addition, RNAs and oligonucleotides are not actively transported to cells. See, for example, Vajdy, M., et al., Mucosal adjuvants and delivery systems for protein-, DNA- and RNA- based vaccines, Immunol Cell Biol, 2004. 82 (6): p. 617-27.
Ying et al. (Nature Medicine, vol. 5, pages 823-827, 1999) describes a self-replicating RNA vaccine in which the naked RNA encoding β-galactosidase has been delivered and induction of CD8 + cells has been reported.
Montana et al. (Bioconjugate Chem. 2007, 18, pages 302-308) describes the use of solid cationic lipid nanoparticles as RNA transporters for gene transfer. It was shown that solid lipid nanoparticles protected the RNA molecule from degradation, and the expression of reporter protein (fluorescein) was detected after microinjection of the RNA-particle complex into sea urchin eggs.
WO 2010/009277 discloses Nanolipid Peptide Particles (NLPPs) which comprise (a) an antipathic peptide, (b) a lipid, and (c) at least one immunogenic species. In certain embodiments, NLPPs also incorporate a positively charged "capture agent", such as a cationic lipid. The capture agent is used to anchor a negatively charged immunogenic species (for example, a DNA molecule or an RNA molecule). The preparation of NLPP requires antipathic peptides, which are used to solubilize the lipid component and form nanoparticles.
Therefore, there is a need to provide delivery systems for nucleic acid molecules or other negatively charged molecules. Delivery systems are useful for vaccine-based nucleic acid, in particular RNA-based vaccines. SUMMARY OF THE INVENTION
The present invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule to cells. The emulsion particles comprise an oily core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule, thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules (such as an RNA molecule encoding an antigen) to cells and formulating nucleic acid-based vaccines.
In one aspect, the invention provides a composition comprising an RNA molecule complexed with a particle of an oil-in-cation water emulsion, wherein the particle comprises (a) an oily core that is in liquid phase, at 25 ° C, and (b) a cationic lipid. Preferably, the oil emulsion particle in cationic water is not a Nanolipid Peptide Particle (NLPP). Preferably, the oil core is in the liquid phase, at 4 ° C. Optionally, the average diameter of the emulsion particles is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the emulsion is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0; preferably about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (e.g., NaCl). Optionally, the emulsion further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the emulsion isotonic.
In certain embodiments, the oil-in-cationic water emulsion further comprises a surfactant, such as a nonionic surfactant. Examples of nonionic surfactants include, for example, SPAN85 (sorbtian trioleate), Tween 80 (polysorbate 80; polyoxyethylene monooleate), or a combination thereof. The cationic oil-in-water emulsion may comprise from about 0.01% to about 2.5% (v / v) of surfactant. For example, the oil in water cationic emulsion may comprise about 0.08% (v / v) of Tween 80, or alternatively about 0.5% (v / v) of Tween 80 and about 0, 5% (v / v) SPAN85. A polyethylene glycol (PEG), or PEG-lipid, such as PEG2000PE, PEG5000PE, PEGIQOQDMG, PEG2000DMG, PEG3QQ0DMG, or a combination thereof, can also be used.
The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water can comprise from about 0.005% to about 1.25% (v / v) of surfactant. For example, the composition comprising the RNA-emulsion complex can comprise about 0.04% (v / v) of Tween 80 (polysorbate 80; polyoxyethylene monooleate) or, alternatively, about 0.25% (v / v) ) of Tween 80 and about 0.25% (v / v) SPAN85 (sorbitan trioleate).
In certain embodiments, the oil-in-cationic water emulsion further comprises a phospholipid. Exemplary phospholipids include 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE), 1,2-diptanoyl-sn-glycero-3-phosphoethanolamine (DPyPE), or egg phosphatidylcholine (egg PC). For example, the oil in water cationic emulsion may comprise from about 0.1 mg / ml to about 20 mg / ml (preferably, from about 0.1 mg / ml to about 10 mg / ml) DOPE or , alternatively, from about 0.1 mg / ml to about 20 mg / ml (preferably, from about 0.1 mg / ml to about 10 mg / ml) of DPyPE or, alternatively, from about 0, 1 mg / ml to about 20 mg / ml (preferably, about 0.1 mg / ml to about 10 mg / ml) of egg PC.
The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water can comprise from about 0.05 mg / ml to about 10 mg / ml (preferably, between about 0.05 mg / ml to about 5 mg / ml of DOPE) or, alternatively, from about 0.05 mg / ml to about 10 mg / ml (preferably, between about 0.05 mg / ml to about 5 mg / ml) DPyPE, or, alternatively, from about 0.05 mg / ml to about 10 mg / ml of egg PC (preferably, between about 0.05 mg / ml to about 5 mg / ml).
In certain embodiments, the oil-in-cationic water emulsion further comprises a polymer or a surfactant in the aqueous phase of the emulsion. Examples of polymers include poloxamers, such as Pluronic® F127 (ethylene oxide / propylene oxide block copolymer: H (OCH2CH2) x (OCH3CH (CH3)) y (OCH2CH2) zOH). For example, the oil in water cationic emulsion can comprise from about 0.05% to about 20% (w / v) of polymer, or from about 0.1% to about 10% (w / v) polymer, such as 0.5% (w / v) or 1% (w / v) Pluronic® F127. The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water can comprise from about 0.025% to about 10% (v / v) of polymer, or about 0.5 % to about 5% (v / v) polymer, such as 0.25% (w / v), or 0.5% (w / v) Pluronic® F127.
Emulsions can comprise components that can promote particle formation, improve the complexation between negatively charged molecules and cationic particles, facilitate proper decompression / release of negatively charged molecules (such as an RNA molecule), increase the stability of the charged molecule negatively (for example, to prevent degradation of an RNA molecule), or to prevent aggregation of the emulsion particles.
In certain embodiments, the oily core may comprise an oil that is selected from the following: castor oil, coconut oil, corn oil, cottonseed oil, primula oil, fish oil, jojoba oil, oil lard oil, linseed oil, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene,. sunflower, wheat germ oil, mineral oil, or a combination thereof. Preferably, the oil is soybean oil, sunflower oil, olive oil, squalene, or a combination thereof. The oil-in-cationic water emulsion may comprise from about 0.2% to about 20% (v / v) of oil, preferably about 0.08% to about 5% oil, about 0, 08% oil, about 4% to about 5% oil, about 4% oil, about 4.3% oil, or about 5% oil. The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water can comprise from about 0.1% and about 10% (v / v) of oil, preferably from about 2% to about 2.5% (v / v) of oil.
In certain embodiments, the cationic lipid is selected from one of the following: 1,2-dioleoyloxy 3- (trimethylammonium) propane (DOTAP), 3β- [N- (N ', N /' - Dimethylaminoethane) -carbamoyl] Cholesterol (Cholesterol DC), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3-Trimethyl- Ammonium-Propane (DMTAP), dipalmitoyl (C16: o) trimethyl ammonium propane (DPTAP), distearoyl-trimethyl-ammonium propane (DSTAP) , Lipideo E0001-E0118 or E0119-E0180 as described in Table 6 (pages 112-139) of WO 2011/076807 (hereby incorporated by reference), or a combination thereof.
Particularly preferred cationic lipids include DOTAP, Cholesterol DC, and DDA.
In certain embodiments, the cationic lipid is selected from one of the following: 1,2-dioleoyloxy 3- (trimethylammonium) propane (DOTAP), 3β- [N- (N ', N'-Dimethylaminoethane) -carbamoyl] Cholesterol (DC cholesterol), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3-Trimethyl-Ammonium-Propane (DMTAP), dipalmitoyl (C16: o) trimethyl ammonium propane (DPTAP), distearoyl-trimethyl-ammonium propane (DSTAP), Lipid E0001-E0118 or E0119-E0180 as described in Table 6 (pages 112-139) of WO 2011/076807 (incorporated herein by reference), N- [1- (2,3-dioleyloxy) propyl] -N chloride, N, N-trimethylammonium (DOTMA), N, N-dioleoyl-N, N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3 -dimethyl-ammonium-propane (DODAP), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), or a combination thereof. Particularly preferred cationic lipids include DOTAP, Cholesterol DC, DDA, DOTMA, DOEPC, DSTAP, DODAC, DODAP and DLinDMA.
In certain embodiments, the oil-in-cationic water emulsion comprises from about 0.8 mg / ml to about 3 mg / ml, preferably from about 0.8 mg / ml to about 1.6 mg / ml of DOTAP.
The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water may comprise from about 0.4 mg / ml to about 1.5 mg / ml, preferably from about 0.4 mg / ml to about 0.8 mg / ml DOTAP. Optionally, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about β, 0 to about 8.0, and contains no more than than 30 mM inorganic salt (eg NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In certain embodiments, the oil in water cationic emulsion comprises from about 0.62 mg / ml to about 4.92 mg / ml of cholesterol DC.
The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water can comprise from about 0.31 mg / ml to about 2.46 mg / ml of DC cholesterol. Optionally, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0; preferably, about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (e.g., NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In certain embodiments, the oil in water cationic emulsion comprises from about 0.73 mg / ml to about 1.45 mg / ml DDA.
The composition comprising an RNA molecule complexed with a particle of an oil-in-cation water emulsion may comprise from about 0.365 mg / ml to about 0.725 mg / ml DDA. Optionally, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has one. pH from about 6.0 to about 8.0; preferably, about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In certain embodiments, the oil-in-cationic water emulsion comprises from about 0.8 mg / ml to about 3 mg / ml, preferably from about 0.8 mg / ml to about 1.6 mg / ml of DOTMA.
The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water may comprise from about 0.4 mg / ml to about 1.5 mg / ml, preferably from about 0.4 mg / ml to about 0.8 mg / ml DOTMA. Optionally, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0; preferably, about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In certain embodiments, the oil in water cationic emulsion comprises from about 0.8 mg / ml to about 3 mg / ml, preferably from about 0.8 mg / ml to about 1.8 mg / ml of DOEPC.
The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water may comprise from about 0.4 mg / ml to about 1.5 mg / ml, preferably from about 0.4 mg / ml to about 0.9 mg / ml DOEPC. Optionally, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0; preferably, about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in a quantity sufficient to render the composition isotonic.
In certain embodiments, the oil-in-cationic water emulsion comprises from about 0.73 mg / ml to about 1.45 mg / ml DODAC.
The composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water can comprise from about 0.365 mg / ml to about 0.725 mg / ml DODAC. Optionally, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0; preferably, about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In one example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cationic water emulsion, wherein the oil-in-cationic water emulsion comprises (a) about 0.5% v / v ( of oil), and (b) a cationic lipid.
In one example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cationic water emulsion, wherein the composition comprises (a) about 0.25% (v / v) of oil, and (b) a cationic lipid.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, wherein the particle comprises (a) an oily core, (b) a cationic lipid and, (c) a phospholipid. Preferred phosphclipids include, for example, DPyPE, DOPE, and egg PC. Preferably the composition (with a negatively charged emulsion-molecule complex) comprises from about 0.05 µg / ml to about 10 mg / ml (more preferably, between about 0.05 mg / ml to about 5 mg / ml ) of DOPE, or, alternatively, from about 0.05 mg / ml to about 10 mg / ml (more preferably, between about 0.05 mg / ml to about 5 mg / ml) of DPyPE, or, alternatively, from about 0.05 mg / ml to about 10 mg / ml (more preferably, between about 0.05 mg / ml to about 5 mg / ml egg PC).
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, where the particle comprises (a) an oily core and (b) DOTAP, and in which the emulsion of oil in water comprises from about 0.8 mg / ml to about 3.0 mg / ml of DOTAP, preferably from about 0.8 mg / ml to about 1.6 mg / ml of DOTAP. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0, and contains no more than than 30 mM inorganic salt (eg NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, where the particle comprises (a) an oily core and (b) DOTAP, and where the composition comprises between about 0.4 mg / ml to about 1.5 mg / ml DOTAP, such as 0.4 mg / ml, 0.6 mg / ml, 0.7 mg / ml, 0.8 mg / ml , etc. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0; preferably, about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, where the particle comprises (a) an oily core and (b) DC cholesterol, and in which the emulsion of oil in water comprises from about 2.46 mg / ml to about 4.92 mg / ml of cholesterol DC. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0; preferably, about 6.2 to about 6.8, and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, where the particle comprises (a) an oily core and (b) DC cholesterol, and in which the composition comprises from about 1.23 mg / ml to about 2.46 mg / ml of cholesterol DC, such as 1.23 mg / ml. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0, preferably about 6 , 2 and about 6.8; and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, where the particle comprises (a) an oily core and (b) DDA, and in which the emulsion of oil in water comprises from about 0.73 mg / ml to about 1.45 mg / ml DDA. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0, preferably about 6 , 2 and about 6.8; and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, wherein the particle comprises (a) an oily core and (b) DDA, and where the composition comprises from about 0.365 mg / ml to about 0.725 mg / ml DDA, such as 0.725 mg / ml. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0, preferably about 6 , 2 and about 6.8; and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, where the particle comprises (a) an oily core and (b) DOTMA, and where the composition comprises between about 0.4 mg / ml to about 1.5 mg / ml, preferably from about 0.4 mg / ml to about 0.8 mg / ml DOTMA. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0, preferably about 6 , 2 and about 6.8; and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, where the particle comprises (a) an oily core and (b) DOEPC, and where the composition comprises between about 0.4 mg / ml to about 1.5 mg / ml, preferably from about 0.4 mg / ml to about 0.9 mg / ml DOEPC. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0, preferably about 6 , 2 and about 6.8; and contains no more than 30 mM inorganic salt (for example, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in / an amount sufficient to make the composition isotonic.
In another example, the invention provides a composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, wherein the particle comprises (a) an oily core and (b) DODAC, and where the composition comprises from about 0.365 mg / ml to about 0.725 mg / ml of DODAC. In some embodiments, the negatively charged molecule is RNA, the average particle diameter of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. Optionally, the composition is buffered (for example, with a citrate buffer, succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0, preferably about 6 , 2 and about 6.8; and concern no more than 30 mM inorganic salt (eg, NaCl). Optionally, the composition further comprises a non-ionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the composition isotonic.
Examples of negatively charged molecules include antigens containing negatively charged peptides, nucleic acid molecules (e.g., RNA or DNA), which encode one or more peptide-containing antigens, negatively charged small molecules and negatively charged immunological adjuvants. Negatively charged immunological adjuvants include, for example, immunostimulating oligonucleotides (eg CpG oligonucleotides), single-stranded RNA, small molecule immune enhancers (SMIPs), etc. Small negatively charged molecules include, for example, phosphonate, fluorophosphonate, etc.
In certain embodiments, the negatively charged molecule is a nucleic acid molecule, such as an RNA molecule, which encodes an antigen. In certain embodiments, the RNA molecule is a self-replicating RNA molecule, such as an alphavirus-derived RNA replicon.
In another aspect, the invention provides oil emulsion in immunogenic cationic water comprising emulsion particles that contain an oily core (preferably, which is in liquid phase, at 25 ° C) and a cationic lipid and a nucleic acid molecule that is complexed with the particles of the emulsion, and where the average diameter of the particles of the emulsion is about 80 nm to about 180 nm and the N / P of the emulsion is at least 4: 1. In certain embodiments, the nucleic acid molecule is an RNA, such as RNA author rep .1 lean Le. Preferably, the oil emulsion in immunogenic cationic water is buffered (for example, with a citrate buffer, a succinate buffer, acetate buffer, etc.) and has a pH of about 6.0 to about 8.0 , Preferably, about 6.2 and about 6.8; and contains no more than 30 mM inorganic salt (for example, NaCl). Preferably, the oil emulsion in immunogenic cationic water additionally comprises a nonionic toning agent, such as a sugar, a sugar alcohol or a combination thereof, in an amount sufficient to make the emulsion isotonic.
In another aspect, the invention provides a method of preparing a composition that comprises a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, which comprises: (A) preparing an oil-in-cation water emulsion in which the emulsion comprises: (1) from about 0.2% to about 20% (v / v) of oil, (2) from about 0.01 to about 2.5% (v / v) of surfactant , and (3) a cationic lipid that is selected from the group consisting of: (i) about 0.8 mg / ml to about 1.6 mg / ml DOTAP, (ii) about 2 , 46 mg / ml to about 4.92 mg / ml of cholesterol DC, and (iii) from about 0.73 mg / ml to about 1.45 mg / ml of DDA, and (B) add to negatively charged molecule for the cationic oil-in-water emulsion so that the negatively charged molecule complexes with the emulsion particle.
In another aspect, the invention provides a method of preparing a composition comprising a negatively charged molecule 30 complexed with a particle of an oil-in-cation water emulsion, comprising: (A) preparing an oil-in-cation water emulsion in which the emulsion comprises: (1) from about 0.2% to about 20% (v / v) of oil (2), from about 0.01% to about 2.5% (v / v) of surfactant, and (3) a cationic lipid that is selected from the group consisting of: (i) about 0.8 mg / ml to about 1.6 mg / ml DOTAP, (ii) about 2 , 46 mg / ml to about 4.92 mg / ml of cholesterol DC, (iii) about 0.73 mg / ml to about 1.45 mg / ml DDA, (iv) about 0, 8 mg / ml to about 1.6 mg / ml of DOTMA, (v) from about 0.8 mg / ml to about 1.8 mg / ml of DOEPC, and (vi) from about 0.73 mg / ml to about 1.45 mg / ml DODAC, and (B) adding the negatively charged molecule to the oil-in-cation water emulsion so that the negatively charged molecule complex c with the particle of the emulsion.
In certain embodiments, the oil-in-cationic water emulsion is prepared by the process comprising: (1) combining the oil and the cationic lipid to form the oil phase of the emulsion; (2) supplying the aqueous phase (i.e., the continuous phase) of the emulsion; and (3) dispersing the oil phase in the aqueous phase by homogenization. The cationic lipid can be dissolved directly in the oil. Alternatively, the cationic lipid can be dissolved in any suitable solvent, such as chloroform (CHC13) or dichloromethane (DCM). Isopropyl alcohol can also be used. The solvent can be evaporated before the oil phase is added to the aqueous phase, or after the oil phase is added to the aqueous phase, but before homogenization. Alternatively, in cases where lipid solubility can be a problem, a primary emulsion can be made with the solvent (for example, DCM), still in the oil phase. In this case, the solvent would be evaporated directly from the emulsion, before secondary homogenization.
Other optional steps to promote particle formation, to improve the complexation between negatively charged molecules and cationic particles, to increase the stability of the negatively charged molecule (for example, to prevent the degradation of an RNA molecule), to facilitate the appropriate decompression / release of negatively charged molecules (such as an RNA molecule), or to prevent aggregation of the emulsion particles can be included. For example, a polymer (for example, Pluronic® F127) or a surfactant can be added to the aqueous phase of the emulsion. In an exemplary embodiment, Pluronic® F127 is added to the RNA molecule prior to complexation with the emulsion particles. The addition of Pluronic® F127 can increase the stability of the RNA molecule and further reduce RNA degradation. Poloxamer polymers can also promote the release of the RNA molecule and prevent aggregation of the emulsion particles. Finally, poloxamer polymers also have an immunomodulatory effect. See, for example, Westerink et al. Vaccine ,. Dec. 2001 12; 20 (5-6): 711-23.
Preferably, the RNA molecule of the cationic particle-RNA complex is more resistant to RNase degradation compared to an uncomplexed RNA molecule.
In another aspect, the invention provides a pharmaceutical composition comprising a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, as described herein, and may further comprise one or more pharmaceutically acceptable carriers, diluents, or excipients. In preferred embodiments, the pharmaceutical composition is a vaccine.
In another aspect, the invention provides a method for generating an immune response in a subject, comprising administering to a subject in need thereof a composition as described herein.
The invention also relates to a pharmaceutical composition as described herein for use in therapy, and the use of a pharmaceutical composition as described herein for the manufacture of a medicament to enhance or generate an immune response. BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the stability of the RNA of the mouse thymus in the presence of RNase after the RNA molecule has been complexed with cationic nanoemulsion particles (CNE). All samples were incubated with RNase for 30 minutes. RNase was inactivated with proteinase K. The samples that were formulated with CNEs were decomplexed and analyzed for RNA integrity by denaturation using gel electrophoresis. The unmarked lane contains molecular weight markers. Lanes 1 and 2: RNA from the mouse thymus before (1) and after (2) digestion with RNase; lanes 3 and 4: RNA from mouse thymus complexed with CNE01 with a 10: 1 N / P ratio before (3) and after (4) RNase digestion; lanes 5 and 6: RNA from the mouse thymus complexed with CNE01 with an N / P ratio of 4: 1 before (5) and after (6) of RNase digestion; lanes 7 and 8: mouse thymus RNA complexed with a CNE17 at a 10: 1 N / P ratio, before (7) and after (8) of RNase digestion; lane 9: mouse thymus RNA complexed with CNE17 at a N / P ratio of 4: 1, before (9) digestion with RNase.
Figure 2 shows the stability of the mouse thymus RNA in the presence of RNase after the RNA molecule is complexed with CNE particles. All samples were incubated with RNase for 30 minutes. RNase was inactivated with proteinase K. The samples that were formulated with CNEs were decomplexed and analyzed for RNA integrity by denaturation using gel electrophoresis. The unmarked lane contains molecular weight markers. Lane 10: RNA from mouse thymus complexed with CNE17 with an N / P ratio of 4: 1 after (10) digestion with RNase; lanes 11 and 12: RNA from the mouse thymus before (11) and after (12) digestion with RNase; lanes 13 and 14: mouse thymus RNA complexed with CNE 12 with an N / P ratio of 10: 1 before (13) and after (14) of RNase digestion; lanes 15 and 16: mouse thymus RNA complexed with CNE12 with an N / P ratio of 4: 1 before (15) and after (16) of RNase digestion; lanes 17 and 18: RNA from mouse thymus complexed with CNE13 with an N / P ratio of 10: 1 before (17) and after (18) of RNase digestion; lanes 19 and 20: RNA from the mouse thymus complexed with CNE13 with an N / P ratio of 4: 1 before (19) and after (20) of RNase digestion.
Figure 3 shows the stability of the mouse thymus RNA in the presence of RNase after the RNA molecule is complexed with CNE particles. All samples were incubated with RNase for 30 minutes. RNase was inactivated with proteinase K. The samples that were formulated with CNEs were decomplexed and analyzed for RNA integrity by denaturation using gel electrophoresis. The unmarked lane contains molecular weight markers. Lanes 1 and 2: RNA from the mouse thymus before (1) and after (2) digestion with RNase; lanes 3 and 4: RNA from the mouse thymus complexed with CNE01 with an N / P ratio of 10: 1, before (3) and after (4) digestion with RNase; lanes 5 and 6: RNA from the mouse thymus complexed with CNE01 with an N / P ratio of 4: 1 before (5) and after (6) of RNase digestion; lanes 7 and 8: mouse thymus RNA complexed with CNE02 at a 10: 1 N / P ratio, before (7) and after (8) of RNase digestion; lane 9: mouse thymus RNA complexed with CNE02 with a N / P ratio of 4: 1, before (9) digestion with RNase.
Figure 4 shows the stability of the mouse thymus RNA in the presence of RNase after the RNA molecule is complexed with CNE particles. All samples were incubated with RNase for 30 minutes. RNase was inactivated with proteinase K and samples that were formulated were decomplexed and analyzed for RNA integrity by denaturation using gel electrophoresis. The unmarked lane contains molecular weight markers. Lanes 15 and 16: RNA from the mouse thymus before (15) and after (16) digestion with RNase; lanes 17 and 18: mouse thymus RNA complexed with CNE04 with an N / P ratio of 10: 1 before (17) and after (18) of RNase digestion; lanes 19 and 20: RNA from the mouse thymus complexed with CNE04 with an N / P ratio of 4: 1 before (19) and after (20) of RNase digestion; lanes 21 and 22: mouse thymus RNA complexed with CNE05 at an N / P ratio of 10: 1 before (21) and after (22) of RNase digestion; lanes 23 and 24: RNA from the mouse thymus complexed with CNE05 with an N / P ratio of 4: 1 before (23) and after (24) of RNase digestion.
Figure 5 shows the stability of the mouse thymus RNA in the presence of RNase after the RNA molecule is complexed with CNE particles. All samples were incubated with RNase for 30 minutes. RNase was inactivated with proteinase K and samples that were formulated were decomplexed and analyzed for RNA integrity by denaturation using gel electrophoresis. Unmarked lanes contain molecular weight markers. Lanes 1 and 2: RNA from the mouse thymus before (1) and after (2) digestion with RNase; lanes 3 and 4: mouse thymus RNA complexed with CNE17 with a 10: 1 N / P ratio before (3) and after (4) RNase digestion; lanes 5 and 6: mouse thymus RNA complexed with CNE17 in an N / P ratio of 4: 1, before (5) and after (6) of RNase digestion; lanes 7 and 8: with a CNE27 in the 10: 1 N / P ratio, before (7) and after (8) digestion with RNase; lanes 9 and 10: RNA from the mouse thymus complexed with CNE27 with an N / P ratio of 4: 1 before (9) and after (10) of RNase digestion; lanes 11 and 12: RNA from the mouse thymus before (11) and after (12) digestion with RNase; lanes 13 and 14: mouse thymus RNA complexed with CNE32 with an N / P ratio of 10: 1 before (13) and after (14) of RNase digestion; lanes 15 and 16: RNA from the mouse thymus complexed with CNE32 with an N / P ratio of 4: 1 before (15) and after (16) of RNase digestion.
Figure 6 shows the stability of the mouse thymus RNA in the presence of RNase after the RNA molecule is complexed with CNE particles. All samples were incubated with RNase for 30 minutes. RNase was inactivated with proteinase K and samples that were formulated were decomplexed and analyzed for RNA integrity by denaturation using gel electrophoresis. Unmarked lanes contain molecular weight markers. Lanes 1 and 2: RNA from the mouse thymus before (1) and after (2) digestion with RNase; lanes 3 and 4: RNA from the mouse thymus complexed with CNE35 with an N / P ratio of 10: 1 before (3) and after (4) digestion with RNase; lanes 5 and 6: mouse thymus RNA complexed with CNE35 with an N / P ratio of 4: 1, before (5) and after (6) of RNase digestion; lane 7: mouse thymus RNA before digestion with RNase.
Figure 7 shows the sequence of vectors used in the examples. Figure 7A shows the plasmid sequence A317 (SEQ ID NO: 1), which encodes the RSV-F antigen. Figure 7B shows the plasmid sequence A306 (SEQ ID NO: 2), which encodes secreted human placenta alkaline phosphatase (SEAP). Figure 70 shows the A375 plasmid sequence (SEQ ID NO: 3), which encodes an RSV-F antigen.
Figure 8A shows the results of the SEAP assay in vivo, using 1 μg of A306 RNA replicon complexed with CNE17 at a 10: 1 N / P ratio. Figure 8B shows the titrations of: total IgG in BALB / c mice at 2wpl and 2wp2 time points (RNA A317 replicon complexed with CNE17 was administered to BALB / c mice).
Figures 9A-9C show the effects of different buffer compositions on the particle size. Figure 9A shows the effects of sugar, salt and F127 polymer on the particle size of CNE17 emulsions with 10: 1 N / P complexed RNA. Figure 9B shows the effect of the citrate buffer on the particle size of the CNE17 emulsion. Figure 9C shows the effect of polymers (F68, F127 and PEG300) on the particle size. DETAILED DESCRIPTION OF THE INVENTION 1. OVERVIEW
The present invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule to cells. The emulsion particles comprise an oily core and a cationic lipid. The cationic lipid can interact with the negatively charged molecule, for example, through electrostatic forces and hydrophobic / hydrophilic interactions, thus anchoring the molecule to the emulsion particles. The cationic emulsions described herein are particularly suitable for delivering nucleic acid molecules, such as an RNA molecule (e.g., RNA encoding a protein or peptide, small interfering RNAs, self-replicating RNA, and the like) to cells in vivo.
The present invention is based on the finding that cationic oil-in-water emulsions can be used to deliver negatively charged molecules to cells. The emulsion particles comprise an oily core and a cationic lipid that can interact with the negatively charged molecule. In preferred embodiments, an RNA molecule is complexed, for example, through electrostatic forces and hydrophobic / hydrophilic interactions, with a particle of an oil emulsion in cationic water. The complexed RNA molecule is stabilized and protected from RNase-mediated degradation, and is more efficiently absorbed by cells compared to free RNA. In addition, when RNA is provided to induce the expression of an encoded protein, such as, in the context of an RNA vaccine, the immunogenicity of the encoded protein can be improved due to the adjuvant effects of the emulsion. Therefore, in addition to more efficient distribution of a negatively charged molecule (for example, an RNA molecule encoding an antigen), cationic emulsions can also increase the immune response through adjuvant activity.
For example, as described and exemplified here, the inventors evaluated the in vivo effects of a series of cationic oil-in-water emulsions, using a mouse model and a cotton rat model of immunization of the respiratory syncytial virus (RSV) . The results demonstrate that formulations in which RNA molecules were complexed with cationic emulsions generated significantly greater immune responses compared to RNA-free formulations. In some cases, the mean antibody titers against an RNA-encoded protein were obtained after administration of 1 μg of RNA complexed with oil emulsion in cationic water, were comparable to the titers obtained using 10 times more free RNA (10 μg dose free RNA). Another advantage of the formulations as described here, in addition to the increased immune response in the host, is that there was less fluctuation in the immune responses in the host animals between the different studies and different host animals, compared to free RNA (Not formulated).
Thus, in one aspect, the invention provides a composition comprising an RNA molecule complexed with a particle of an oil emulsion in cationic water, wherein the particle comprises (a) an oily core that is in liquid phase, at 25 ° C , and (b) a cationic lipid. Preferably, the oil emulsion particle in cationic water is not a Nanolipid Peptide Particle (NLPP). Preferably, the oil core is in the liquid phase, at 4 ° C
The cationic emulsion particles may further comprise a surfactant (for example, Tween 80 (polysorbate 80; polyoxyethylene monooleate), SPAN85 (sorbitan trioleate), or a combination thereof), a phospholipid, or a combination thereof. The emulsion can also comprise a polymer (for example, Pluronic® F127) in the aqueous (continuous phase) of the emulsion.
In another aspect, the invention also provides a number of specific formulations of cationic oil-in-water emulsions that can be used to deliver negatively charged molecules.
In another aspect, the invention provides a method of preparing a composition comprising a negatively charged molecule complexed with a particle of an oil emulsion in cationic water. An exemplary approach to producing cationic emulsions described here is by dispersing the oil phase in the aqueous phase by homogenization. Additional optional steps to promote particle formation, to increase the complexation between negatively charged molecules and cationic particles, to increase the stability of the negatively charged molecule (for example, to prevent the degradation of an RNA molecule) in order to facilitating the proper decompression / release of negatively charged molecules (such as an RNA molecule), or to prevent aggregation of the emulsion particles include, for example, adding dichloromethane (DCM or methylene chloride) to the oil phase, and allowing the DCM evaporates before or after homogenization; mixing the cationic lipid with a suitable solvent to form a liposome suspension; or add a polymer (for example, Pluronic® F127) or a surfactant to the aqueous phase of the emulsion. Alternatively, the cationic lipid can be dissolved directly in the oil.
The cationic emulsions of this invention can be used to distribute a negatively charged molecule, such as a nucleic acid (for example, RNA). The compositions can be administered to a subject in need of them, to generate or enhance an immune response. The compositions can also be co-distributed with another immunogenic molecule, composition or immunogenic vaccine to understand the effectiveness of the induced immune response. 2. DEFINITIONS
As used here, the singular forms "one", "one" and "o, a" include plural references unless the content clearly dictates otherwise.
The term "fence", as used herein, refers to +/- 10% of a value.
The term "surfactant" is a term of the technique and generally refers to any molecule containing both a hydrophilic group (for example, a polar group), which energetically prefers solvation by water, and a hydrophobic group that is not well solvated by water. The "non-ionic surfactant" is a term known in the art and generally refers to a hydrophilic surfactant molecule, the group of which (for example, the polar group) is not electrostatically charged.
The term "polymer" refers to a molecule consisting of individual chemical units, which can be the same or different, which are joined together. As used herein, the term "polymer" refers to individual chemical groups that are joined end-to-end to form a linear molecule, as well as individual chemical groups joined together in the form of a branched structure (for example, an "arm- multi "or" star shape "). Examples of polymers include, for example, poloxamers. Poloxamers are non-ionic triblock copolymers having a central hydrophobic polyoxypropylene (poly (propylene oxide)) chain flanked by two hydrophilic polyoxyethylene (poly (ethylene oxide)) chains.
A "buffer" refers to an aqueous solution that resists changes in the pH of the solution.
Ta.l as used herein, "nucleotide analog" or "modified nucleotide" refers to a nucleotide that contains one or more chemical modifications (for example, substitutions) in, or on the nitrogenous nucleoside base (for example, cytosine (C), thymine (T) or uracil (U), adenine (A) or guanine (G)). A nucleotide analog can contain other chemical modifications in, or about the sugar fraction of the nucleoside (for example, ribose, deoxyribose, modified ribose, modified deoxyribose, six-membered sugar analog, or open chain sugar analog), or phosphate.
As used herein, "saccharide" encompasses monosaccharides, oligosaccharides or polysaccharides, in linear or ring forms, or a combination thereof, to form a saccharide chain. Oligosaccharides are saccharides having two or more monosaccharide residues. Examples of saccharides include glucose, maltose, maltotriose, maltotetraose, sucrose and trehalose.
The terms "self-replicating RNA", "RNA replicon" or "RNA vector" are terms of the technique and, in general, refer to an RNA molecule that is capable of directing its own amplification or self-replication in vivo, typically within a target cell. The RNA replicon is used directly, without the need to introduce DNA into a cell and transport it to the nucleus, where transcription can take place. Using the RNA vector for direct distribution to the host cell cytoplasm, replication and autonomous translation of the heterologous nucleic acid sequence takes place efficiently. An alphavirus-derived self-replicating RNA can contain the following elements in sequential order: 5 'viral sequences needed in cis for replication (also referred to as 5' CSE, at the base), the sequences that, when expressed, encode non-structural alphavirus proteins biologically active (for example, nsPl, nsP2, nsP3, nsP4), 3 'viral sequences needed in cis for replication (also referred to as 3' CSE, at the base), and a polyadenylate tract. The alphavirus-derived self-replicating RNA may also contain a viral subgenomic "junction region" promoter, sequences of one or more structural protein genes or portions thereof, foreign nucleic acid molecule (s) that are large enough to allow the production of recombinant alphavirus particles, as well as heterologous sequences, to be expressed.
The term "adjuvant" refers to any substance that assists or modifies the action of a drug, including but not limited to, immunological adjuvants, which enhance and / or diversify the immune response to an antigen. Thus, immunological adjuvants include compounds that are capable of potentiating an immune response to antigens. Immunological adjuvants can enhance humoral and / or cellular immunity. Substances that stimulate an innate immune response are included within the definition of immunological adjuvants in this document. Immunological adjuvants can also be referred to as "immunopotentiators".
As used herein, an "antigen" or "immunogen" refers to a molecule that contains one or more epitopes (for example, linear, conformational, or both), which elicit an immune response. As used here, an "epitope" is the part of the given species (for example, an antigenic molecule or antigenic complex), which determines its immunological specificity. An epitope is within the scope of the present definition of antigen. The term "antigen" or "immunogen", as used herein, includes subunit antigens, that is, antigens that are separated and discrete from a complete organism with which the antigen is associated in nature. Antibodies, such as anti-idiotype antibodies, or fragments thereof, and synthetic peptide mimotopes, which can mimic an antigen or antigen determinant, are also captured under the definition of antigen as used herein.
An "immune response" or "immune response" is the development in a subject of a cellular and / or humoral immune response to an antigen or an immunological adjuvant.
Immune responses include innate and adaptive immune responses. Innate immune responses are fast-acting responses that provide a first line of defense for the immune system. In contrast, adaptive immunity uses clonal selection and expansion of immune cells having somatically rearranged receptor genes (for example, T- and B- cell receptors) that recognize antigens for a given pathogen or disorder (for example, a tumor), thus providing specificity and immune memory. Innate immune responses, among their various effects, lead to a rapid disruption of inflammatory cytokines and the activation of antigen presenting cells (APCs) such as macrophages and dendritic cells. To distinguish pathogens from auto-components, the innate immune system uses a variety of relatively invariable receptors that detect pathogen signatures, known as pathogen-associated molecular patterns or PAMPs. The addition of microbial components to experimental vaccines is known to lead to the development of durable and robust adaptive immune responses. The mechanism underlying this enhancement of immune responses has been reported to involve standard recognition receptors (PRRs), which are differentially expressed in a variety of immune system cells, including neutrophils, macrophages, dendritic cells, natural killer cells, B cells and some non-immune cells, such as epithelial and endothelial cells. The involvement of PRRs leads to the activation of some of these cells and their secretion of cytokines and chemokines, as well as the maturation and migration of other cells. In parallel, this creates an inflammatory ambience that leads to the establishment of the adaptive immune response. PRRs include non-phagocytic receptors, such as Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) proteins, and receptors that induce phagocytosis, such as sequestering receptors, mannose receptors and β- receptors glucan. The reported TLRs (along with some examples of reported ligands, which can be used as an immunogenic molecule in various embodiments of the invention) include the following: TLR1 (bacterial lipoproteins from Mycobacteria, Neisseria), TLR2 (zymosan yeast particles, peptidoglycan, lipoproteins , lipopeptides, glycolipids, lipopolysaccharide), TLR3 (double-stranded viral RNA, poly: IC), TLR4 (bacterial lipopolysaccharides, taxol plant product), TLR5 (bacterial agar in bacteria), TLR6 (zymosan yeast particles, lipoteconic acid , mycoplasma lipopeptides), TLR7 (single-stranded RNA, imiquimod, resimiquimod, and other synthetic compounds, such as loxoribine and bropyrimine), TLR8 (single-stranded RNA, resimiquimod) and TLR9 (CpG oligonucleotides), among others. Dendritic cells are recognized as some of the most important cell types for the initiation of initiation of naive auxiliary CD4 + T (TR) and for inducing CD8 + T cells to differentiate into killer cells. TLR signaling has been reported to play an important role in determining the quality of these helper T cell responses, for example, with the nature of the TLR signal that determines the specific type of TR response that is observed (eg, response TH1 versus TH2). A combination of antibodies (humoral) and cellular immunity is produced as part of a TH1 type response, whereas a TH2 type response is predominantly an antibody response. Several TLR ligands, such as CpG DNA (TLR9) and imidazoquinolines (TLR7, TLR8) have been documented to stimulate the production of cytokines from immune cells in vitro. Imidazoquinolines are the first small drug-like compounds shown to be agonists of TLR. For more information, see, for example, A. Pashine, N.M. Valiante and J.B. Ulmer, Nature Medicine 11, S63-S68 (2005), K.S. Rosenthal and D.H. Zimmerman, Clinical and Vaccine Immunology, 13 (8), 821-829 (2006), and the references cited therein.
For the purposes of the present invention, a humoral immune response refers to an immune response mediated by antibody molecules, while a cellular immune response is a response mediated by T lymphocytes and / or other white blood cells. An important aspect of cellular immunity involves a specific antigen response by cytolytic T cells (CTLs). CTLs have specificity for peptide antigens that are presented in association with proteins encoded by the major histocompatibility complex (MHC) and expressed on the cell surface. CTLs help to induce and promote the intracellular destruction of intracellular microorganisms, or the lysis of cells infected with such microorganisms. Another aspect of cellular immunity involves a specific antigen response by helper t cells. Helper T cells act to help stimulate function, and to concentrate the activity of nonspecific effector cells against cells that have peptide antigens in association with MHC molecules on their surface. A "cellular immune response" also refers to the production of cytokines, chemokines and other such molecules produced by activated T cells and / or other white blood cells, including those derived from CD4 + and CD8 + T-cell cells.
A composition such as an immunogenic composition or vaccine that elicits a cellular immune response can thus serve to sensitize a vertebrate subject by presenting antigen in association with MHC molecules on the cell surface. The cell-mediated immune response is directed at, or close to, antigen presenting cells on its surface. In addition, antigen-specific T lymphocytes can be generated to allow future protection of an immunized host. The ability of a determined antigen or composition to stimulate a cell-mediated immune response can be determined by a series of assays known in the art, such as by lymphoproliferation assays (lymphocyte activation), CTL cytotoxic cell assays, by assay for antigen-specific T lymphocytes in a sensitized subject, or by measuring cytokine production by T cells in response to antigen stimulation. Such assays are well known in the art. See, for example, Erickson et al. (1993) J. Immunol 151: 4189-4199; Doe et al. (1994) Eur. J. Immunol 24: 2369-2376. Thus, an immune response, as used here, may be one that stimulates the production of CTLs and / or the production or activation of T-helper cells. The antigen of interest can also elicit an antibody-mediated immune response. Thus, an immune response can include, for example, one or more of the following effects, among others: the production of antibodies, for example, by B-cells; and / or the activation of suppressor T cells and / or yδ T cells directed specifically to an antigen or antigens present in the composition or vaccine of interest. These responses can serve, for example, to neutralize infectivity and / or mediate the complement antibody, or the antibody-dependent cellular cytotoxicity (ADCC) to provide protection to an immunized host. Such responses can be determined using standard immunoassays and neutralization assays, well known in the art.
The compositions according to the present invention show "enhanced immunogenicity" for a given antigen, since they have a greater ability to elicit an immune response than the immune response elicited by an equivalent amount of the antigen in a different composition (for example, where the antigen is administered as a soluble protein). Thus, the composition may exhibit enhanced immunogenicity, for example, because the composition generates a stronger immune response, or because a lower dose or lower doses of the antigen are necessary to achieve an immune response in the subject to which it is administered. Such enhanced immunogenicity can be determined, for example, by administering a composition of the invention and a control antigen for animals and comparing the test results of the two. 3. CATIONIC WATER OIL EMULSIONS
The cationic oil-in-water emulsions described here are generally described in the manner that is conventional in the art, by concentrations of components that are used to prepare the emulsions. It is understood in the art that during the emulsion production process, including sterilization and other downstream processes, small amounts of oil (eg squalene), cationic lipid (eg DOTAP), or other components, can be lost, and the actual concentrations of one of these components in the final product (for example, a sterile packaged emulsion, which is ready for administration) may be slightly less than the starting quantities, sometimes around 10%, or about 20%.
The present invention generally relates to cationic oil-in-water emulsions that can be used to deliver negatively charged molecules, such as an RNA molecule. The emulsion particles comprise an oily core and a cationic lipid. The cationic lipid can interact with the variant negatively charged molecule, for example, through electrostatic forces and hydrophobic / hydrophilic interactions, thereby anchoring the molecule to the emulsion particles.
The cationic emulsions described herein are particularly suitable for delivering a negatively charged molecule, such as an RNA molecule encoding an antigen or small interfering RNA to cells in vivo. For example, the cationic emulsions described here provide advantages for the distribution of RNA encoding antigens, including self-replicating RNAs, such as vaccines.
The particles of the oil-in-water emulsions resemble a micelle with a central oil core. The core is coated with oil with the cationic lipid, which disperses the drop of oil in the aqueous phase (continuous) as micelle-like drops. One or more optional components may be present in the emulsion, such as surfactants and / or phospholipids, as described below. For example, one or more surfactants can be used to promote particle formation and / or stabilize the emulsion particles. In this case, the oil core is coated with the cationic lipid as well as the surfactant (s) in order to form droplet-like micelles. Likewise, one or more lipids (for example, neutral lipids, glycol-lipids or phospholipids) may also be present on the surface of the emulsion particles, if such lipids are used as nucleosides to disperse the oil droplets.
Particles of oil-in-water emulsions have an average diameter (ie, the numerical average diameter) of 1 micron or less. It is particularly desirable that the average particle size (i.e., the numerical mean diameter) of the cationic emulsions is about 900 nm or less, about 800 nm or less, about 700 nm or less, about 600 nm or less , about 500 nm or less, about 400 nm or less, 300 nm or less, or 200 nm or less, for example, from about 1 nm to about 1 μm, from about 1 nm to about 900 nm , from about 1 nm to about 800 nm, from about 1 nm to about 700 nm, from about 1 nm to about 5 from 600 nm, from about 1 nm to about 500 nm, from about 1 nm at about 400 nm, from about 1 nm to about 300 nm, from about 1 nm to about 200 nm, from about 1 nm to about 175 nm, from about 1 nm to about 150 nm, from about 1 nm to about 125 nm, from about 1 nm to about 100 nm, from about 1 nm to about 75 nm, or between about 1 nm to about 50 nm.
It is particularly desirable for the average particle diameter of the cationic emulsions to be about 180 nm or less, about 170 nm or less, about 160 nm or less, about 150 nm or less, about 140 nm or less, about. 3.30 nm or less, about 120 nm or less, about 110 nm or less, or about 100 nm or less, for example, from about 80 nm to 180 nm, from about 80 nm to 170 nm , from about 80 nm to 160 nm, from about 80 nm to 150 20 nm, from about 80 nm to 140 nm, from about 80 nm to 130 nm, from about 80 nm to 120 nm, about 80 nm and 110 nm, or from about 80 nm to 100 nm. Particularly the average particle diameter is about 100 nm.
The size of the emulsion particles can be varied 25 by changing the ratio of surfactant to oil (increasing the ratio decreases the size of the drops), operating the homogenization pressure (increasing the operating pressure of the homogenization typically reduces the size of the drops ), temperature (increasing the temperature decreases the size of the 30 drops), changing the type of oil, and other process parameters, as described in detail below. The inclusion of certain types of buffers in the aqueous phase can also affect the particle size.
In some cases, in the context of an RNA vaccine, the size of the emulsion particles can affect the immunogenicity of the emulsion-RNA complex. Therefore, the preferred emulsion particle size range should be about 80 nm to about 180 nm in diameter.
The emulsion particles described here can be complexed with a negatively charged molecule. Before cornplexing with the negatively charged molecule, the overall net charge of the particles (typically measured as zeta-potential) must be positive (cationic). The overall net charge of the particles can vary, depending on the type of the cationic lipid and the amount of cationic lipid in the emulsion, the amount of oil in the emulsion (for example, the higher percentage of oil usually results in less charge on the surface of the particles) , and can also be affected by any additional components (for example, surfactant (s) and / or phospholipids (s)) that are present in the emulsion. In the exemplary modalities, the zeta potential of the pre-complexing particles is typically greater than 10 mV.
Preferably, the zeta potential of the pre-connection particles is no more than about 50 mV, no more than about 45 mV, no more than about 40 mV, no more than about 35 mV, no more than about 30 mV, no more than about 25 mV, no more than about 20 mV, from about 5 mV to about 50 mV, from about 10 mV to about 50 mV, from about 10 mV to about 45 mV, from about 10 mV to about 40 mV, from about 10 mV to about 35 mV, from about 10 mV to about 30 mV, from about 10 mV to about 25 mV, mV or about 10 to about 20 mV. The zeta potential can be affected by (i) pH of the emulsion, (ii) conductivity of the emulsion (for example, salinity), and (iii) concentration of the various components of the emulsion (polymer, non-ionic surfactants, etc.). The zeta potential of CNEs is measured using a Malvern Nanoseries Zetasizer (Westborough, MA). The sample is diluted 1: 100 in water (viscosity: 0.8872cp RI: 1.330, die-metric constant: 78.5) and added to a polystyrene latex hair cell (Malvern, Westborough, MA). The zeta potential is measured at 25 ° C with an equilibrium time of 2 minutes and analyzed using the Smoluchowski model (F (Ka) value = 1.5). The data are reported in mV.
An exemplary cationic emulsion of the present invention is CNE17. The oily core of squalene is CNE17 (at 4.3% w / v) and the cationic lipid is DOTAP (at 1.4 mg / ml). CNE17 also includes surfactants SPAN85 ((sorbitan trioleate) 0.5% v / v) and Tween 80 ((polysorbate 80; polyoxyethylene monooleate) 0.5% v / v). Thus, the CNE17 particles comprise a squalene core coated with SPAN85, TweenSO, and DOTAP. The RNA molecules have been shown to complex with CNE17 particles efficiently at an N / P ratio of 4: 1 and an N / P ratio of 10: 1. Other examples of cationic emulsions include, for example, CNE05 (0.5% w / v squalene, 0.08% Tween 80, and 1.2 mg / ml DOTAP), CNIO2 (4.3% squalene, 0.5% SPAN85, 0.5% Tween 80, and 2.46 mg / mL of cholesterol DC), CNE13 (4.3% squalene, 0.5% SPAN85, 0.5% Tween 80 , and 1.45 mg / ml DDA), and other emulsions described herein.
The individual components of the oil-in-water emulsions of the present invention are known in the art, although such compositions are not combined in the form described herein. Therefore, the individual components, although described below, globally and in some detail for the preferred embodiments, are well known in the art, and the terms used herein, such as the oil core, surfactant, phospholipids, etc., are sufficiently well known one skilled in the art without further description. In addition, although the preferred ranges of the quantity of the individual components of the emulsions are provided, the actual ratios of the components of a particular emulsion may have to be adjusted in such a way that the emulsion particles of desired size and physical properties can be properly formed. . For example, if a particular amount of oil is used (for example, 5% v / v oil), then the amount of surfactant must be at a level that is sufficient to disperse the drop of oil into the aqueous phase to form a stable emulsion. The actual amount of surfactant required to disperse the drop of oil in the aqueous phase depends on the type of surfactant and the type of oily core used for the emulsion; and the amount of oil can also vary according to the size of the droplet (as this changes the surface area between the two phases). The actual quantities and the relative proportions of the components of a desired emulsion can be pronately determined by one skilled in the art. A. Oily core
The particles of the cationic oil-in-water emulsions comprise an oily core. Preferably, the oil is a non-toxic, metabolizable oil, more preferably one of about 6 to about 30 carbon atoms including, but not limited to, alkanes, alkenes, alkynes and their corresponding acids and alcohols, ethers and esters of them, and mixtures thereof. The oil can be any vegetable oil, fish oil, animal oil or synthetically prepared oil that can be metabolized by the subject's body to which the emulsion is to be administered, and is non-toxic to the subject. The subject may be an animal, typically a mammal and, preferably, a human.
In certain embodiments, the oil core is in the liquid phase at 25 ° C. The oily core is in the liquid phase at 25 ° C, when it has the properties of a fluid (as distinguished from solid and gas, and having a defined volume, but no defined shape), when stored at 25 ° C. The emulsion, however, can be stored and used at any suitable temperature. Preferably, the oil core is in the liquid phase, at 4 ° C.
The oil may be any alkane, alkene or long-chain alkaline, or an acid or alcohol derivative thereof, either as the free acid, its salt or an ester such as a mono-, di- or triester, such as triglycerides and 1,2-propanediol esters or similar polyhydroxy alcohols. Alcohols can be acylated using a functional mono- or polyacid, for example, acetic acid, propanoic acid, citric acid, or the like. Ethers derived from long-chain alcohols, which are oils and fulfill the other criteria established here can also be used.
The fraction of individual alkane, alkene or alkane and its alcohol and acid derivatives will generally have about 6 to about 30 carbon atoms. The radical can have a straight or branched chain structure. It can be completely saturated or have one or more double or triple bonds. Whenever oils based on ethers or mono- or polyesters are used, the limitation of about 6 to about 30 carbon atoms applies to the fatty acid fractions or individual fatty alcohols, not to the count of total carbon.
It is particularly desirable that the oil can be metabolized by the host to which the emulsion is administered.
Any suitable oils from a fish, animal or vegetable source can be used. Sources of vegetable oils include nuts, seeds and grains and suitable oils include peanut oil, soy oil, coconut oil, olive oil and others. Other suitable seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil, and oil from other cereal grains, such as wheat, oats, rye, rice, millet, triticale and the like can also be used. The technology for obtaining vegetable oils is well developed and well known. The compositions of these and other similar oils can be found, for example, in the Merck index, and the raw materials in food, nutrition and food technology.
About six to about ten carbons of glycerol and 1,2-propanediol fatty acid esters, although not naturally occurring in seed oils, can be prepared by hydrolysis, separation and esterification of materials from nut and seed oils appropriate. These products are commercially available under the names of NEOBEES from PVO International, Inc., Chemical Specialties Division, 416 Division Street, Boongon, N.J. and others.
Animal oils and fats are often in solid phase, at physiological temperatures due to the fact that they exist as triglycerides and have a higher degree of saturation than fish or vegetable oils. However, fatty acids are obtained from animal fats by partial or complete saponification of the triglycerides that provide the free fatty acids. Mammalian milk fats and oils are metabolizable and can therefore be used in the practice of the present invention. The procedures for separation, purification, saponification and other means necessary to obtain pure oils of animal origin are well known in the art.
Most fish contain metabolizable oils that can be easily recovered. For example, cod liver oil, shark liver oils and whale oil such as spermaceti exemplify several of the fish oils that can be used in the present invention. A series of branched-chain oils are synthesized biochemically in isoprene units with 5 carbons and are generally referred to as terpenoids. Squalene (2,6,1 0, 15, .1 9,23-hexamethyl-2,6, 10,14,18,22-tetracosa-hexaene), a branched unsaturated terpenoid, is particularly preferred herein. One of the main sources of squalene is shark liver oil, although plant oils (mainly vegetable oils), including amaranth seed oil, rice bran, wheat germ, and olive oil, are also suitable sources. Squalane, the saturated analogue of squalene, is also preferred. Fish oils, including squalene and squalane, are readily available from commercial sources or can be obtained by methods known in the art.
In certain embodiments, the oily core comprises an oil that is selected from the group consisting of: castor oil, coconut oil, corn oil, cottonseed oil, evening primrose oil, fish oil, jojoba oil, lard oil, linseed oil, olive oil, peanut oil, safflower oil, sesame oil, soy oil, squalene, sunflower oil, wheat germ oil, and mineral oil. In exemplary embodiments, the oily core comprises soybean oil, sunflower oil, olive oil, squalene, or a combination thereof. Squalane can also be used as the oil. In exemplary embodiments, the oil core comprises squalene, squalane, or a combination thereof.
The oily component of the emulsion can be present in an amount of about 0.2% to about 20% (v / v). For example, the oil in water cationic emulsion can comprise from about 0.2% to about 20% (v / v) of oil, from about 0.2% to about 15% of oil (v / v) ), from about 0.2% to about 10% (v / v) of oil, from about 0.2% to about 9% (v / v) of oil, from about 0.2%) about 8% oil (v / v), about 0.2% to about 7% (v / v) oil, about 0.2% to about 6% (v / v) oil, from about 0.2% to about 5% (v / v) of oil, from about 0.2% to about 4.3% (v / v) of oil, from about 0.3 % to about 20% (v / v) oil, from about 0.4% to about 20% (v / v) oil, from about 0.5% to about 20% oil (v / v), from about 1% to about 20% (v / v) of oil, from about 2% to about 20% (v / v) of oil, from about 3% to about 20% (v / v) oil, from about 4% to about 20% (v / v) oil, from about 4.3% to about 20% (v / v) oil, from about 5 % to about 20% (v / v) oil, about 0.5% (v / v) oil, about 1% (v / v) oil, about 1.5% (v / v) ) of oil, about 2% (v / v ) of oil, about 2.5% (v / v) of oil, about 3% (v / v) of oil, about 3.5% (v / v) of oil, about 4% (v / v) oil, about 4.3% (v / v) oil, about 5%> * 1.5 (v / v) oil, or about 10% oil (v / v).
Alternatively, the oil in water cationic emulsion can comprise from about 0.2% to about 10% (w / v) of oil, from about 0.2% to about 9% (w / v) of oil , from about 0.2% to about 8% (w / v) of oil, from about 0.2% to about 7% (w / v) of oil, from about 0.2% to about from 6% (w / v) of oil, from about 0.2% to about 5% (w / v) of oil, from about 0.2% to about 4.3% (w / v) of oil, or about 4.3% (w / v) of oil.
In an exemplary embodiment, the cationic oil-in-water emulsion 25 comprises about 0.5% (v / v) of oil. In another exemplary embodiment, the oil-in-cationic water emulsion comprises about 4.3% (v / v) of oil. In another exemplary embodiment, the oil-in-cationic water emulsion comprises about 5% (v / v) of oil. In another exemplary embodiment, the oil-in-cationic water emulsion comprises about 4.3% (w / v) squalene.
As noted above, the percentage of oil described above is determined based on the initial amount of oil that is used to prepare the emulsions. It is understood in the art that the actual concentration of the oil in the final product (for example, a sterile packaged emulsion that is ready for administration) may be slightly lower, sometimes at about 10% or about 20%. B. Cationic Lipids
The emulsion particles described herein comprise a cationic lipid, which can interact with the negatively charged molecule, thereby anchoring the molecule to the emulsion particles.
Any suitable cationic lipid can be used. r 15 Generally, the cationic lipid contains an atom. of nitrogen that is positively charged under physiological conditions. Suitable cationic lipids include, benzalkonium chloride (BAK), benzethonium chloride, cetrimide (which contains tetradecyltrimethylammonium bromide and possibly small amounts of dodecyltrimethylammonium bromide and hexadecyltrimethyl ammonium bromide), cetylpyridinium chloride (cetylpyridinium chloride) - 'trimethylammonium (CTAC), primary amines, secondary amines, tertiary amines, including, but not limited to, N, N', N'-polyoxyethylene (10) -N-tallow-1,3-diaminopropane, other amine salts quaternary, including, but not limited to, dodecyltrimethylammonium bromide, hexadecyltrimethyl ammonium bromide, mixed trimethyl-alkyl-ammonium bromide, benzyl-dimethyl-dodecyl-ammonium chloride, benzyl-dimethyl-hexadecyl-ammonium chloride, benzyl methoxide trimethyl-ammonium, cetyl-dimethyl-ethyl-ammonium bromide, dimethyl-diocta-decyl ammonium bromide (DDAB), methylbenzethonium chloride, decamethonium chloride, mixed trialkyl ammonium chloride, methyl trioctylamonium chloride), N, N-dimethyl-N- [2 (2-methyl-4- (1,1,3,3-tetramethylbutyl) -phenoxy] -ethoxy) -ethyl] -benzenomethanaminium (DEBDA) chloride, dialkyldimethylammonium salts, chloride of [l- (2,3-dioleyloxy) -propyl] -N, N, N, trimethylammonium, 1,2-diacyl-3- (trimethylammonium) propane (acyl group = dimiristoil, dipalmitoil, diestearoil, dioleoyl), l, 2-diacyl-3 (dimethylammonium) propane (acyl group = dimiristoyl, dipalmitoyl, distearoil, dioleoyl), 1,2-dioleoyl-3- (4'-trimethyl-ammonium) butanoyl-sn-glycerol, choline ester of 1 , 2-dioleoyl-3-succinyl-sn-glycerol, cholesteryl (4'-trimethylammonium) butanoate), N-alkyl-pyridinium salts (for example, cetylpyridinium bromide and cetylpyridinium chloride), N-alkylpiperidinium salts, electrolytes dicatonic ballforms (C ^ Mee; CI2BU6), dialkylglycethylphosphorylcholine, lysolecithin, L-dioleoylphosphatidylethanolamine, cholesterol hemisuccinate choline ester, lipopolyamines, including, but not limited to, dioctadecylamidoglycylspermine (DOGS), lipid-amylethyl-amide lysine (LPLL, LPDL), poly (L (or D) -lysine conjugated to N-glutarylphosphatidylethanolamine, didodecyl glutamate ester with the pendant amino group (C ^ GluBhCnN1), ditetradecyl glutamate ester with the pendent amino group (Ci4GluCnN +) cationic cholesterol derivatives, including, but not limited to, teryl-3β-oxisuccinamidoethylenetrimethylammonium salt, terol-3β - ox.:i succinamidoe ti lenodime ti lamina cholesterol, 3-β-carboxyamidoethylenetrimethylammonium cholesterol-3β -carboxyamidoethylenedimethylamine, and 3y- [N- ([N ', N-dimethylaminoethanecarbomoyl cholesterol]) (Cholesterol-DC), 1,2-dioleoyloxy-3- (trimethylammonium) propane (DOTAP), dimethyldioctadecylammonium (DDA), 1,2 -Dimi ristoil-3-Trimethyl-Ammonium-Propane (DMTAP), dipalmitoyl (C16: o) trimethyl ammonium propane (DPTAP), distearoyl-trimethyl-ammonium propane (DSTAP), and combination thereof. Other cationic lipids suitable for use in the presence of the invention include, for example, the cationic lipids described in U.S. Patent Publications 2008/0085870 (published April 10, 2008) and 2008/0057080 (published March 6, 2008). Other cationic lipids suitable for use in the present invention include, for example, Lipids E0001- E0118 or E0119-E0180, as disclosed in Table 6 (pages 112-139) of; WO 2011/076807 (which also describes methods of preparation, and method of using these cationic lipids). Suitable additional cationic lipids include N- [1- (2,3-dioleyloxy) propyl] -N, N, N-trimethylammonium chloride (DOTMA), N, N-dioleoyl-N, N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleo.L 1-3-dimethyl-propane (DODAP), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA).
The emulsion can comprise any combination of two or more of the cationic lipids described in this document.
In preferred embodiments, the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3- (trimethylammonium) propane (DOTAP), 3 β- [N- (N ', N'-dimethylaminoethane) -carbamoyl] Cholesterol (DC cholesterol), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3-trimethyl-ammonium-propane (DMTAP), dipalmitoyl (C6: 0) trimethyl ammonium propane (DPTAP), distearoyl-trimethyl-ammonium propane (DSTAP), Lipids E0001-E0118 or E0119-E0180 as described in Table 6 (pages 112-139) of WO 2011/076807, and combinations thereof.
In other preferred embodiments, the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3- (trimethylammonium) propane (DOTAP), 3β- [N- (N ', N'-Dimethylaminoethane) -carbamoyl] Cholesterol (DC cholesterol), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3-trimethyl-ammonium-propane (DMTAP), dipalmitoyl (C6: 0) trimethyl ammonium propane (DPTAP), distearoyl-trimethyl-ammonium propane (DSTAP), N- [1- (2,3-dioleyloxy) propyl] -N, N, N-trimethylammonium chloride (DOTMA), N, N-dioleoyl-N, N-dimethamonium chloride (DODAC), 1,2-dioleoyl -sn-glycero-3-ethylphosphocyanine (DOEPC), 1,2-dioleoyl-3-dimethyl-propane (DODAP), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), Lipids E0001-E0118 or E0119 - E0180 as disclosed in Table 6 (pages 112-139) of WO 2011/076807, and combinations thereof.
In certain embodiments, the cationic lipid is DOTAP. The oil in water cationic emulsion can comprise from about 0.5 mg / ml to about 25 mg / ml of DOTAP. For example, the oil in water cationic emulsion may comprise DOTAP from about 0.5 mg / ml to about 25 mg / ml, from about 0.6 mg / ml to about 25 mg / ml, from about 0.7 mg / ml to about 25 mg / ml, from about 0.8 mg / ml to about 25 mg / ml, from about 0.9 mg / ml to about 25 mg / ml, from about from 1.0 mg / ml to about 25 mg / ml, from about 1.1 mg / ml to about 25 mg / ml, from about 1.2 mg / ml to about 25 mg / ml, about 1.3 mg / ml to about 25 mg / ml, from about 1.4 mg / ml to about 25 mg / ml, from about 1.5 mg / ml to about 25 mg / ml, from about 1.6 mg / ml to about 25 mg / ml, from about 1.7 mg / ml to about 25 mg / ml, from about 0.5 mg / ml to about 24 mg / ml , from about 0.5 mg / ml to about 22 mg / ml, from about 0.5 mg / ml to about 20 mg / ml, from about 0.5 mg / ml to about 18 mg / ml ml, from about 0.5 mg / ml to about 15 mg / ml, from about 0.5 mg / ml to about 12 mg / ml, from about 0.5 mg / ml to about 10 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, from about 0.5 mg / ml ac about 2 mg / ml, from about 0.5 mg / ml to about 1.9 mg / ml, from about 0.5 mg / ml to about 1.8 mg / ml, about 0, 5 mg / ml to about 1.7 mg / ml, from about 0.5 mg / ml to about 1.6 mg / ml, from about 0.6 mg / ml to about 1.6 mg / ml ml, from about 0.7 mg / ml to about 1.6 mg / ml, from about 0.8 mg / ml to about 1.6 mg / ml, from about 0.8 mg / ml to about 3.0 mg / ml, about 0.5 mg / ml, about 0.6 mg / ml, about 0.7 mg / ml, about 0.8 mg / ml, about 0.9 mg / ml, about 1.0 mg / ml, about 1.1 mg / ml, about 1.2 mg / ml, about 1.3 mg / ml, about 1.4 mg / ml, about 1.5 mg / ml, about .1.6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 20 mg / ml, about 21.8 mg / ml, about 24 mg / ml, etc.
In an exemplary embodiment, the oil in water cationic emulsion comprises from about 0.8 mg / ml to about 1.6 mg / ml of DOTAP, such as 0.8 mg / ml, 1.2 mg / ml, 1.4 mg / ml or 1.6 rng / ml.
In certain embodiments, the cationic lipid is cholesterol DC. The oil-in-cation water emulsion may comprise DC cholesterol from about 0.1 mg / ml to about 5 mg / ml of cholesterol DC. For example, the oil in water cationic emulsion may contain DC cholesterol from about 0.1 mg / ml to about 5 mg / ml, from about 0.2 mg / ml to about 5 mg / ml, from about 0.3 mg / ml to about 5 mg / ml, from about 0.4 mg / ml to about 5 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, about 0.62 mg / ml to about 5 mg / ml, from about 1 mg / ml to about 5 mg / ml, from about 1.5 mg / ml to about 5 mg / ml, about from 2 mg / ml to about 5 mg / ml, from about 2.46 mg / ml to about 5 mg / ml, from about 3 mg / ml to about 5 mg / ml, from about 3, 5 mg / ml to about 5 mg / ml, from about 4 mg / ml to about 5 mg / ml, from about 4.5 mg / ml to about 5 mg / ml, from about 0.1 mg / ml to about 4.92 mg / ml, from about 0.1 mg / ml to about 4.5 mg / ml, from about 0.1 mg / ml to about 4 mg / ml, about 0.1 mg / ml to about 3.5 mg / ml, from about 0.1 mg / ml to about 3 mg / ml, from about 0.1 mg / ml to about 2.46 mg / ml, from about 0.1 mg / ml to about 2 mg / ml, from about 0.1 mg / ml to about 1.5 mg / ml, from about 0.1 mg / ml to about 1 mg / ml, from about 0.1 mg / ml to about 0.62 mg / ml, about 0.15 mg / ml, about 0.3 mg / ml, about 0.6 mg / ml, about 0.62 mg / ml, about 0.9 mg / ml, about 1.2 mg / ml, about 2.4 6 mg / ml, about 4.92 mg / ml, etc.
In an exemplary embodiment, the oil in water cationic emulsion comprises from about 0.62 mg / ml to about 4.92 mg / ml of cholesterol DC, such as 2.46 mg / ml. oil in water cationic emulsion can comprise from about 0.1 mg / ml to about 5 mg / ml DDA. For example, the oil-in-cationic water emulsion may comprise ADD of from about 0.1 mg / ml to about 5 mg / ml, from about 0.1 mg / ml to about 4.5 mg / ml, from about 0.1 mg / ml to about 4 mg / ml, from about 0.1 mg / ml to about 3.5 mg / ml, from about 0.1 mg / ml to about 3 mg / ml, from about 0.1 mg / ml to about 2.5 mg / ml, from about 0.1 mg / ml to about 2 mg / ml, from about 0.1 mg / ml to about from 1.5 mg / ml, from about 0.1 mg / ml to about 1.45 mg / ml, from about 0.2 mg / ml to about 5 mg / ml, from about 0.3 mg / ml to about 5 mg / ml, from about 0.4 mg / ml to about 5 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, from about 0, 6 mg / ml to about 5 mg / ml, from about 0.73 mg / ml to about 5 mg / ml, from about 0.8 mg / ml to about 5 mg / ml, from about 0 , 9 mg / ml to about 5 mg / ml, from about 1.0 mg / ml to about 5 mg / ml, from about 1.2 mg / ml to about 5 mg / ml, from about 1.45 mg / ml to about 5 mg / ml, from about 2 mg / ml to about 5 mg / ml, from about 2.5 mg / ml to about 5 mg / ml, from about 3 mg / ml to about 5 mg / ml, from about 3.5 mg / ml to about 5 mg / ml, from about 4 mg / ml to about 5 mg / ml , from about 4.5 mg / ml to about 5 mg / ml, about 1.2 mg / ml, about 1.45 mg / ml, etc. Alternatively, the oil emulsion in cationic water may comprise less ADI about 20 mg / ml, about 21 mg / ml, about 21., 5 mg / ml, about 21.6 mg / ml, about 25 mg / ml.
In an exemplary embodiment, the oil in water cationic emulsion comprises from about 0.73 mg / ml to about 1.45 mg / ml DDA, such as 1.45 mg / ml. Oil emulsion in cationic water can comprise from about 0.5 mg / ml to about 25 mg / ml of DOTMA. For example, the oil in water cationic emulsion may comprise DOTMA from about 0.5 mg / ml to about 25 mg / ml, from about 0.6 mg / ml to about 25 mg / ml, from about 0.7 mg / ml to about 25 mg / ml, from about 0.8 mg / ml to about 25 mg / ml, from about 0.9 mg / ml to about 25 mg / ml, from about from 1.0 mg / ml to about 25 mg / ml, from about 1.1 mg / ml to about 25 mg / ml, from about 1.2 mg / ml to about 25 mg / ml, about 1.3 mg / ml to about 25 mg / ml, from about 1.4 mg / ml to about 25 mg / ml, from about 1.5 mg / ml to about 25 mg / ml, from about 1.6 mg / ml to about 25 mg / ml, from about 1.7 mg / ml to about 25 mg / ml, from about 0.5 mg / ml to about 24 mg / ml , from about 0.5 mg / ml to about 22 mg / ml, from about 0.5 mg / ml to about 20 mg / ml, from about 0.5 mg / ml to about 18 mg / ml ml, from about 0.5 mg / ml to about 15 mg / ml, from about 0.5 mg / ml to about 12 mg / ml, from about 0.5 mg / ml to about 10 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, from about 0.5 mg / ml to ce about 2 mg / ml, from about 0.5 mg / ml to about 1.9 mg / ml, from about 0.5 mg / ml to about 1.8 mg / ml, about 0, 5 mg / ml to about 1.7 mg / ml, from about 0.5 mg / ml to about 1.6 mg / ml, from about 0.6 mg / ml to about 1.6 mg / ml ml, from about 0.7 mg / ml to about 1.6 mg / ml, from about 0.8 mg / ml to about 1.6 mg / ml, from about 0.8 mg / ml to about 3.0 mg / ml, about 0.5 mg / ml, about 0.6 mg / ml, about 0.7 mg / ml, about 0.8 mg / ml, about 0.9 mg / ml, about 1.0 mg / ml, about 1.1 mg / ml, about 1.2 mg / ml, about 1.3 mg / ml, about 1.35 mg / ml, about 1.4 mg / ml, about 1.5 mg / ml, about 1.6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 20 mg / ml, about 22.5mg / ml, about 25 mg / ml etc ...
In an exemplary embodiment, the oil in water cationic emulsion comprises from about 0.8 mg / ml to about 1.6 mg / ml of DOTMA, such as 0.8 mg / ml, 1.2 mg / ml, 1.4 mg / ml or 1.6 mg / ml.
In. certain modalities, the cationic lipid is DOEPC. The cationic oil-in-water emulsion can comprise from about 0.5 mg / ml to about 25 mg / ml DOEPC. For example, the oil-in-cationic water emulsion may comprise DOEPC from about 0.5 mg / ml to about 25 mg / ml, from about 0.6 mg / ml to about 25 mg / ml, from about 0.7 mg / ml to about 25 mg / ml, from about 0.8 mg / ml to about 25 mg / ml, from about 0.9 mg / ml to about 25 mg / ml, from about from 1.0 mg / ml to about 25 mg / ml, from about 1.1 mg / ml to about 25 mg / ml, from about 1.2 mg / ml to about 25 mg / ml, about 1.3 mg / ml to about 25 mg / ml, from about 1.4 mg / ml to about 25 mg / ml, from about 1.5 mg / ml to about 25 mg / ml, from about 1.6 mg / ml to about 25 mg / ml, from about 1.7 mg / ml to about 25 mg / ml, from about 0.5 mg / ml to about 24 mg / ml , from about 0.5 mg / ml to about 22 mg / ml, from about 0.5 mg / ml to about 20 mg / ml, from about 0.5 mg / ml to about 18 mg / ml ml, from about 0.5 mg / ml to about 15 mg / ml, from about 0.5 mg / ml to about 12 mg / ml, from about 0.5 mg / ml to about 10 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, from about 0.5 mg / ml to ce about 4 mg / ml, from about 0.5 mg / ml to about 3 mg / ml, from about 0.5 mg / ml to about 2 mg / ml, about 0.5 rng / ml about 1.9 mg / ml, about 0.5 mg / ml to about 1.8 mg / ml, about 0.5 mg / ml to about 1.7 mg / ml, about from 0.5 mg / ml to about 1.6 mg / ml, from about 0.6 mg / ml to about 1.7 mg / ml, from about 0.7 mg / ml to about 1.7 mg / ml, from about 0.8 mg / ml to about 1.7 mg / ml, from about 0.8 mg / ml to about 3.0 mg / ml, about 0.5 mg / ml , about 0.6 mg / ml, about 0.7 mg / ml, about 0.8 mg / ml, about 0.9 mg / ml, about 1.0 mg / ml, about 1.1 mg / ml, about 1.2 mg / ml, about 1.3 mg / ml, about 1.4 mg / ml, about 1.5 mg / ml, about 1.6 mg / ml, about 1.7 mg / ml, about 1.8 mg / ml, about 1.9 mg / ml, about 2.0 mg / ml, about 12 mg / ml, about 18 mg / ml, about 20 mg / ml, about 22.5 mg / ml, about 25 mg / ml, etc.
In an exemplary embodiment, the oil in water cationic emulsion comprises from about 0.8 mg / ml to about 1.8 mg / ml DOEPC, such as 0.8 mg / ml, 1.2 mg / ml, 1.4 mg / ml, 1.6 mg / ml, 1.7 mg / ml, or 1.8 mg / ml.
In certain embodiments, the cationic lipid is DSTAP. The oil in water cationic emulsion may comprise from about 0.5 mg / ml to about 50 mg / ml DSTAP. For example, the oil in water cationic emulsion may comprise DSTAP from about 0.5 mg / ml to about 25 mg / ml, from about 0.6 mg / ml to about 25 mg / ml, from about 0.7 mg / ml to about 25 mg / ml, from about 0.8 mg / ml to about 25 mg / ml, from about 0.9 mg / ml to about 25 mg / ml, from about from 1.0 mg / ml to about 25 mg / ml, from about 1.1 mg / ml to about 25 mg / ml, from about 1.2 mg / ml to about 25 mg / ml, about 1.3 mg / ml to about 25 mg / ml, from about 1.4 mg / ml to about 25 mg / ml, from about 1.5 mg / ml to about 25 mg / ml, from about 1.6 mg / ml to about 25 mg / ml, from about 1.7 mg / ml to about 25 mg / ml, from about 0.5 mg / ml to about 24 mg / ml , from about 0.5 mg / ml to about 22 mg / ml, from about 0.5 mg / ml to about 20 mg / ml, from about 0.5 mg / ml to about 18 mg / ml ml, from about 0.5 mg / ml to about 15 mg / ml, from about 0.5 mg / ml to about 12 mg / ml, from about 0.5 mg / ml to about 10 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, from about 0.5 mg / ml ac about 4 mg / ml, from about 0.5 mg / ml to about 3 mg / ml, from about 0.5 mg / ml to about 2 mg / ml, about 0.5 mg / ml to about 1.9 mg / ml, from about 0.5 mg / ml to about 1.8 mg / ml, from about 0.5 mg / ml to about 1.7 10 mg / ml, about 0.5 mg / ml to about 1.6 mg / ml, from about 0.6 mg / ml to about 1.7 mg / ml, from about 0.7 mg / ml to about 1, 7 mg / ml, from about 0.8 mg / ml to about 1.7 mg / ml, from about 0.8 mg / ml to about 3.0 mg / ml, about 0.5 mg / ml ml, about 0.6 mg / ml, about 0.7 mg / ml, about 15 0.8 mg / ml, about 0.9 mg / ml, about 1.0 mg / ml, about 1 , 1 mg / ml, about 1.2 mg / ml, about 1.3 mg / ml, about 1.4 mg / ml, about 1.5 mg / ml, about 1.6 mg / ml , about 1.7 mg / ml, about 1.8 mg / ml, about 1.9 mg / ml, about 2.0 mg / ml, about 12 mg / ml, about 18 mg / ml , about 20 20 mg / ml, about 22.5 mg / ml, about 25 mg / ml, etc.
In an exemplary embodiment, the oil in water cationic emulsion comprises from about 0.8 mg / ml to about 1.6 mg / ml OSTAP, such as 0.8 mg / ml, 1.2 mg / ml, 1 , 4 mg / ml or 1.6 mg / ml.
In certain embodiments, the cationic lipid is DODAC. The oil in water cationic emulsion can comprise from about 0.5 mg / ml to about 50 mg / ml DODAC. For example, the oil-in-cationic water emulsion may comprise DODAC from about 0.5 mg / ml to about 25 mg / ml, from about 0.6 mg / ml. to about 25 mg / ml, from about 0.7 mg / ml to about 25 mg / ml, from about 0.8 mg / ml to about 25 mg / ml, from about 0.9 mg / ml ml to about 25 mg / ml, from about 1.0 mg / ml to about 25 mg / ml, from about 1.1 mg / ml to about 25 mg / ml, from about 1.2 mg / ml to about 25 mg / ml, from about 1.3 mg / ml to about 25 mg / ml, from about 1.4 mg / ml to about 25 mg / ml, from about 1.5 mg / ml to about 25 mg / ml, from about 1.6 mg / ml to about 25 mg / ml, from about 1.7 mg / ml to about 25 mg / ml, from about 0, 5 mg / ml to about 24 mg / ml, from about 0.5 mg / ml to about 22 mg / ml, from about 0.5 mg / ml to about 20 mg / ml, from about 0 , 5 mg / ml to about 18 mg / ml, from about 0.5 mg / ml to about 15 mg / ml, from about 0.5 mg / ml to about 12 mg / ml, from about 0.5 mg / ml to about 10 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, from about 0.5 mg / ml to about 4 mg / ml, from about from 0.5 mg / ml to about 3 mg / ml, from about 0.5 mg / ml to about 2 mg / ml, from about 0.5 mg / ml to about 1.9 mg / ml, from about 0.5 mg / ml to about 1.8 mg / ml, from about 0.5 mg / ml to about 1.7 mg / ml, from about 0.5 mg / ml ml to about 1.6 mg / ml, from about 0.6 mg / ml to about 1.7 mg / ml, from about 0.7 mg / ml to about 1.7 mg / ml, from about from 0.8 mg / ml to about 1.7 mg / ml, from about 0.8 mg / ml to about 3.0 mg / ml, about 0.5 mg / ml, about 0.6 mg / ml, about 0.7 mg / ml, about 0.8 mg / ml, about 0.9 mg / ml, about 1.0 mg / ml, about 1.1 mg / ml, about 1.15 mg / ml, about 1.16 mg / ml, about 1.17 mg / ml, about 1.2 mg / ml, about 1.3 mg / ml, about 1.4 mg / ml ml, about 1.5 mg / ml, about 1.6 mg / ml, about 1.7 mg / ml, about 1.8 mg / ml, about 1.9 mg / ml, about 2 , 0 mg / ml, about 12 mg / ml, about 18 mg / ml, about 20 mg / ml, about 22.5mg / ml, about 25 mg / ml etc ..
In an exemplary embodiment, the oil in water cationic emulsion comprises from 0.73 mg / ml to about 1.45 mg / ml DODAC, such as 1.45 mg / ml.
In certain embodiments, the cationic lipid is DODAP. The oil in water cationic emulsion may comprise from about 0.5 mg / ml to about 50 mg / ml DODAP. For example, the oil in water cationic emulsion may comprise DODAP from about 0.5 mg / ml to about 25 mg / ml, from about 0.6 mg / ml to about 25 mg / ml, from about 0.7 mg / ml to about 25 mg / ml, from about 0.8 mg / ml to about 25 mg / ml, from about 0.9 mg / ml to about 25 mg / ml, from about from 1.0 mg / ml to about 25 mg / ml, from about 1.1 mg / ml to about 25 mg / ml, from about 1.2 mg / ml to about 25 mg / ml, about 1.3 mg / ml to about 25 mg / ml, from about 1.4 mg / ml to about 25 mg / ml, from about 1.5 mg / ml to about 25 mg / ml, from about 1.6 mg / ml to about 25 mg / ml, from about 1.7 mg / ml to about 25 mg / ml, from about 0.5 mg / ml to about 24 mg / ml , from about 0.5 mg / ml to about 22 mg / ml, from about 0.5 mg / ml to about 20 mg / ml, from about 0.5 mg / ml to about 18 mg / ml, from about 0.5 mg / ml to about 15 mg / ml, from about 0.5 mg / ml to about 12 mg / ml, from about 0.5 mg / ml to about 10 mg / ml, from about 0.5 mg / ml to about 5 mg / ml, from about 0.5 mg / ml ac about 4 mg / ml, from about 0.5 mg / ml to about 3 mg / ml, from about 0.5 mg / ml to about 2 mg / ml, about 0.5 mg / ml about 1.9 mg / ml, about 0.5 mg / ml to about 1.8 mg / ml, about 0.5 mg / ml to about 1.7 mg / ml, about from 0.5 mg / ml to about 1.6 mg / ml, from about 0.6 mg / ml to about 1.7 mg / ml, from about 0.7 mg / ml to about 1.7 mg / ml, from about 0.8 mg / ml to about 1.7 mg / ml, from about 0.8 mg / ml to about 3.0 mg / ml, about 0.5 mg / ml , about 0.6 mg / ml, about 0.7 mg / ml, about 0.8 mg / ml, about 0.9 mg / ml, about 1.0 mg / ml, about 1.1 mg / ml, about 1.2 mg / ml, about 1.3 mg / ml, about 1.4 mg / ml, about 1.5 mg / ml, about 1.6 mg / ml, about 1.7 mg / ml, about 1.8 mg / ml, about 1.9 mg / ml, about 2.0 mg / ml, about 12 mg / ml, about 18 mg / ml, about 20 mg / ml, about 22.5 mg / ml, about 25 mg / ml, etc.
In an exemplary embodiment, the oil in water cationic emulsion comprises from about 0.8 mg / ml to about 1.6 mg / ml DODAP, Lais as 0.8 mg / ml, 1.2 mg / ml, 1 , 4 mg / ml or 1.6 mg / ml.
In some cases, it may be desirable to use a cationic lipid that is soluble in the oily core. For example, DOTAP DOEPC, DODAC, and DOTMA are soluble in squalene or squalane. In other cases, it may be the use of a cationic lipid that is not soluble in an oily core. For example, DDA and DSTAP is not soluble in squalene. It is within the skill of the art to determine whether a particular lipid is soluble or insoluble in the oil and to choose a suitable oil and lipid combination accordingly. For example, solubility can be predicted based on the structures of lipids and oils (for example, the solubility of a lipid can be determined by the structure of its tail). For example, lipids that have one or two chains of unsaturated fatty acids (for example, oleoil tails), such as DOTAP, DOEPC, DODAC, DOTMA, are soluble in squalene or squalane, and that lipids that have chains of acid Saturated greases (eg, stearoyl tails) are not soluble in squalene. Alternatively, solubility can be determined according to the amount of lipids, which is dissolved in a certain amount of oil to form a saturated solution.
As noted above, the concentration of a lipid described above is determined based on the initial amount of lipid that is used to prepare the emulsions. It is understood in the art that the actual concentration of the oil in the final product (for example, a sterile packaged emulsion, which is ready for administration) may be slightly lower, sometimes at about 20%. C. Additional Components
The cationic oil in water reactions described herein may further comprise additional components. For example, emulsions may contain components that can promote particle formation, improve the complexation between negatively charged molecules and cationic particles, or increase the stability of the negatively charged molecule (for example, to prevent degradation of an RNA molecule ). Surfactants
In certain embodiments, the oil emulsion particles in cationic water further comprise a surfactant.
A substantial number of surfactants have been used in the pharmaceutical sciences. These include materials of natural origin, such as tree gums, vegetable proteins, sugar-based polymers like alginates and cellulose, and the like. Determined oxipolymers or polymers having a hydroxide or other hydrophilic substituent on the carbon backbone have surfactant activity, for example, povidone, polyvinyl alcohol, and mono- and polyfunctional glycol ether-based compounds. The compounds derived from long-chain fatty acids form a substantial third group of emulsifying agents and suspending agents that can be used in the present invention.
Specific examples of suitable surfactants include the following: 1. Water-soluble soaps, such as the sodium, potassium, ammonium and alkanol-ammonium salts of higher fatty acids (C] 0_C22), in particular, sodium and tallow with potassium and coconut. 2. Anionic synthetic non-soap surfactants, which can be represented by the water-soluble salts of ■ 15 organic sulfuric acid reaction products having in their molecular structure an alkyl radical containing from 8 to 22 carbon atoms and a radical selected from from the group consisting of sulfonic acid radicals and sulfuric acid esters. Examples of these are the 20 sodium or potassium alkyl sulfates, derived from tallow or coconut oil; alkyl benzene sodium or potassium sulfonates; alkyl glyceryl sodium ether sulfonates; sulfates and sulfonates of monoglyceride fatty acids from sodium coconut oil; sodium or potassium salts 25 of sulfuric acid esters of the reaction product of one mole of a higher fatty alcohol and about 1 to 6 moles of ethylene oxide; alkyl phenol ethyl oxide ether sulfonates of sodium or potassium, with 1 to 10 ethylene oxide units per molecule and in which the alkyl radicals contain 8 to 12 carbon atoms; the reaction product of fatty acids esterified with isethionic acid and neutralized with sodium hydroxide; sodium or potassium salts of a fatty acid amide of a methyl tauride, and the sodium and potassium salts of S-sulfonated C10-C24 α-olefins. 3. Non-ionic synthetic surfactants produced by the condensation of alkylene oxide groups with a hydrophobic organic compound. Typical hydrophobic groups include condensation products of propylene oxide with 10 propylene glycol, alkyl phenols, condensation products of propylene oxide and ethylene diamine, aliphatic alcohols having 8 to 22 carbon atoms, and fatty acid amides. 4. Non-ionic surfactants, such as amine oxides, phosphine oxides and sulfoxides, having - 15 semipolar characteristics. Specific examples of tertiary long chain amine oxides include dimethyldodecylamine oxide and bis- (2-hydroxyethyl) dodecylamine. Specific examples of phosphine oxides are found in U.S. Patent No. 3,304,263, issued February 14, 20, 3967, and include dimethyldodecylphosphine oxide and dimethyl (2-hydroxydecyl]) phosphine oxide. 5. Long chain sulfoxides, including the 19 19 corresponding to formula R -SO-R in which R and R are substituted or unsubstituted alkyl radicals, the latter 25 containing from about 10 to about 28 carbon atoms, while that R "contains from 1 to 3 carbon atoms. Specific examples of these sulfoxides include dodecyl methyl sulfoxide and 3-hydroxy tridecyl methyl sulfoxide. 6. Ampholytic surfactants, such as 3-30 sodium dodecLlaminopropionate and 3-dodecylaminopropane south surfactant sodium 7. Synthetic Zwitterionic surfactants, such as 3 - (N, N-dimethyl-N-hexadecylammonium) propane-1-sulfonate and 3- (N, N-dimethyl-N-hexadecylammonium) -2-hydroxy-propane -l- sulfone to.
In addition, all of the following types of surfactants can be used in a composition of the present invention: (a) soaps (i.e., alkali metal salts) of fatty acids; rosin acids, and tall oil, (b) alkyl arene sulfonates; (c) alkyl sulfates including surfactants with branched and straight chain hydrophobic groups, as well as primary and secondary sulfate groups; (d) sulfates and sulfonates containing an intermediate bond between hydrophobic and hydrophilic groups, such as fatty acylated methyl taurides and fatty sulfated monoglycerides; (e) esters of long chain polyethylene glycol acids, especially tall oil esters; (f) polyethylene glycol ethers of alkyl phenols; (g) polyethylene glycol ethers of long-chain alcohols and mercaptans; and (h) acyl-diethanol fatty amides. Since surfactants can be classified in more than one way, several classes of surfactants set out in this paragraph coincide with classes of surfactants previously described.
There are a number of surfactants specifically designed for and commonly used in biological situations. These surfactants are divided into four basic types: anionic, cationic, zwitterionic (amphoteric), and non-ionic. Examples of anionic surfactants include, for example, perfluorooctanoate (PEOA or PFO), ■ perfluorooctanesulfonate (PFOS), alkyl sulfate salts, such as sodium dodecyl sulfate (SDS) or ammonium lauryl sulfate, sodium laureth sulfate (also known as sodium lauryl ether sulfate, SLES), 5 alkyl benzene sulfonate, and fatty acid salts. Examples of cationic surfactants include, for example, alkylthimethylammonium salts, such as cetyl trimethylammonium bromide (CTAB or hexadecyl trimethyl ammonium bromide), cetylpyridinium chloride (CPC), polyethylene] tallow amine (POEA), chloride benzalkonium (BAC), benzene chloride (BZT). Examples of zwitterionic (amphoteric) surfactants include, betaine, for example, dodecyl, cocamidopropyl betaine, and coconut glyphate anfo. Examples of nonionic surfactants include, for example, poly - 15 alkyl (ethylene oxide), poly (phenylene alkyl) alkyl, poly (ethylene oxide) copolymers and poly (propylene oxide) (commercially called poloxamers or poloxamines) ), AAYL polyglucosides (eg octylglucoside or decyl maltoside), fatty alcohols (eg 20 cetyl alcohol or oleyl alcohol), MEA cocamide, DEA cocamide, Pluronic® F-68 (polyoxyethylene-polyoxypropylene copolymer block), and the polysorbates, such as Tween 20 (polysorbate 20), Tween 80 (polysorbate 80; polyoxyethylene monooleate), dodecyl-25-dimethylamine oxide, and tocopherol vitamin E propylene glycol succinate (Vitamin E TPGS).
A particularly useful group of surfactants are sorbitans based on nonionic surfactants. These surfactants are prepared by dehydrating sorbitol 30 to generate 1,4-sorbitan, which is then reacted with one or more equivalents of a fatty acid. The substituted fatty acid radical can be further reacted with ethylene oxide to generate a second group of surfactants.
Fatty acid-substituted sorbitan surfactants are produced by reacting 1,4-sorbitan with a fatty acid such as lauric acid, palmitic acid, stearic acid, oleic acid, or a similar long-chain fatty acid to generate the monoester 1,4-sorbitan, 1,4-sorbitan sesquiester or 1,4-sorbitan triester. Common names for these surfactants include, for example, sorbitan monolaurac, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan sesquioleate and sorbitan trioleate. These surfactants are available commercially under the name SPAN® or ARLACEL®, usually with a letter or number designation that distinguishes between the various mono-, di- and triesters of substituted sorbitans.
SPAN® and ARLACEL® surfactants are hydrophilic and are generally soluble or dispersible in oil. They are also soluble in most organic solvents. In water they are generally insoluble, but dispersible. Generally these surfactants will have a hydrophilic-lipophilic balance (HLB) number of 1.8 to 8.6. These surfactants can be easily made by means known in the art or are commercially available.
A related group of surfactants comprises olioxethylene sorbitan monoesters and olioxiet triester, leno sorbitan. These materials are prepared by adding ethylene oxide to a 1,4-sorbitan monester or triester. The addition of polyoxyethylene converts the lipophilic sorbitan mono- or triester surfactant to a hydrophilic surfactant generally soluble or dispersible in water and soluble to varying degrees in organic liquids.
These materials, commercially available under the brand name TWEEN®, are useful for the preparation of oil-in-water emulsions and dispersions or for the solubilization of oils and the production of anhydrous water-soluble or washable ointments. TWEEN® surfactants can be combined with a respective triester surfactant or sorbitan monester to promote emulsion stability. TWEEN® surfactants generally have an HLB value between 9.6-16.7. TWEEN® surfactants are commercially available.
A third group of non-ionic surfactants that can be used individually or in conjunction with SPANS, ARLACEL® and TWEENS surfactants are polyoxyethylene fatty acids produced by reacting ethylene oxide with a long chain fatty acid. The most common surfactant available of this type is solid under the name MYRJS® and is a polyoxyethylene derivative of stearic acid. MYRJ® surfactants are hydrophilic and soluble or dispersible in water, like TWEEN® surfactants. MYRJ® surfactants can be mixed with TWEEN® surfactant or with mixtures of TWEEN® / SPAN® or ARLACEL® surfactants for use in forming emulsions. MYRJ® surfactants can be prepared by methods known in the art or are commercially available.
A fourth group of polyoxyethylene based on nonionic surfactants are the polyoxyethylene fatty acid ethers derived from lauryl, acetyl, stearyl and oleyl alcohols. These materials are prepared as above by adding ethylene oxide to a fatty alcohol. The commercial name for these surfactants is BRIJ®. BRIJ® surfactants can be hydrophilic or lipophilic, depending on the size of the polyoxyethylene fraction in the surfactant. Although the preparation of these compounds is available from the art, it is also readily available from commercial sources.
Other nonionic surfactants that can potentially be used are, for example, polyoxyethylene, polyol fatty acid esters, polyoxyethylene ethers, polyoxyethylene fatty ethers, beeswax derivatives containing polyoxyethylene, polyoxyethylene lanolin derivative, polyoxyethylene fatty glycerides , glycerol fatty acid esters or other polyoxyethylene acid alcohols or long chain fatty acid ether derivatives of 12-22 carbon atoms.
As the emulsions and formulations of the invention are intended to be multiphase systems, it is preferable to choose an emulsion-forming nonionic surfactant that has an HLB value in the range of about 7 to 16. This value can be obtained by use of a single non-ionic surfactant such as a TWEEN® surfactant or can be achieved through the use of a mixture of surfactants such as a surfactant based on mono- di- or sorbitan triester; a sorbitan ester polyoxyethylene fatty acid, a sorbitan ester in combination with a surfactant derived from lanoxy polyoxyethylene, a sorbitan ester surfactant in combination with a high HLB polyoxyethylene fatty ether surfactant.e or a surfactant .and polyethylene fatty ether or polyoxyethylene sorbitan fatty acid.
In certain. embodiments, the emulsion comprises a single non-ionic surfactant, more particularly, a TWEEN® surfactant, such as an emulsion non-ionic surfactant. In an exemplary embodiment, the emulsion comprises TWEEN® 80, also known as polysorbate 80 or polyoxyethylene 20 sorbiran monooleate. In other embodiments, the emulsion comprises two or more nonionic surfactants, in particular, a TWEEN® surfactant and a SPAN® surfactant. In an exemplary embodiment, the emulsion comprises TWEEN®80 and SPAN®85.
Oil-in-water emulsions may contain from - 15 0.01% to about 2.5% surfactant (v / v or w / v), about 0.01% to about 2% surfactant, 0.01% to about 1.5% surfactant, 0.01% to about 1% surfactant, about 0.01% to 0.5% surfactant, 0.05% to about 0.5 % surfactant, 0.08% to about 0.5% surfactant, about 20 0.08% surfactant, about 0.1% surfactant, about 0.2% surfactant, about 0, 3% surfactant, about 0.4% surfactant, about 0.5% surfactant, about 0.6% surfactant, about 0.7% surfactant, about 0.8% surfactant, about 0.9% surfactant, or about 1% surfactant.
Alternatively, or in addition, oil-in-water emulsions may contain from 0.05% to about 1%, 0.05% to about 0.9%, 0.05% to about 0.8%, 0.05% to about 0.7%, 0.05% to about 0.6%, 0.05% to about 0.5%, about 0.08%, 30 about 0.1% , about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1% Tween 80 (polysorbate 80; polyoxyethylene monooleate).
In an exemplary embodiment, the oil-in-water emulsion contains 0.08% Tween 80.
Alternatively, or in addition, oil-in-water emulsions may contain from 0.05% to about 1%, 0.05% to about 0.9%, 0.05% to about 0.8%, 0.05% to about 0.7%, 0.05% to about 0.6%, 0.05% to about 0.5%, about 0.08%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1% SPAN85 (sorbitan trioleate).
Alternatively, or in addition, oil-in-water emulsions may contain a combination of surfactants described herein. For example, a combination of Tween 80 (polysorbate 80; polyoxyethylene monooleate) and SPAN85 (sorbitan trioleate) can be used. Emulsions can contain various amounts of Tween80 and SPAN85 (for example, those exemplified above), including equal amounts of these surfactants. For example, oil-in-water emulsions may contain about 0.05% Tween80 and about 0.05% SPAN8 5, about 0.1% Tween 80 and about 0.1% S PAN 8 5, about 0.2% Tween 80 and about 0.2% SPAN85, about 0.3% Tween 80 and about 0.3% SPAN85, about 0.4% Tween 80 and about 0.4% S PAN 8 5, about 0.5% Tween 80 and about 0.5% SPAN85, about 0.6% Tween 80 and about 0.6% SPAN85 , about 0.7% Tween 80 and about 0.7 SPAN85%, about 0.8% Tween 80 and about 0.8% SPAN85 about 0.9% Tween 80 and about 0 , 9% SPAN85, or about 1% Tween 80 and about 1.0% SPAN85. olylethylene glycol (PEG) -lipids, such as PEG coupled to dialkyloxypropyl (PEG-DAA), PEG attached to diacylglycerol (DAG-PEG), PEG coupled to phosphatidiiethanolamine (PE) (PEG-PE), or some other phospholipids (PEG-phospholipids), PEG conjugated to ceramides (PEG-Cer), or a combination thereof, can also be used as surfactants (see, for example, US Patent Nos. 5,885,613 ,. Patent Application publications US No. 2003/0077829, 2005/0175682 and 2006/0025366). Other suitable PEG-lipids include, for example, PEG-dialkyloxypropyl (DAA) lipids or PEG-diacylglycerol (DAG) lipids. Examples of PEG-DAG lipids include, for example, PEG-dilauroylglycerol- (C12) lipids, PEG-dimiristoylglycerol- (C14) lipids, PIP-dipalmitoylglycerol- (Cie) lipids, or PEG-distea ríglycerol (Ci8) lipids. Examples of PEG-DAA lipids include, for example, PEG-dilauroyloxypropyl (C14) lipids, PEG-dimyristyloxypropyl (C14) lipids, PEG-dipalmityloxypropyl (Cis) lipids, or PEG-distearyloxypropyl (Cig) lipids.
PEGs are classified by their molecular weights, for example, PEG 2000 has an average molecular weight of about 2,000 daltons, and PEG 5000 has an average molecular weight of about 5,000 daltons. PEGs are commercially available from Sigma Chemical Co., as well as other companies and include, for example, the following: monomethoxypolyethylene glycol (MePEG-OH), monomethoxypolyethylene glycol succinate (MePEG-S), succinimidyl glycol succinate monomethoxypolyethylene (MePEG-S-NHS), monomethoxypolyethylene glycol-amine (MePEG-NH2), monomethoxypolyethylene tresylate (MePEG-TRES; and glycol-imidazolyl-carbonyl monomethoxypolyethylene (MePEG-IM). CH2COOH), is particularly useful for the preparation of PEG-lipid conjugates, including, for example, PEG-DAA conjugates.
Preferably, PEG has an average molecular weight of about 1000 to about 5000 daltons (for example, PEGiooo, PEG2OOO, PEG3000, PEG4000, PEG5000) • PEG can be optionally substituted by an alkyl, alkoxy, acyl or aryl group. PEG can be conjugated directly to the lipid or it can be linked to the lipid, through a linker fraction. Any suitable linker moiety to couple the PEG to a lipid can be used, including, for example, the linker fractions containing non-ester and linker fractions containing ester.
In exemplary embodiments, PEG2QOOPE, PEG5OOQPE, PEGKJCO ^ MG, PEG2OOODMG, PEG30OODMG, OR a combination thereof is used as a surfactant. In certain exemplary embodiments, the oil-in-water emulsion contains between about 1 mg / ml to about 80 mg / ml PEG2000PE, PEG5000PE, PEGIQOQDMG, PEG2OO () BMG OR PEG3000DMG. Phospholipids
In certain embodiments, the oil emulsion particles in cationic water further comprise a phospholipid.
Phospholipids are the esters of fatty acids in which the alcohol component of the molecule contains a phosphate group. Phospholipids include glycerophosphatides (containing glycerol) and sphingomyelin (containing sphingosine). Exemplary phospholipids include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and sphingomyelin; and synthetic phospholipids comprising 5 dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, distearoyl phosphatidylglycerol dipalmitoyl phosphatidylglycerol, dimiristoyl phosphatidylserine, distearoyl and distearoyl phosphorylate.
The following exemplary phospholipids can be used.


In certain embodiments, the use of a neutral lipid may be advantageous. It may also be advantageous to use a phospholipid, including a zwitterionic phospholipid, for example, a phospholipid containing one or more alkyl or alkenyl radicals of about 12 to about 22 carbons in length (for example, about 12 to about 14, about 16, about 18, about 20, about 22 carbon atoms), the radicals of which may contain, for example, 0 to 1 to 2 to 3 double bonds. It may be advantageous to use a zwitterionic phospholipid.
Preferred phospholipids include, for example, 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE), egg phosphatidylcholine (egg PC), palmitoyl oleoyl phosphatidylcholine (POPC), dimyristoyl phosphatidylcholine (DMPC), dichloyl phosphate DOPC), DPPC, dipalmitoyl phosphatidylcholine (DPPC), palmitoyl phosphatidylcholine linoleyl (PLPC), DPyPE, or a combination thereof.
In certain embodiments, the phospholipid is DOPE. The oil in water cationic emulsion can comprise from about 0.1 mg / ml to about 20 mg / ml DOPE. For example, the oil in water cationic emulsion may comprise DOPE of less than about 0.5 mg / ml to about 10 mg / ml, from about 0.1 mg / ml to about 10 mg / ml, or from about 1.5 mg / ml to about 7.5 mg / ml DOPE.
In an exemplary embodiment, the oil-in-cationic water emulsion comprises about 1.5 mg / ml DOPE.
In certain embodiments, the phospholipid is egg PC. The oil-in-cationic water emulsion may comprise from about 0.1 mg / ml to about 20 mg / ml egg PC. For example, the oil in water cationic emulsion may comprise egg PC from about 0.1 mg / ml to about 10 mg / ml, from about 1.0 mg / ml to about 10 mg / ml, or from about 1.5 mg / ml to about 3.5 mg / ml of egg PC.
In an exemplary embodiment, the oil in water cationic emulsion comprises about 1.55 mg / ml egg PC.
In certain embodiments, the phospholipid is DPyPE. The cationic oil-in-water emulsion may comprise from about 0.1 mg / ml to about 20 mg / ml of DPyPE. For example, the oil in water cationic emulsion may comprise DPyPE at about 0.1 mg / ml to about 10 mg / ml, from about 1.5 mg / ml to about 10 mg / ml, or about from 1.5 mg / ml to about 5 mg / ml DPyPE.
In an exemplary embodiment, the oil in water cationic emulsion comprises about 1.6 mg / ml of DPyPE.
In certain embodiments, the emulsion particles may comprise a combination of a surfactant and a phospholipid described herein. D. Water phase (continuous phase)
The aqueous phase (continuous phase) of oil-in-water emulsions is a buffered saline solution (for example, saline), or water. The buffered saline is an aqueous solution comprising a salt (eg NaCl), a buffer (eg a citrate buffer), and may further comprise an osmolality-adjusting agent (eg, a saccharide), a polymer, a surfactant, or a combination thereof. If emulsions are formulated for parenteral administration, it is preferable to make final buffered solutions so that the tonicity, that is, the osmolality is essentially the same as normal physiological fluids in order to avoid undesirable consequences after administration, such as as rapid absorption or expansion of the composition after administration. It is also preferable to buffer the aqueous phase in order to maintain a pH compatible with normal physiological conditions.
In addition, in certain cases, it may be desirable to maintain the pH at a particular level in order to ensure the stability of certain components of the emulsion.
For example, it may be desirable to prepare an emulsion, 25 which is isotonic (i.e., the same permeable solute concentration (e.g., salt) as normal body and blood cells) and isosmotic. To control tonicity, the emulsion may comprise a physiological salt, such as a sodium salt. Sodium chloride (NaCl), for example, can be used at about 0.9% (w / v) (physiological saline). Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate, magnesium chloride, calcium chloride, etc. Nonionic tonicity agents can also be used to control tonicity. A number of nonionic tonicity modifying agents are commonly known to those skilled in the art. These are typically carbohydrates of various classifications (see, for example, Voet and Voet (1990) Biochemistry (John Wiley & 10 Sons, New York). Monosaccharides classified as aldoses such as glucose, mannose, arabinose, and ribose, as well such as those classified as ketosis, such as fructose, sorbose, and xylulose, can be used as non-ionic tonicity agents in the present invention Disaccharides 15 such as sucrose, maltose, trehalose, lactose and can also be used. (acyclic polyhydroxy alcohols, also referred to as sugar alcohols), such as glycerol, mannitol, xylitol, and sorbitol are nonionic tonicity agents useful in the present invention. Nonionic tonicity modifying agents may be present in a concentration of about 0.1% to about 10% or about 1% to about 10%, depending on the agent that is used.
The aqueous phase can be buffered. Any physiologically acceptable buffer 25 can be used in the present invention, such as water, citrate buffers, phosphate buffers, acetate buffers, Tris buffers, bicarbonate buffers, carbonate buffers, succinate buffer, or the like. The pH of the aqueous component will preferably be between 6.0-8.0, preferably at about 6.2 and about 6.8. In an exemplary embodiment, the buffer is 10 mM citrate buffer with a pH of 6.5. In another exemplary embodiment, the aqueous phase is either the buffer prepared using water-free RNase or water treated with DEPC. In some cases, the high amount of salt in the buffer can interfere with the complexation of the negatively charged molecule into the emulsion particle, therefore, it is avoided. In other cases, a certain amount of salt in the buffer may be included.
In an exemplary embodiment, the buffer is 10 mM citrate buffer with a pH of 6.5. In another exemplary embodiment, the aqueous phase is, or the buffer is, prepared using water-free RNase and water-treated DEPC.
The aqueous vessel can also comprise additional components, such as molecules that alter the osmolarity of the aqueous phase, or molecules that stabilize the negatively charged molecule after complexation. Preferably, the osmolarity of the aqueous phase is adjusted using a nonionic toning agent, such as sugar (eg trehalose, sucrose, dextrose, fructose, reduced palatinose, etc.), a sugar alcohol (such as mannitol , sorbitol, xylitol, erythritol, lactitol, glycerol, maltitol, etc.), or combinations thereof. If desired, a nonionic polymer (for example, a (polyalkyl) glycol such as polyethylene glycol, polypropylene glycol, or polybutylene glycol) or nonionic surfactant can be used.
In some cases, unadulterated water may be preferred as the aqueous phase of the emulsion when the emulsion is initially prepared. For example, increasing the salt concentration may make it more difficult to achieve the desired particle size (for example, less than about 200 nm).
In certain embodiments, the aqueous phase of the oil emulsion in cationic water may further comprise a polymer or a surfactant, or a combination thereof. In an exemplary embodiment, the oil-in-water emulsion contains a polaxamer. Poloxamers are non-ionic triblock copolymers having a hydrophobic polyoxypropylene (poly (propylene oxide)) chain flanked by two hydrophilic polyoxyethylene (poly (ethylene oxide)) chains. Poloxamers are also known by the trade names of Pluronic® polymers. Poloxamer polymers can lead to increased stability and resistance to increased RNase of the RNA molecule after RNA complexation.
Alternatively, or in addition, the oil-in-cation water emulsion may comprise from about 0.1% to about 20% (w / v) of polymer, or from about 0.05% to about 10% ( w / v) polymer. For example, the oil-in-cationic water emulsion may comprise a polymer (for example, a Pluronic® poloxamer such as F127), from about 0.1% to about 20% (w / v), from about 0, 1% to about 10% (w / v), from about 0.05% to about 10% (w / v), or from about 0.05% to about 5% (w / v).
In an exemplary embodiment, the oil-in-water emulsion comprises about 4% (w / v), or about 8% (w / v) of Pluronic® El 27.
The amount of the aqueous component used in these compositions will be the amount necessary to bring the value of the composition to the unit. That is, an amount of aqueous component sufficient to cause 100% to be mixed with the other components listed above, in order to bring the compositions to the desired volume. 4. MOLECULES LOADED NEGATIVELY
When a negatively charged molecule must be emitted, it can be complexed with the particles of the oil-in-cation water emulsion. The negatively charged molecule is complexed with the particles of the emulsion, for example, the interactions between the negatively charged molecule and the cationic lipid on the surface of the particles, as well as the hydrophobic / hydrophilic interactions between the negatively charged molecule and the surface of the particles. Although not intended to stick to any particular theory, it is believed that negatively charged molecules interact with the cationic lipid through interactions of non-covalent ionic charges, (electrostatic forces), and the strength of the complex, as well as the amount of the negatively charged compound that can be complexed with a particle is related to the amount of cationic lipid in the particle. In addition, hydrophobic / hydrophilic interactions between the negatively charged molecule and the surface of the particles can also play an important role.
Examples of negatively charged molecules include negatively charged peptides, polypeptides or proteins, nucleic acid molecules (for example, single or double-stranded DNA or RNA), small molecules (for example, immune enhancers (SMTPs), phosphonate, fluorophosphonate, etc.) and the like. In preferred aspects, the negatively charged molecule is an RNA molecule, such as an RNA that encodes self-replicating RNA molecules including a protein, peptide, polypeptide or a small interfering RNA.
The complex can be formed by techniques known in the art, examples of which are described herein. For example, a nucleic acid-particuia complex can be formed by mixing a cationic emulsion with the nucleic acid molecule, for example, by vortexing. The amount of the negatively charged molecule and cationic lipid in the emulsions can be adjusted or optimized to provide a desired bond strength and bonding capacity.
For example, as described and exemplified in the present invention, examples of RNA-particle complexes were produced by varying the RNA: cationic lipid ratios (as measured by the "N / P ratio"). The N / P ratio refers to the amount (moles) of protonable nitrogen atoms in the cationic lipid divided by the amount (moles) of phosphates in the RNA. Preferred N / P ratios are from about 1: 1 to about 20: 1, from about 2: 1 to about 18: 1, from about 3: 1 to 16: 1, about 4: 1 to about 14: 1, about 6: 1 to about 12: 1, about 3: 1, about 4: 1, about 5: 1, about 6: 1, about 7 : 1, about 8: 1, about 9: 1, about 10: 1, about 11: 1, about 12: 1, about 13: 1, about 14: 1, about 15: 1, or about 16: 1. Alternatively, the preferred N / P ratios are at least about 3: 1, at least about 4: 1, at least about 5: 1, at least about 6: 1, at least about 7: 1, at least about 8: 1, at least about 9: 1, at least about 10: 1, at least about 11: 1, at least about 12: 1, at least about 13: 1, at least about 14: 1, at least about 15: 1, or at least about 16: 1. The most preferred N / P ratio is about 4: 1 or more.
Each emulsion can have its own ideal or preferred N / P ratio to produce the desired effects (for example, the desired level of expression of complexed RNA), 10 which can be determined experimentally (for example, using assays, such as as described herein, or other techniques known in the art, such as measuring the level of expression of a protein that is encoded by RNA, or measuring the percentage of RNA molecules to be released from the complex in the presence of heparin) . Generally, the N / P ratio should be at a value that is at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35 %, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85 % o, about 90%, or about 95% of the RNA molecules are released from the RNA-particle complexes when the RNA-particle complexes are absorbed by the cells. An N / P ratio of at least 25 4: 1 is preferred.
The cationic oil-in-water emulsions described here are the a: i ::: A! Le armen suitable for the formulation of nucleic acid-based vaccines (eg DNA vaccines, RNA vaccines). The formation of an emulsion nucleic acid-particle complex facilitates the absorption of nucleic acid in host cells, and protects the nucleic acid molecule from nuclease degradation. The transected cells can then express the antigen encoded by the nucleic acid molecule, which can produce an immune response to the antigen. Like live or attenuated viruses, nucleic acid-based vaccines can effectively involve both MHC-I and MHC-II pathways that allow the induction of CD8 + and CD4 + T cell responses, while the antigen present in soluble form, such as recombinant protein, usually induces only antibody responses.
The sequence of the RNA molecule can be codon optimized or de-optimized for expression in a desired host, such as a human cell.
In certain embodiments, the negatively charged molecule described herein is an RNA molecule. In certain embodiments, the RNA molecule encodes an antigen (peptide, polypeptide or protein) and the oil emulsion in cationic water is suitable for use as an RNA-based vaccine. The composition can contain more than one RNA molecule encoding an antigen, for example, two, three, five or ten RNA molecules that are complexed with the emulsion particles. That is, the composition can contain one or more different species of RNA molecules, each encoding a different antigen. Alternatively or add J, a RNA molecule may also encode more than an antigen, for example, a biconic, or tristristronic RNA molecule encoding different or identical antigens. Therefore, the oil-in-cationic water emulsion is suitable for use as an RNA-based vaccine that is monovalent or multivalent.
The sequence of the RNA molecule can be modified, if desired, for example, to increase the efficiency of RNA expression or replication, or to provide additional stability or resistance to degradation. For example, the RNA sequence can be modified with respect to its use of the codon, for example, to increase the translation and half-life efficiency of the RNA. The poly-A tag (for example, from about 30 residues of adenosine 10 or more) can be attached to the 3 'end of the RNA to increase its half-life. The 5 'end of the RNA can be leveled with a modified ribonucleotide with the m7G (5') ppp (5 ') N structure (cap 0 structure) or a derivative thereof, which can be incorporated during RNA synthesis or can be enzymatically engineered after RNA transcription (for example, through the use of Vaccinia virus leveling enzyme (VCE) consisting of mRNA triphosphatase, guanylyl transferase and guanine-7-methyltransferase, which catalyzes the construction of cap structures 0 N7 -monomethylated). The Cap 0 structures play an important role in maintaining the stability and effectiveness of the translation of the RNA molecule. The 5 'cap of the RNA molecule can be added.) Mostly modified by a 2' -O-methyltransferase which results in the generation of a cap 1 25 structure (m7Gppp [m2'-O] N), the which can furthermore increase translation efficiency.
If desired, the RNA molecule can comprise one or more modified nucleotides. This can be in addition to any 5 'cap structure. There are more than 96 30 naturally occurring nucleoside modifications found in mammalian RNA. See, for example, Limbach et al., Nucleic Acids Research, 22 (12): 2183-2196 (1994). Preparations of nucleotides and modified nucleotides and nucleosides are well known in the art, for example, from US Patent Nos. 4,373,071, 4,458,066, 4,500,707, 4,668,777, 4,973,679, 5,047,524, 5,132,418, 5,153,319, 5,262,530, 5,700,642 all of which are incorporated by reference in their entirety in this document, and many modified nucleosides and modified nucleotides are commercially available.
The modified nucleobases that can be incorporated into modified nucleosides and nucleotides and be present in RNA molecules include: m5C (5-methylcytidine), m5U (5-methyluridine), m6A (N6-methyladenosine), s2U (2-thiouridine), Um (2'-O-methyluridine), mlA (1-methyladenosine); m2A (2-methyladenosine); Am (2-1-O-methyladenosine); ms2m6A (2-methylthio-N6-methyladenosine); io6A (N6-isopentenyladenosine); ms2i6A (2-methylthio-N6-isopentenyladenosine); io6A (N6- (cis-hydroxy-isopentenyl) adenosine); ms2io6A (2-methyl-thio-N6- (cis-hydroxy-isopentenyl) adenosine); g6A (N6-glycine.Lcarbamoyladenosine); t6A (N6-threonyl carbamoyladenosine); ms2t6A (2-methyl-thio-N6-threonyl carbamoylamidine); m6t6A (N6-methyl-N6-treoni 1 carbarnori ladenosine); hn6A (N6-hydroxy-norvalylcarbamoyl adenosine); ms2hn6A (2-methyl-thio-N6-hydroxy-norvalyl carbamoyladenosine); Ar (p) (2 "-O-ribosi1adenosine (phosphate)); I (inosine); mil timet 4 L1nosine); m'lm (1,2 '-O-dimethylinosine); m3C (3-methyldinine) ); Cm (2T-0-methylcytidine); s2C (2-thiocyltidine); ac4C (N4-acetylcytidine); f5C (5-phonylcytidine); m5Cm (5.2-0-dimethylcytidine); ac4Cm (N4-acetyl) '1 2T0metj Icitidina); K2C (lysidine); mlG (1-methylguanosine); m2G (N2-methylguanosine); m7G (7-methylguanosine); Gm (2'-O-methylguanosine); m22G (N2, N2-dimethylguanosine) ; m2Gm (N2,2'-O-dimethylguanosine); m22Gm (N2, N2,2'-O-trimethylguanosine); Gr (p) (2'-0-ribosylguanosine (phosphate)); yW (wybutosine); o2yW ( peroxy-wybutosine); OHyW (hydroxy-wybutosine); OHyW * (modified hydroxy-wybutosine); imG (wyosine); mimG (methylguanosine); Q (queuosine); oQ (epoxy-queuosine); galQ (galtactosyl-queuosine); manQ (mannosyl-queuosine); price (7-cyano-7-deazaguanosine); preQi (7-aminomethyl-7-deazaguanosine); G * (arqueoosine); D (dihydrochloridine); m5Um (5,2'-O-dimethyluridine) ); s4U (4-thiouridine); m5s2U (5-methyl-2 -triouridine); s2Um (2-thio-2'-O-methyluridine); acp3U (3- (3-amino-3-carboxy-propyl) -uridine); ho5U (5-hydroxy-uridine); mo5U (5-methoxyuridine); cmo5U (uridine 5-20 oxyacetic); mcmo5U (5-oxyacetic uridine methyl ester); chm5U (5- (carboxyhydroxy-methyl) uridine)); mchm5U (5- (carboxyhydroxy-methyl) uridine methyl ester); mcm5U (5-methoxy-carbonyl-methyluridine); mcm5Um (S-rnetc'x i carbon i J me'i. I-2-O-methyluridine); mcm5s2U (5-25 methoxycarboni.; - 2-thiouridine); nm5s2U (5-aminomethyl-2-thiounidine); mnm5U (5-methylaminomethyluridine); mnm5s2U (5-methylaminomethyl-2-thiouridine); mnm5se2U (5-methylaminomethyl-2-Lenou ri d.i na); ncm5U (5-carbamoylmethyl uridine); ncm5Um (5-carbamoyl-2'-O-methyluridine); cmnm5U (5-carboxymethylamethyluridine); cnmm5Um (5-carboxymethylamine 1 -2-L-u.ridine Omethyl); cmnm5s2U (5-carboxymethyl Lnome t i ..! -2-1iouridina); m62A (N6, N6-dimethyladonosine); Tm (2'-O-methylinosine); m4C (N4-methylethylidine); m4Cm (N4,2-0-dimethylcytidine); hm5C (5-hydroxy.-myileiuidine); m3U (3-methyluridine); cm5U (5-carboxymethyluridine); ■ mβAm (N6, T-O-dimethyladenosine); rn62Am (N6, N6,2-0-trimethyladenosine); m2'7G (N2,7-dimethyguanosine); m2'2'7G (N2, N2,7-trimethylguanosine); m3Um (3,2T-O-dimethyluridine); m5D (5-methyldihydrouridine); f5Cm (5-formi .1-2'-O-methylcytidine); mlGm (1,2'-0-dimethylguanosine); m'Am (1,2-0-dimethyl adenosine) irinomethyluridine); tm5s2U (S-taurinomethyl-2-thiouridine)); imG-14 (4-demethyl guanosine); imG2 (Isoguanosine); acβA (N6-acetyl-adenosine), hypoxanthine, inosine, 8-oxo-adenine, its 7-substituted derivatives, dihydrouracil, pseudouracilíi, 2-t iouracila, 4-thiouracila, 5-aminouracila, 5- (CA -C; 0 -alkyluracil, 5-methyluracil, 5- (C2-C6) - alkenyl.lurac11, 5- (C2 ~ C6) -alkynyluracil, 5- (hydroxymethyl) uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxy-cytosine, 5- (C1-Cg) -alkylcytosine, 5-methylcytosine, 5- (C2-C6) -alkenyl cytosine, 5- (C2-C6) - alquin.i.lcitosi na, 5 -chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N2-dimethylguanine, 7-deazaguanine, 8-azaguanine, 7-deaza-7-substituted guanine, 7-deaza-7- (C2 ~ Cfi) to i.qu i. ni Iquanine, substituted 7-deaza-8-guanine, 8-hydroxy i-guanine, 6-thioguanine, 8-oxoguanine, 2-aminopurine, 2-amino-G-chloropurine, 2,4-diaminopurine, 2 , 6- dianiinopurine, 8-azapurine, substituted 7-deazapurine, substituted 7-deaza-7-purine, substituted 7-deaza-8-purine, hydrogen (abasic residue), m5C, m5U, m6A, s2U, W, or 2 '- 0-methyl-U. of these modified nucleobases and their corresponding ribonucleosides are available from commercial suppliers. See, for example, WO 2011/005/99 which is incorporated herein by reference.
The RNA used with the invention preferably includes only phosphodiester bonds between the nucleosides but, in some embodiments, may contain phosphoramidate, phosphorothioate and / or methylphosphonate bonds.
In some embodiments, the RNA molecule does not include modified nucleotides, for example, it does not include modified nucleobases, and all nucleotides in the RNA molecule are standard A, U, G and C standard ribonucleotides, with the exception of an optional 5 'cap which may include, for example, 7-methylguanosine. In other embodiments, the RNA can include a 5 'cap comprising a 7'-methylguanosine, and the first 1,2 or 3,5'-ribonucleotides can be methylated at the 2'-position of the ribose. A. Self-replicating RNA
In some respects, the cationic oil-in-water emulsion contains a self-replicating RNA molecule. In certain embodiments, the self-replicating RNA molecule is derived from, or based on, an alphavirus.
Self-replicating RNA molecules are well known in the art and can be produced by using replication elements derived from, for example, alphavirus, and replacing viral structural proteins with a nucleotide sequence that encodes a protein of interest. The self-replicating RNA molecule is typically a ribbon molecule - (+) that can be directly translated after distribution to a cell, and this translation provides an RNA-dependent RNA polymerase that then produces antisense and sensory transcripts from the RNA distributed. Thus, the distributed RNA leads to the production of multiple child RNAs. These child RNAs, as well as collinear subgenomic transcripts, can be translated by themselves to provide in situ expression of a coded antigen, or can be transcribed to provide additional transcripts with the same sense as the distributed RNA that are translated to provide the expression in situated antigen. The overall results of the present transcription sequence is an enormous amplification in the number of replicon RNAs introduced so that the encoded antigen becomes a major polypeptide product of cells. Cells transfected with self-releasing RNA briefly produce the antigen before undergoing death from apoptosis. This death is a likely result of requirements for double-stranded RNA (ds) intermediates, which have also been shown to overactivate dendritic cells. Thus, the increased immunogenicity of RNA self-replication may be a result of the production of pro-inflammatory dsRNA, which mimics an infection by host cell RNA viruses.
Advantageously, cellular machinery is used by self-replicating RNA molecules to generate an exponential increase in encoded gene products, such as proteins or antigens, that can accumulate in cells or can be secreted from cells. Overexpression of proteins by self-replicating RNA molecules takes advantage of immunostimulatory adjuvant effects, including stimulation of toll-like receptors (TLR) 3, 7 and 8 and non-TLR pathways (eg, RIG-1, MD-5) by products of RNA replication and, amplification and translation that induces apoptosis of the transfected cell.
Self-replicating RNA generally contains at least one or more genes selected from the group consisting of viral replicases, viral proteases, viral helicases and other non-structural viral proteins, and also comprises replication sequences active at the 5 'and 3'e cis end, if desired , heterologous sequences that encode a desired amino acid sequence (for example, an antigen of interest). A subgenomic promoter that directs the expression of the heterologous sequence can be included in the self-replicating RNA. If desired, the heterologous sequence (for example, an antigen of interest) can be fused in the structure to other coding regions in the self-replicating RNA and / or can be under the control of an internal ribosome entry site (IRES).
In certain embodiments, the self-replicating RNA molecule is not encapsulated in a virus-like particular. The self-replicating RNA molecules of the present invention can be designed so that the self-replicating RNA molecule cannot induce the production of infectious viral particles. This can be achieved, for example, by omitting one or more viral genes that encode the structural proteins that are necessary for the production of viral particles in self-replicating RNA. For example, when the self-replicating RNA molecule is based on an alpha virus, such as Sinebis virus (SIN), Semliki forest virus and Venezuelan equine encephalitis (VEE) virus, one or more genes that encode viral structural proteins, such as capsid and / or envelope glycoproteins can be omitted.
If desired, the self-replicating RNA molecules of the invention can also be designed to induce the production of infectious viral particles that are attenuated or virulent, or for the production of viral particles that are capable of a single round of subsequent infection.
A suitable system for performing self-replication in this way is the use of an alphavirus-based replicon. Alphaviruses comprise a set of viruses that carry genetically, structurally, and serologically related arthropods from the Togaviridae family. Twenty-six known viruses and virus subtypes have been classified within the alphavirus genus, including, Sindbis virus, Semliki Forest virus, Ross River virus, and Venezuelan equine encephalitis virus. As such, the self-replicating RNA of the invention can incorporate an RNA replicase derived from Semliki forest virus (SFV), Sindbis virus (SIN), Venezuelan equine encephalitis virus (VEE), Ross river virus (RRV), The virus Eastern Equine Encephalitis, or other viruses belonging to the alphavirus family.
Alphavirus-based replicon expression vectors can be used in the invention. Rep] icon vectors can be used in a variety of formats, including DNA, RNA, and recombinant replicon particles. Such replicon vectors were derived from alphaviruses that include, for example, Sindbis virus (Xiong et al. (1989) Science 243: 1188-1191; Dubensky et al., (1996) J. Virol. 70: 508-519; Hariharan et al. (1998) J. Virol. 72: 950-958;
Polo et al. (1999) PNAS 96: 4598-4 603), Forest Semliki virus (Liljestrom (1991) Bio / Technology 9: 1356-1361; Berglund, et al. (1998) Nat. Biotech. 16: 562-565), and Venezuelan equine encephalitis virus (Pushko et al. (1997) 5 Virology 239: 389-401). Alfavirus-derived replicons are generally quite similar in general characteristics (for example, structure, replication), individual alphaviruses may have some particular property (for example, receptor binding, sensitivity to interferon, and disease profile) that is unique . Therefore, replicas of chimeric alphaviruses made from different virus families can also be useful.
Alfavirus-based RNA replicons are typically ribbon - (+) RNAs that lead to the translation of a - 15 replicase (or replicase-transcriptase) after delivery to a cell. The replicase is translated as a polyprotein, which self-clamps to provide a replication complex that creates genomic strand copies (-) of the RNA distributed to strand - (+). These - (-) strand transcripts can themselves be transcribed to generate more copies of strand-origin RNA - (+), and also to generate the subgenomic transcription encoding the antigen. The translation of the subgenomic transcription thus leads to the expression of the antigen in situp by the infected cell. Suitable alphavirus replicons can use a replicase of a Sindbfs virus, a Semliki forest virus, an eastern equine encephalitis virus, a Venezuelan equine encephalitis virus, etc.
An RNA replicon preferably comprises an RNA genome from a picornavirus, togavirus, flaviv.irus, coronavirus, paramixovirus, yellow fever virus, or alfavirus (for example, Sindbis virus, Sem.liki forest virus , Venezuelan equine encephalitis virus or Ross river virus), which has been modified by replacing one or more structural protein genes from a selected heterologous nucleic acid sequence encoding a product of interest.
A preferred replicon encodes (i) an RNA-dependent RNA polymerase that can transcribe replicon RNA and (ii) an antigen. The polymerase can be an example of an alpha favirus replicase comprising one or more of the alpha proteins virus nsPl, nsP2, nsP3 and nsP4. Although natural alphavirus genomes encode structural virion proteins, in addition to non-structural polyprotein replicase, it is preferred that the replicon does not encode structural alphavirus proteins. Thus, a preferred replicon can lead to the production of genomic RNA copies of a cell itself, but not the production of RNA containing virions. The inability to produce these virions means that, unlike a wild-type alphavirus, the preferred replicon cannot be perpetuated in infectious form. The structural proteins of alphavirus necessary for the perpetuation of wild-type viruses are absent from the preferred replicon and their place is taken by the gene (s) encoding the antigen of interest, such that the subgenomic transcription encodes the antigen, rather than the structural alphavirus virion proteins.
A useful replicon according to the invention can have two open reading frames. The first open reading frame (5 ') encodes a replicase, the second open reading frame (3') encodes an antigen. In some embodiments, the RNA may have additional open reading frames (for example, downstream), for example, for encoding additional antigens or for encoding accessory polypeptides.
A preferred replicon has a 5 'cap (for example, a 7-methylguanosine), which can often improve in vivo translation of RNA. In some embodiments, the 5 'sequence of the replicon may need to be selected to ensure compatibility with the encoded replicase.
A replicon can have a 3 'poly-A tail. Can you also include a poly-A poll me recognition sequence (e.g., AAUAAA) near its 3 'end.
The replicons can be of various lengths, but are typically 5000-25000 nucleotides in length, for example, 8000-15000 nucleotides 9000-12000, or nucleotides.
The replicon can be conveniently prepared by in vitro transcription (IVT). IVT can use a template (cDNA) created and propagated as a plasmid in bacteria, or created synthetically (for example by gene synthesis and / or polymerase chain reaction (PCR) engineering methods). For example, an RNA-dependent DNA polymerase (such as bacteriophage T7, T3 or SP6 RNA polymerases) can be used to transcribe from replicon of a DNA template. O Poly-A addition reactions and proper leveling can be used as needed (although the poly-A replicon is generally encoded within the DNA template). These RNA polymerases may have strict requirements for the 5 'transcribed nucleotide (s) and in some embodiments these requirements have to be combined with the requirements of the encoded replicase, to ensure that the IVT transcribed RNAs can function efficiently as a substrate for its autocoded replicase. Specific examples include plasmids based on Sindbis virus (pSIN) such as pSINCP, described, for example, in U.S. Patent Nos. 5,814,482 and 6,015,686, as well as in International Publications no. WO 97/38087, WO 99/18226 and WO 02/26209. The construction of such replicons, in general, is described in U.S. Patent Nos. 5,814,482 and 6,015,686.
In other respects, the self-replicating RNA molecule is derived from, or based on, a virus other than an alphavirus, preferably a positive stranded RNA virus, and more preferably, a picornavirus, flavivirus, rubivirus, pestivirus, hepacivirus , calicivirus, or coronavirus. Suitable wild-type alphavirus sequences are well known and available from sequence depositors, "such as the American Type Culture Collection, Rockville, Md. Representative examples of suitable alphaviruses include Aura (ATCC VR-368), Bebaru virus (ATCC VR-600, ATCC VR-1240), Cabassou (ATCC VR-922), Chikungunya virus (ATCC VR-64, ATCC VR-1241), western equine encephalomyelitis virus (ATCC VR-65, ATCC VR-1242 ), Fort Morgan (ATCC VR-924), Getah virus (ATCC VR-369, ATCC VR-1243), Kyzylagach (ATCC VR-927), Mayaro (ATCC VR-66), Mayaro virus (ATCC VR-1277), Middleburg (ATCC VR-370), Mucambo virus (ATCC VR-580, ATCC VR-1244), Ndumu (ATCC VR-371), Pixuna virus (ATCC VR-372, ATCC VR-1245), Ross River virus (ATCC VR -373, ATCC VR-1246), Semliki Forest (ATCC VR-67, ATCC VR-1247), Sindbis virus (ATCC VR-68, ATCC VR-1248), Tonate (ATCC VR-925), Triniti (ATCC VR -469), Una (ATCC VR-374), Venezuelan equine encephalomyelitis 5 (ATCC VR-69, ATCC VR-923, ATCC VR-1250 ATCC VR-1249, ATCC VR -532), western equine encephalomyelitis (ATCC VR-70, ATCC VR-1251, ATCC VR-622, ATCC VR-1252), Whataroa (ATCC VR-926), and Y- 62-33 (ATCC VR-375).
The self-replicating RNA molecules of the present invention are larger than other types of RNA (e.g., mRNA) that were prepared using the modified nucleotides. Typically, the self-replicating RNA molecules of the invention contain at least about 4kb. /
For example, the self-replicating RNA can contain at least about 15 and 5 kb, at least about 6 kb, at least about 7 kb, at least about 8 kb, at least about 9 kb, at least about 10 kb, at least about 11KB, at least about 12kb or 'more than 12kb. In certain examples, the self-replicating RNA is about 4kb to about 12kb, about 5kb to about 12kb, about βkb to about 12kb, about 7kb to about 12kb, about 8kb to about 12kb, about from 9kb to about 12kb, about 10kb to about 12kb, about 11k to about 12kb, about 5kb to about 11kB, about 5kb to about 10kb, about 5kb to about 9kb, about about 5kb to about 8kb, about 5kb to about 7kb, about 5kb to about βkb, about βkb to about 12kb, about βkb to about llkB, about βkb to about 10kB, about βkb about 9kb, about βkb to about 8kb, about βkb to about 7kb, about 7kb to about 11kB, about 7kb to about 10kb, about 7kb to about 9kb, about ao / kb to about about 8kb, about 8kb to about 11kB, about 8kb to about 10kb, about 8kb to about 9kb, about 9kb to about 11kB, about 9kb to about 10kB, or about 10kB to about 1 LKB.
The self-replicating RNA molecules of the present invention can comprise one or more types of modified nucleotides (for example, pseudouridine, N6-methyladenosine, 5-methylcytidine, 5-methyluridine).
The self-replicating RNA molecule can encode a single heterologous polypeptide antigen or, optionally, two or more heterologous polypeptide antigens linked together in such a way that each of the sequences maintains its identity (for example, linked in series), when expressed as a sequence of amino acids. The heterologous polypeptides generated from the self-replicating RNA can then be produced as a fusion polypeptide or constructed to result in different sequences of polypeptides or peptides.
The self-replicating RNA of the invention can encode one or more polypeptide antigens that contain a variety of epitopes. Preferably epitopes capable of inducing either a T-cell helper response or a cytotoxic Las-l 'cell response, or both.
The self-replicating RNA molecules described here can be constructed to express several nucleotide sequences, from two or more open reading structures, thus allowing the coexpression of proteins, such as two or more antigens together with cytokines or other immunomodulators , which can increase the generation of an immune response. Such a self-repeating RNA molecule can be particularly useful, for example, in the production of several gene products (for example, proteins), at the same time, for example, as a bivalent or multivalent vaccine.
The self-replicating RNA molecules of the invention can be prepared using any suitable method. Several suitable methods are known in the art for producing RNA molecules that contain the modified nucleotides. For example, a self-replicating RNA molecule that contains modified nucleotides can be prepared by transcribing (for example, in vitro transcription) a DNA encoding the self-replicating RNA molecule using a suitable RNA-dependent DNA polymerase, such as RNA polymerase from phage T7, RNA polymerase from phage SP6, RNA polymerase from phage T3, and the like, or mutants of these polymerases that allow efficient incorporation of modified nucleotides into RNA molecules. The transcription reaction will contain modified nucleotides and nucleotides, and other components that support the selected polymerase activity, such as a suitable buffer, and suitable salts. The incorporation of nucleotide analogs into a self-replicating RNA can be constructed, for example, to alter the stability of such RNA molecules, to increase resistance against RNases, to establish replication after introduction into appropriate host cells ("RNA affectivity") ), and / or induce or reduce innate and adaptive immune responses.
Suitable synthetic methods can be used individually, or in combination with one or more other methods (for example, recombinant DNA or RNA technology), to produce a self-replicating RNA molecule of the present invention. Suitable methods for de novo synthesis are well known in the art and can be adapted for specific applications. Exemplary methods include, for example, chemical synthesis, using suitable protecting groups, such as CEM (Masuda et al., (2007) Nucleic Acids Symposium Series 57: 3-4), the β-cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) Tetrahedron Lett22: 1859); nucleoside H-phosphonate method (Garegg P et al. (1986) Tetrahedron Lett27: 4051-4 ;. Froehler BC et al. (1986) Nucl Acid Res14: 5399-407; Garegg.! 'or al (1986) Tetrahedron Lett27: 4055-8; Gaffney BL et al. (1988) Tetrahedron Lett29: 2619-22). These chemicals can be made or adapted for use with commercially available automated nucleic acid synthesizers. Additional suitable synthetic methods are described in Uhlmann et al. (1990) Chem Rev 90: 544-84, and Goodchild J (1990) Biocong uga te Chem 1: 16'5. Nucleic acid synthesis can also be performed using suitable recombinant methods, which are well known and conventional in the art, including cloning, processing and / or expression of polynucleotides and gene products encoded by these polynucleotides. DNA embedding by random fragmentation and PCR reconstitution of fragments of genes and synthetic polynucleotides are examples of known techniques that can be used to design and construct polynucleotide sequences. Targeted mutagenesis can be used to alter nucleic acids and encoded proteins, for example, to insert new restriction sites, alter glycosylation patterns, alter codon preference, produce processing variants, introduce mutations and the like. Suitable methods for the transcription, translation and expression of nucleic acid sequences are known and conventional in the art. (See, in general, Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel et al., Greene Publish Assoc & Wiley Interscience, Ch. 13, 1988; Glover, DNA Cloning, Vol. II, IRL Press, Wash. , DC, Ch. 3, 1986 ;. Bitter, et al., In Methods in Enzymology 153: 516-544 (1987); The Molecular Biology of the Yeast Saccharomyces, Eds Strathern et al, Cold Spring Harbor Press, Vols I and II, 1 982, and Sarnbrook et al., Molecular Cloning: A Laboratory Manual., Cold Spring Harbor Press, 1989).
The presence and / or quantity of one or more modified nucleotides in a self-replicating RNA molecule can be determined using any suitable method. For example, a self-replicating RNA can be digested for monophosphates (for example, using PI nuclease) and dephosphorylated (for example, using an appropriate phosphatase, such as CIAP), and the resulting nucleosides analyzed by reverse phase HPLC (for example, using an ODS-AQ column packed with YMC (5 microns, 4.6 x 250 mm) and elute using a gradient, B at 30% (0-5 min) to B at 100% (5-13 min) and B at 100% (13-40) min, Flow rate (0.7 ml / min), UV detection (wavelength: 260 nm), column temperature (30 ° C), Buffer A (20 mM acetic acid - ammonium acetate pH 3.5), buffer B (20 mM acetic acid - ammonium acetate pH 3.5 / methanol. [90/10])).
Optionally, the self-replicating RNA molecules of the present invention can include one or more modified nucleotides so that the self-replicating RNA molecule will have less immunomodulatory activity at the time of introduction or entry into a host cell (for example, a human cell ) compared to the corresponding self-replicating RNA molecule that does not contain modified nucleotides.
If desired, self-replicating RNA molecules can be screened or analyzed to confirm their therapeutic and prophylactic properties using various methods of in vitro or in vivo testing that are known to those skilled in the art. For example, vaccines that comprise self-replicating RNA molecules can be tested for their effect on the induction of lymphocyte proliferation or effector function of the specific type of interest, for example, B-cells, T-cells, cell-cell lines T and T cell clones For example, spleen cells from immunized mice can be isolated and enable cytotoxic T lymphocytes to lyse 20 autologous target cells that contain a self-replicating RNA molecule encoding a polypeptide antigen. In addition, differentiation of helper T-cells can be analyzed by measuring the proliferation or production of cytokines TH1 (IL-2 and IFN-y) and / or TH2 (IL-4 and 25 IL-5) by lyTSA, either directly by CD4 + T cells by cytoplasmic staining of cytokines and flow cytometry.
Self-replicating RNA molecules encoding a polypeptide antigen can also be tested for the ability to induce humoral immune responses, as evidenced, for example, by inducing the production of B cells of antibodies specific for an antigen of interest. These assays can be performed using, for example, peripheral B lymphocytes from immunized individuals.
Such test methods are known to those skilled in the art. Other assays that can be used to characterize the self-replicating RNA molecules of the present invention may involve the detection of expression of the antigen encoded by the target cells. For example, FACS can be used to detect the expression of antigen on the cell surface or in the intracellular environment. Another advantage of FACS selection is that you can classify the different levels of expression since sometimes the lowest expression can be desired. Another suitable method for identifying cells that express a particular antigen involves panning using monoclonal antibodies on a plate or capturing using magnetic beads coated with monoclonal antibodies. B. Antigens
In certain embodiments, the negatively charged molecule described herein is a nucleic acid molecule (for example, an RNA molecule) that encodes an antigen. Suitable antigens include, but are not limited to, a bacterial antigen, a viral antigen, a fungal antigen, a protozoan antigen, a hooting antigen, ta, a cancer antigen, or a combination thereof.
Suitable antigens include proteins and peptides from a pathogen such as a virus, bacterium, fungus, protozoan, plant or from a tumor.
Viral antigens and immunogens that can be encoded by the self-replicating RNA molecule include, but are not limited to, proteins and peptides from an orthomyxovirus, such as Influenza A, B and C; Virus Paramyxov.i ridae (from rinderpest), such as Pneumoviruses (RSV), Paramixovirus (PIV), Metapneumovirus and Morbilliviruses (for example, measles virus); Pneumoviruses, such as respiratory syncytial virus (RSV), bovine respiratory syncytial virus, mouse pneumonia virus, and turkey rhinotracheitis virus; Paramixovirus, such as parainfluenza virus types 1-4 (PIV), mumps virus, Sendai virus, Simian virus 5, bovine parainfluenza virus, Nipahvirus, Henipavirus and Newcastle disease virus; Poxviridae, including an Orthopoxvirus such as Smallpox vera (including, but not limited to, Smallpox major and Smallpox minor);
Metapneumovirus, such as human metapneumovirus (hMPV) and avian metapneumovirus (aMPV); Morbilliviruses, such as Measles; Picornaviruses, such as Enterovirus, Rhinovirus, Heparnavirus, Parecovirus, Cardiovirus and Aphthovirus; Enteroviruses, such as Poliovirus types 1, 2 or 3, Coxsackie A virus types 1 to 22 and 24, Coxsackie B virus types 1 to 6, Echovirus (ECHO) types 1 to 9, 11 to 27 and 29 to 34 and Ennorovirus 68 to 71, Buniavirus, including an Orthobuciavirus like the California encephalitis virus, a Phlebovirus, like the Rift Valley fever virus; a Nairovú rus, like the Crimean-Congo hemorrhagic fever virus; Heparnaviruses, such as hepatitis A virus (HAV); Togaviruses (rubella), such as a Rubivirus, an Alfavirus, or an Arterivirus; Flavivirus, such as tick encephalitis virus (TBE), Dengue (types 1, 2, 3 or 4), yellow fever virus, Japanese encephalitis virus, Forest virus, Kyasanur virus, Nile Ocicentai encephalitis virus, virus St. Louis encephalitis, Russian spring-summer encephalitis virus, Powassan encephalitis virus; Pestiviruses, such as bovine viral diarrhea (BVDV), classical swine fever (CSFV) or Borderline disease (BDV); Hepadnaviruses, such as hepatitis B virus, hepatitis C virus; Rhabdoviruses, such as Lyssavirus (rabies virus) and Vesiculovirus (VSV), Caliciviridae, such as Norwalk virus and Norwalk virus, such as Hawaii Virus and Snow Mountain Virus; Coronavirus, such as SARS, the human respiratory coronavirus, infectious avian bronchitis (IBV), mouse hepatitis virus (MHV); and transmissible porcine gastroenteritis virus (TGEV); retroviruses such as an Oncovirus, a Lentivirus or a Spumav.irus; Reovirus, such as an Ortoreovirus, a rotavirus, an Orbivirus, or a Coltivirus; Parvoviruses; like Parvovirus B19; hepatitis delta virus (HDV), hepatitis E virus (HEV), hepatitis G virus (HGV); human herpesvirus, such as Herpes Simplex Virus (HSV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV) Cytomegalovirus (CMV), Human Herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), and Herpesvirus Human 8 (HHV8); Papovavirus, such as the bovine papilloma virus and PoLiomavíras, Adenovirus and Arenavirus.
In handcuffs modalities, the antigen provokes an immune response against a virus that infects fish, such as: the infectious salmon anemia virus (ISAV), the pancreatic salmon disease virus (SPDV), the infectious pancreatic necrosis virus (IPNV), channel catfish virus (CCV), fish lymphocytic disease virus (FLDV), hematopoietic infectious necrosis virus (IHNV), koi herpesvirus, virus such as Salmon Quail (also known as Atlantic Salmon Picorrhage virus), coastal salmon virus (LSV), Atlantic salmon rotavirus (ASR), strawberry trout disease virus (TSD), coho salmon tumor virus (CSTV), or viral hemorrhagic septicemia virus (VHS).
In some embodiments, the antigen elicits an immune response against a parasite of the genus Plasmodium, such as P. falciparum, P. vivax, P. ovale or P.malariae. Thus, the invention can be used for immunization against malaria. In some modalities, the antigen provokes an immune response: against a parasite of the Caligidae family, particularly those of the genus Lepeophtheirus and Caligus, for example, sea lice, such as Lepeophtheirus salmon is or Caligus rogercresseyi.
Bacterial antigens and immunogens that can be encoded by the self-replicating RNA molecule include, but are not limited to, proteins and peptides from Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Moraxella catarrhalis, Bordetella pertussis, Burkholderia sp. (For example, Burkholderia mal , Burkholderia pseudomallei and Burkholderia cepacia), Staphyl.ococcus aureus, Staphylococcus epidermis, Haemophilus influenzae, Clostridium tetani (Tetanus), Clostridium perfrIngens, Clostridium botulinums (Botulism), Cornynoeaioniae Pneumia, Pneumia, Pneumidea and pneumonia
Brucella sp. (For example, B. abortus, B. canis, B. melitensi s, B. neotomae, B. ovis, B. suis and B. pinnipediae), Francisella sp. (For example, F. novicida, F. tularensis and F. philomiragia), Streptococcus agalactiae, Neiser ria gonorrhoeas, Chlamydia trachomatis, Treponema pallidum (syphilis), Haemophilus ducreyi, Enterococcus faecalis, Enterococcus faecium, Helicobacteri E. colicis, ETEC), Enteroaggregative E. coli (EAggEC), E. colidifusively adherent (DAEC), E. colienteropathogenic (EPEC), Extraintestinal colipathogenic (ExPEC; such as E. coliuropathogenic (UPEC) and E. colias associated with meningitis / sepsis ( MNEC)), and / or E. collenterohemorrágica (EHEC), Bacillus anthracis (anthrax), Yersinia pestis (plague), Mycobacterium tuberculosis, Rickettsia, Listeria monocytogenes, Chlamydia pneumoniae, Vibrio cholerae, Salmonella typhi (typhoid fever), Burgdorfer, Porphyromonas gingivalis, Klebsiella, Mycoplasma, pneumoniae, etc.
Fungal antigens and immunogens that can be encoded by the self-replicating RNA molecule include, but are not limited to, Dermatophytres proteins and peptides, including: Epidermophyton floccusum, Microsporum audouini, Microsporum canis, Microsporum distor turn, MLcrosporum equinum, Microsporum gypson, Microsporum nanum, Trichophyton concentricum, Trichophyton equinum, Trichophyton gallinae, Trichophytoh gypseum, Trichophyton megnini, Trichophyton mentagrophytes, Trichophyton qui nckeanum, Trichophyton rubrum, Trichophyton schoonl o l.ni, Trichophyton tonsurans, Trichophyton ver. album, var. discoids, var. ochraceum, Trichophyton violaceum, and / or Trichophyton faviforme, or from Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus nidulans, Aspergillus terreus, Aspergillus sydowi, Aspergillus flavusis, Candida, Aspergillus flask, Candida, Aspergillus, , Candida glabrata, Candida krusej. , Candida parapsilosis, Candida stellatoidea, Candida kusei, Candida parakwsei, Candida lusitaniae, Candida pseudotropicalis, Candida guilliermondi, Cladosporium carrionii, Coccidioides immitis, Blastomyces dermatidis, Cryptococcus neofdrmans, Encyclidone, Microstrich, spindle, Geotrichum Septata intestinalis and Enterocytozoon bieneusi; the least common are Brachiola spp., Microsporidium spp., Nosema spp., Pleistophora spp., Trachipleistophora spp., Vittaforma spp., Paracoccidioides bras iliensis, Pneumocystis carinii, Pythiumn insidiosum, Pityrosporum ovale, Sacharomyces, Sacacharomyces, Scedosporium apiosperum, Sporothrix schenckii, Trichosporon beigelii, Toxoplasma gondii, Penici.llium marneffei, Malassezia spp., Fonsecaea spp., Wanglella spp., Sporothrix spp., Basidiobolus spp., Coni d: i. Mucor spp., Absidia spp., MortiereIla spp., Çunninghamella spp., Saksenaea spp., Alternaria spp., Curvularia spp., Helminthosporium spp., Fusarium spp., Aspergillus spp., Penicillium spp., Monolinla spp., Rhizocton ., Paecilomyces spp., Pithomyces spp. and Cladosporium spp ..
The protozoan antigens and immunogens that can be encoded by the self-replicating RNA molecule include, but are not limited to, Entamoeba histolytic proteins and peptides, Giardia lambli, Cryptosporidium parvum, Cyclospora cayatanensise Toxoplasma.
Plant antigens and immunogens that can be encoded by the self-replicating RNA molecule include, but are not limited to, Ricinus communis proteins and peptides.
Suitable antigens include proteins and peptides to pact.Lr from a virus such as, for example, human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV) ), herpes simplex virus (HSV), cytomegalovirus (CMV), influenza virus (flu), respiratory syncytial virus (RSV), parvovorus, norovirus, human papilloma virus (HPV), rhinovirus, yellow fever virus, rabies, Dengue fever virus, measles virus, mumps virus, rubella virus, varicella zoster virus, enterovirus (eg enterovirus 71), ebola virus, and bovine diarrhea virus. Preferably, the antigenic substance is selected from the group consisting of HSV gD glycoprotein, HIV HIV gpl20 glycoprotein, HIV gp 40 glycoprotein, HIV p55 gag, and polypeptides from the po 1. and tat regions. In other preferred embodiments of the invention, the antigen is a protein or peptide derived from a bacterium, such as, for example, Helicobacter pylori, Haemophilus influenza, Vibrio cholerae (cholera), C. diphtherias (diphtheria), C. tetani (toxoid) , Neisseria meningitidis, B. pertussis, Mycobacterium tuberculosis, and the like.
HIV antigens that can be encoded by the self-replicating RNA molecules of the present invention are described in US Order No. 490,858, filed March 9, 1990, and European Order published number 181150 (May 14, 1986), as well as US Orders #. 60 / 168,471 and 09 / 475,515 and 09 / 475,504, and 09 / 610,313, the descriptions of which are incorporated herein by reference in their total age.
Cytomegalovirus antigens that can be encoded by the self-replicating RNA molecules of the present invention are described in U.S. Patent No. 4,689,225, U.S. Order No. 367,363, filed June 16, 1989 and PCT Publication WO 89/07143, the descriptions of which are incorporated herein by reference in their entirety. hepatitis C that can be encoded by the self-replicating RNA molecules of the present invention are described in PCT / US88 / 04125, European Order published number 328216 (May 31, 1989), Publication of Japanese application number 1-500565 filed on November 18, 1988, Canadian Order 583,561, and EPO 388,232, the disclosures of which are hereby incorporated by reference in their entirety. A different set of HCV antigens is described in European patent application 90 / 302866.0, filed on March 16, 1990, and in U.S. Application no. °. serial 4 56,637, filed on December 21, 1989 and PCT / US90 / 01348, the disclosures of which are hereby incorporated by reference in their entirety.
After some modalities, the antigen is derived from an allergen, such as pollen allergens (allergens to pollen from trees, herbs, weeds, and grass); insect or arachnid allergens (allergens from inhalants, saliva and poison, for example, mites, allergens, for example, cockroach allergens and mosquitoes, hymenopthera poison allergens); animal dander and dander allergens (eg dog, cat, horse, rat, mouse, etc.), and food allergens (eg gliadin). Important pollen allergens from trees, grasses and herbs are as originating from the taxonomic orders of Fagales, Oleales, Pinales and Piatanaceae, including, but not limited to, birch (Bécu.la), alders (Alnus), hazelnut (Corylus), carp (Carpinas) and olive (Olea), cedar (Cryptomeria and Juniperus), plane tree (Platanus), the order of Poales including grasses of the genus Lolium, Phleum, Poa, Cynodon, Dactylis, Holcus, Phalaris, Secale, and Sorghum, the orders of Asterales and Urticales including herbs of the genus Ambrosia, Artemisia, and Parietaria. Other important inhalation allergens are mites of the genera Dermatophagoides and Euroglyphus, mite storage, for example, Lepidoglyphys, Glycyphagus and Tyrophagus, those of cockroaches, mosquitoes and fleas, for example, Blatella, Periplaneta, Chironomus and Ctenocepphajides, and of mammals, such as dogs, cats and horses, such as from poison from insect bites or bites, such as those of the taxonomic order of Hymenoptera, including bees (Apidae), wasps (Vespictea) and ants (Formicoidae).
In such embodiments, a tumor immunogen or antigen, or cancer immunogen or antigen, can be encoded by the self-replicating RNA molecule. In certain embodiments, tumor antigens and immunogens are antigens containing tumor peptides, such as a polypeptide tumor antigen or glycoprotein tumor antigens.
Immunogenes and tumor antigens suitable for use in the present invention include a wide variety of molecules, such as (a) tumor antigens containing polypeptides, including polypeptides (which can range, for example, from 8 to 20 amino acids in length, although lengths outside of this range are also common), lipopolypeptides and glycoproteins.
In certain embodiments, tumor immunogens are, for example, (a) full-length molecules associated with cancer cells, (b) homologues and modified forms thereof, including molecules with deleted, added and / or substituted portions, and ( c) fragments thereof. Tumor immunogenes include, for example, class I restriction antigens recognized by CD8 + lymphocytes or class II restricted antigens recognized by CD4-I- lymphocytes.
In certain embodiments, tumor immunogens include, but are not limited to, (a) testicular cancer antigens, such as NY-ESO-1, SSX2, SCP1, as well as polypeptides from the RAGE, BAGE GAGE and MAGE family, for example , GAGE-1, GAGE-2, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, and MAGE-12 (which can be used, for example, to treat melanoma, lung, head and neck tumors, NSCLC, breast, gastrointestinal, and bladder), (b) mutated antigens, for example, p53 (associated with several solid tumors, for example, colorectal, lung, head and neck), p21 / Ras (associated with, for example, melanoma, pancreatic cancer and colorectal cancer), CDK4 (associated with, for example, melanoma), MUM1 (associated, for example, melanoma), caspase-8 (associated with, for example, head and neck cancer), CIA 0205 (associated with, for example, bladder cancer), HLA-A2-R1701, beta catenin (associated with, for example, melanoma), TCR (associated with, for example example, lymphoma of non-Hodgkins T-cells), BCR-abl (associated with, for example, chronic myelogenous leukemia), triosphosphate isomerase, KIA 0205, CDC-27, and LDLR-FUT, (c) overexpressed antigens, for example, Galectin 4 ( associated with, for example, colorectal cancer), Galectin 9 (associated with, for example, Hodgkins disease), proteinase 3 (associated, for example, with chronic myelogenous leukemia), WT I (associated, for example, with different leukemias) , carbonic aniorase (associated with, for example, renal cancer), aldolase A (associated, for example, with lung cancer), FRAME (associated, for example, with melanoma), HER-2 / neu (associated with, for example , breast, lung, colon and ovarian cancer), alpha-fetoprotein (associated, for example, with hepatoma), KSA (associated with, for example, co-rectal cancer), gastrin (associated, for example, with gastric and pancreatic cancer ), catalytic telomerase protein, MUC-1 (associated, for example, with breast, ovarian cancer), G-250 (associated with, for example, carcinoma renal cell), p53 (associated, for example, with breast, colon cancer), and carcinoembryonic antigen (associated, for example, with breast cancer, lung cancer, and cancers of the gastrointestinal tract, such as colorectal cancer) , (d) shared antigens, for example, melanoma-melanocyte differentiating antigens such as MART-1 / Melan A, gplOO, MC1R, melanocyte stimulating hormone receptor, tyrosinase, tyrosinase-related protein-1 / TRPl and protein-2 Tyrosinase-related / TRP2 (associated, for example, melanoma), (e) prostate-associated antigens, such as PAP, PSA, PSMA, PSH-P1, PSM-P1, PSM-P2, associated with, for example, prostate cancer, (f) immunoglobulin idiotypes (associated with myeloma and B-cell lymphoma, for example).
In certain embodiments, tumor immunogens include, but are not limited to, pl5, Hom / Mel-40, H-Ras, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR antigens, Epstein virus antigens Barr, EBNA, Human Papillomavirus (HPV), including E6 and E7, hepatitis B and C virus antigens, human T-cell lymphotropic virus antigens, TSP-180, pl85erbB2, pl80erbB-3, c-met, mn- 23Hl, TAG-72-4, CA 39-9, CA 72-4, CAM 17.1, NuMa, K-ras, pl6, TAGE, PSCA, CT7, 43-9F, 5T4, 7'91 Tgp72, beta-HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29 / BCAA), CA 195, CA 242, CA-50, CAM43, CD68 KP1, CO-029, FGF-5, Ga733 (EpCAM), HTgp-175 , M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90 (binding protein Mac-2 protein-C associated with cyclo f'i 1 L na), TAAL6, TAG72, TLP, TPS, and the like. C. Aqueous solution for the negatively charged molecule
The negatively charged molecule (such as RNA) is generally supplied in the form of an aqueous solution, or in a form that can be easily dissolved in an aqueous solution (for example, lyophilized). The aqueous solution can be water, or an aqueous solution comprising a salt (for example, NaCl), a buffer (for example, a citrate buffer), an osmolality or tonicity adjusting agent (for example, a saccharide) , a polymer, a surfactant, or a combination thereof. If the formulation is intended for administration in vivo, it is preferable that the aqueous solution is a physiologically acceptable buffer that maintains a pH that is compatible with normal physiological conditions. In addition, in certain cases, it may be desirable to maintain the pH at a particular level in order to ensure the stability of certain components of the formulation.
For example, it may be desirable to prepare an aqueous solution that is isotonic and / or isosmotic. Hypertonic and hypotonic solutions can sometimes cause complications and undesirable effects when injected, such as swelling after administration or rapid absorption of the composition due to differential ion concentrations between the composition and the physiological fluids. To control tonicity, the emulsion may comprise a physiological salt, such as a sodium salt. Sodium chloride (NaCl), for example, can be used at about 0.9% (w / v) (physiological saline). Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, dehydrated disodium phosphate, magnesium chloride, calcium chloride, etc. In an exemplary embodiment, the aqueous solution comprises 10 mM NaCl and other salts or agents nonionic tonicity. As described herein, nonionic tonicity agents can also be used to control tonicity.
The aqueous solution can be buffered. Any physiologically acceptable buffer can be used in the present invention, such as citrate buffers, phosphate buffers, acetate buffers, succinate buffers, Tris buffers, 5 bicarbonate buffers, carbonate buffers, or the like.
The pH of the aqueous solution will preferably be between 6.0 - 8.0, preferably about 6.2 and about 6.8. In some cases, a certain amount of salt may be included in the buffer. In other cases, the salt in the buffer may interfere with the complexation of the negatively charged molecule into the emulsion particle, therefore, it is avoided.
The aqueous solution can also comprise additional components, such as molecules that alter the osmolarity of the aqueous solution or molecules that stabilize the negatively charged molecule after complexation. For example, osmolarity can be adjusted using nonionic toning agents, which are usually carbohydrates, but can also be polymers. (See, for example, Voet and Voet (1990) Biochemistry (John 20 Wiley S Sons, New York) Examples of nonionic tonicity agents include sugars (eg trehalose, sucrose, dextrose, fructose, reduced palatinose, etc.). ), sugar alcohols (such as mannitol, sorbitol, xylitol, erythritol, lactitol, glycerol, maltitol, etc.), and 25 combinations thereof. If desired, a nonionic polymer (eg, a poly (alkyl glycol) such as such as polyethylene glycol, poly ipropylene glycol, or polybutylene glycol) or a nonionic surfactant can be used.These types of agents, especially sugar and sugar alcohols, 30 are also cryoprotectants that can protect RNA, and other charged molecules negatively when lyophilized In exemplary embodiments, the buffer comprises from about 560 nM to 600 mM trehalose, sucrose, sorbitol, or dextrose.
Err. In some cases, it may be preferable to prepare an aqueous solution that comprises the negatively charged molecule as a hypertonic solution, and to prepare the cationic emulsion using unadulterated water or a hypotonic buffer. When the emulsion and the negatively charged molecule are combined, the mixture becomes isotonic. For example, an aqueous solution containing RNA can be a 2X hypertonic solution, and the cationic emulsion can be prepared using 10mM citrate buffer. When the RNA solution and the emulsion are mixed at a ratio of 1: 1 (v / v), the composition becomes isotonic. Based on desired desired amounts of the emulsion for the aqueous solution comprising the negatively charged molecule (e.g. 1: 1 (v / v) mixture, 2: 1 (v / v) mixture, 1: 2 (v / v mixture) ), etc.), one can easily determine the tonicity of the aqueous solution that is needed in order to achieve an isotonic mixture. l) likewise, compositions that have physiological osmolality may be desirable for in vivo administration. The physiological z osmolarity is about 255 mOsm / kg of water to about 315 mOsm / kg of water. Sometimes it may be preferable to prepare an aqueous solution that comprises the negatively charged molecule as a hyperosmolar solution, and to prepare the cationic emulsion using water or a pure hypo-osmolar buffer. When the emulsion and the negatively charged molecule are combined, physiological osmolarity is achieved. Based on desired desired amounts of the emulsion for the aqueous solution comprising the negatively charged molecule (e.g. 1: 1 (v / v) mixture, 2: 1 (v / v) mixture, 1: 2 (v / v mixture) ), etc.), one can easily determine the osmolality of the aqueous solution that is necessary in order to achieve an iso-osmolar mixture.
In certain embodiments, the aqueous solution comprising the negatively charged molecule may further comprise a polymer or a surfactant, or a combination thereof. In an exemplary embodiment, the oil-in-water emulsion contains a polaxamer. In particular, the inventors observed that the addition of Pluronic® F 127 to the aqueous RNA solution prior to complexation to particles of the cationic emulsion led to greater stability and resistance to RNase of the increased RNA molecule. The addition of Pluronic F 127 to the aqueous RNA solution was also observed to reduce the particle size of the RNA / CNE complex. Poloxamer polymers can also facilitate the proper decompression / release of the RNA molecule, prevent aggregation of the emulsion particles, and have an immunomodulatory effect. Other polymers that can be used include, for example, Pluronic® F68 or PEG300.
In a 1 i.ernat: i va, or in addition, the aqueous solution comprising the negatively charged molecule may comprise from about 0.05% to about 20% (w / v) of polymer. For example, the oil-in-cation water emulsion may comprise a polymer (for example, a Pluronic® F127 poloxamer such as Pluronic® F68, or PEG300), from about 0.05% to about 10% (w / v ), such as 0.05%, 0.5%, 1%, or 51.
The buffer system can comprise any combination of two or more molecules described above (salt, saccharide buffer, polymer, etc.). In a preferred embodiment, the buffer is composed of 560 mM sucrose, 20 mM NaCl, and 2 mM citrate, which can be mixed with a cationic oil in the water emulsion described in the present invention to produce a final aqueous phase comprising 280 mM sucrose, 10 mM NaCl and 1 mM citrate. 5. PREPARATION METHODS
In another aspect, the invention provides a method of preparing a composition that comprises a negatively charged molecule complexed with a particle of an oil-in-cation water emulsion, which comprises: the preparation of an oil-in-water emulsion in which the cationic emulsion comprises: (1) from about 0.2% to about 20% (v / v) of oil (2), from about 0.01 to about 2.5%) of surfactant (v / v), and (3) a cationic lipid; and adding the negatively charged molecule to the cationic oil-in-water emulsion so that the negatively charged molecule is complexed with the emulsion particle.
An exemplary method for generating the oil emulsion in cationic water is by a process comprising: (1) combining the oil and the cationic lipid to form the oil phase of the emulsion, (2) providing an aqueous solution to form the aqueous phase of the emulsion. emulsion, and (3) dispersing the oil phase in the aqueous phase, for example, by homogenization. Homogenization can be carried out in any suitable manner, for example, using a commercial homogenizer (eg IKA T25 homogenizer, available from VWR International (West Chester, PA)).
The cationic Jipjdeo can be dissolved in a suitable solvent, such as chloroform (CHCl3), dichloromethane (DCM), ethanol, acetone, tetrahydrofuran (THF), 2,2,2 tr 1 fluoroethane. , acetonitrile, ethyl acetate, hexane, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), etc., and added directly to the oil component of the emulsion. Alternatively, the cationic lipid can be added to a suitable solvent to form a liposome suspension, then the liposome suspension can be added to the oil component of the emulsion. The cationic lipid can also be dissolved directly in the oil.
It may be desirable to heat the oil to a temperature between about 30 ° C to about 65 ° C to facilitate the dissolution of the lipid.
The desired amount of the cationic lipid (e.g., DOTAP) can be measured and / or dissolved in a solvent, in water or directly in oil to achieve a desired final concentration, as described and exemplified here.
Solvents, such as chloroform (CHCl3) or dichloromethane (DCM), can be removed from the oil phase, for example, by evaporation, before combining the aqueous phase and the oil phase, or before homogenization. Alternatively, in cases where lipid solubility can be a problem, a primary emulsion can be made with the solvent (for example, DCM), still in the oil phase. In such cases, the solvent can be removed (for example, allowed to evaporate) from the primary emulsion before secondary homogenization.
If the emulsion comprises one or more surfactants, the surfactant (s) can be included in the oil phase or the aqueous phase according to conventional practice in the art. For example, SPAN85 can be dissolved in the oil phase (for exercis, squalene), and Tween 80 can be dissolved in the water phase (for example, in a citrate buffer).
In another aspect, the invention provides a method of preparing a composition comprising a negatively charged molecule (for example, RNA) complexed with a particle of an oil-in-cationic water emulsion, which comprises: (i) providing an emulsion of oil in cationic water, as described herein, (ii) providing an aqueous solution comprising the negatively charged molecule (for example, RNA), and (iii) combining the emulsion of: oil in water from (i) and the aqueous solution of (iii), so that the negatively charged molecule complexes with the emulsion particle. For example, an oil-in-cationic water emulsion can be combined with an aqueous solution comprising a negatively charged molecule (for example, an aqueous solution of RNA), in desired relative amounts, for example, about 1: 1 (v / v), about 1.5: 1 (v / v), about 2: 1 (v / v), about 2.5: 1 (v / v), about 3: 1 (v / v), about 3.5: 1 (v / v), about 4: 1 (v / v), about 5: 1 (v / v), about 10: 1 (v / v), about 1: 1 , 5 (v / v), about 1: 2 (v / v), about 1: 2.5 (v / v), about 1: 3 (v / v), about: 1: 3.5 (v / v), about 1: 4 (v / v), about 1: 1.5 (v / v), or about 1: 1.10 (v / v), etc.
The concentration of each component of the post-composition composition (eg, RNA-emulsion complex) can be readily determined according to the relative amounts of the oil-in-water emulsion pre-complex and the aqueous solution comprising the negatively charged molecule (for example, an aqueous RNA solution) that are used. For example, when an oil-in-cationic water emulsion is combined with an aqueous solution comprising a negatively charged molecule (for example, an aqueous solution of RNA) at a ratio of 1: 1 (v: v), the oil concentrations and cationic lipid make up 1/2 of the pre-complex emulsion. Therefore, if an emulsion comprising 4.3% (w / v) squalene, 1.4 mg / ml DOTAP, 0.5% v / v SPAN85 and 0.5% v / v Tween 80 (referred to here as "CNF, '! 7") is combined with an aqueous solution of RNA comprising 560 mM sucrose, 20 mM NaCl, 2 mM Citrate, and 1% (w / v) 1: 1 (v: Pluronic F127) v), the post-complex composition comprises 2.15% (w / v) squalene, 0.7 mg / ml DOTAP, 0.25% v / v SPAN85, 0.25% v / v Tween 80, 280 mM sucrose, 10 mM NaCl, 1 mM citrate, and 0.5% (w / v) Pluronic F127.
Additional optional steps to promote particle formation, improve the complexation between negatively charged molecules and cationic particles, increase the stability of the negatively charged molecule (for example, to prevent degradation of an RNA molecule) in order to facilitate decomposition / appropriate release of negatively charged molecules (such as an RNA molecule), or to prevent aggregation of the emulsion particles, can be included. For example, a polymer (for example, Pluronic; ^ F.127) or a surfactant can be added to the aqueous solution comprising the negatively charged molecule (for example, RNA). In an exemplary embodiment, Pluronic® F 127 is added to the RNA molecule prior to complexation with the emulsion particle.
The size of the emulsion particles can be varied by changing the ratio of surfactant to oil (increasing the ratio decreases the size of the drops), operating pressure (increasing the operating pressure reduces the size of the drops), the temperature (increasing the temperature reduces the size of the drops), and other process parameters. The size of the actual particle will also vary according to the particular surfactant, oil and cationic lipid used and the specific operating conditions selected. The particle size emulsion can be checked by using sizing instruments, such as the commercial SubMicron Particulate Analyzer (Model N4MD) manufactured by La Coulter Corporation, and the parameters can be varied, using the guidelines set out above until the average diameter particle size is less than 1 μm, less than 0.9 μm, less than 0.8 μm, less than 0.7 μm, less than 0.6 μm, less than 0.5 μm, less than 0.4 μm, 20 less than 0.3 μm, less than 0.2 μm, or less than 0.1 μm.
Preferably, the particles have an average diameter of about 400 nm or less, about 300 nm or less, about 200 nm or less, about 180 nm or less, about 150 nm or less, or about 140 nm or less, about 25 from 50 nm to 180 nm, about 60 nm to 180 nm, about 70 to 180 nm, or about 80 nm to 180 nm, about 80 nm to 170 nm, from about 80 nm to 160 nm, from about 80 nm to 150 nm, or from about 80 nm to 140 nm. In some cases, it may be desirable for the average particle size of cationic emulsions to be 200 nm or less, to allow for sterile feed. In other cases, filtration sterilization is not necessary and the average particle size of cationic emulsions can be greater than 200 nm.
Optional processes for preparing the oil emulsion in cationic water (complexing pre-emulsion), or the negatively charged molecule-emulsion complex, include, for example, sterilization, particle size selection (eg removal of large particles), loading, packaging, labeling and etc.
For example, if the pre-complexing emulsion, or the negatively charged molecule-emulsion complex is formulated for in vivo administration, it can be sterilized, for example, by filtration through a degree of sterilization (for example, through a 0.22 micron filter). Other sterilization techniques include a thermal process or a radiation sterilization process, or the use of pulsed light to produce a sterile composition.
The oil-in-cationic water emulsion described herein can be used for the manufacture of vaccines. Clinical and / or sterile cationic oil-in-water emulsions can be prepared using methods similar to those described for Mi; "59. See, for example, Ott et al., Methods in Molecular Medicine, 2000, Volume 42, 211-228, VACCINE ADJUVANTS (O'Hagan ed.), Humana Press. For example, similar to the manufacturing process of MF59, the oil phase and the aqueous phase of the emulsion can be combined and treated in an in-line homogenizer to produce a The coarse emulsion can then be fed to a microfluidizer, where it can be further processed to obtain a stable submicron emulsion.The coarse emulsion can be passed through the microfluidizer: interaction chamber repeatedly until the desired particle size is obtained.The mass emulsion can then be filtered (for example, through a 0.22 μm filter in a nitrogen atmosphere), to remove large particles, resulting in the mass of the emulsion that can be introduced and m suitable containers (for example, glass bottles). For vaccine antigens that have demonstrated long-term stability in the presence of o-emulsion and oil in water for self-storage, the antigen and emulsion can be combined and sterilized by filtration (for example, through a 0.22 member filter) μm). The combined single vial vaccine 15 can be filled into single dose containers. For vaccine antigens, where long-term stability has not been demonstrated, the emulsion can be supplied as a separate bottle. In such cases, the mass of the emulsion can be sterilized, filtered (for example, through a 20-member 0.22 μm filter), filled, and packaged in final single-dose bottles.
Quality control can optionally be performed on a small sample of the mass of the emulsion or mixture of the vaccine, and the bulk or mixed vaccine will be packaged in doses only if the sample passes the quality control test. 6. PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION
In another aspect, the invention provides a pharmaceutical composition comprising a negatively charged molecule 30 complexed with a particle of an oil-in-cation water emulsion, as described herein, and may further comprise one or more carriers, diluents, or pharmaceutically excipients. acceptable. In preferred embodiments, the pharmaceutical composition is an immunogenic composition, which can be used as a vaccine.
Alternatively, the compositions described herein can be used to deliver a negatively charged molecule to cells. For example, nucleic acid molecules (for example, DNA or RNA) can be distributed to cells for a variety of purposes, for example, to induce the production of a desired gene product (for example, proteins), to regulate expression of a gene, for gene therapy and the like. The compositions described herein can also be used to supply a nucleic acid molecule (for example, DNA or RNA) to cells for therapeutic purposes, such as for treating a disease, such as cancer or proliferative diseases. metabolic diseases, cardiovascular diseases, infections, allergies, to induce an immune response and the like. For example, nucleic acid molecules can be delivered to cells to inhibit expression of a target gene. Such nucleic acid molecules include, for example, antisense oligonucleotides, double-stranded RNA, such as small interfering RNAs and the like. Double-stranded RNA molecules, such as small interfering RNAs, can trigger RNA interference, which specifically silences the corresponding target gene (knock down gene). Antisense oligonucleotides are single strands of DNA or RNA that are compatible with a chosen sequence. Generally, antisense RNA can prevent the translation of the protein from certain messenger RNA strands by binding to them. Anti-sense DNA can be used to target a complementary, specific RNA (encoding or non-encoding). Therefore, the cationic emissions described here are useful for the distribution of antisense oligonucleotides or double-stranded RNA for the treatment, for example, of cancer, inhibiting the production of an oncology target.
The pharmaceutical compositions provided herein can be administered alone or in combination with one or more additional therapeutic agents. The method of administration included, but is not limited to, oral administration, rectal administration, parenteral administration, subcutaneous administration, intravenous administration, intravitreal, intramuscular administration, by inhalation, intranasal administration, topical administration, ophthalmic administration, or optical administration.
A therapeutically effective amount of the compositions described herein can vary depending, among others, on the indicated disease, the severity of the disease, the age and relative health of the individual, the potency of the compound administered, the route of administration and the desired treatment.
In other embodiments, the pharmaceutical compositions described herein can be administered in combination with one or more additional therapeutic agents. Additional therapeutic agents may include, but are not limited to, antibiotics or antibacterial agents, antiemetic agents, antifungal agents, anti-inflammatory agents, antiviral agents, immunomodulatory agents, cytokines, hormones, antidepressants, alkylating agents , antimetabolites, antitumor antibiotics, anti-mitotic agents, topoisomerase inhibitors, cytostatic agents, anti-invasion agents, anti-anginogenic agents, growth factor inhibitors, inhibitors of viral replication function, inhibitors of viral enzymes, anticancer agents, OI - interferons, β-interferons, ribavirin, hormones, and other toll receptor modulators such as, immunoglobulins (Igs), and antibody-modulating Ig function (such as anti-IgE (Omalizumab)).
In certain embodiments, the pharmaceutical compositions provided herein are used in the treatment of infectious diseases, including, but not limited to, disease caused by pathogens described herein, including viral diseases such as genital warts, common warts, plantar warts, rabies , respiratory syncytial virus (RSV), hepatitis B virus, hepatitis C virus, dengue fever, yellow fever, herpes simplex virus (by way of example only, HSV-I, HSV-II, CMV, or VZV), contagious mollusc , vaccinia, smallpox, lentivirus, human immunodeficiency virus (HIV), human papilloma virus (HPV1, hepatitis virus (hepatitis C virus, hepatitis B virus, hepatitis A virus), cytomegalovirus (CMV), varicella zoster virus (VZV), rhinovirus, enterovirus (eg EV71), adenovirus, coronavirus (eg SARS), influenza, para-influenza, mumps virus, measles virus, rubella virus, papovavirus, hepadnavirus, flavivirus, retrovirus, arenavirus (as an example o only, LCM, Junin virus, Machupo virus, Guanarito virus and Lassa fever), and filovirus (by way of example only, Ebola or Marburg virus).
In certain embodiments, the water pharmaceutical compositions provided are used in the treatment of bacterial, fungal infections by protozoa including, but not limited to, malaria, tuberculosis and mycobacterium avium, leprosy; Pneumocystis carnii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, leishmaniasis, Infections caused by bacteria of the genus Escherichia, Enterobacter, Salmonella, Aureus, Klebsiella, Proteus, Pseudomonas, Streptococcus, and Chlamydia, such as candidiasis, and Chlamydia infections, , and cryptococcal meningitis.
In certain embodiments, the pharmaceutical compositions provided herein are used in the treatment of diseases and / or disorders of the respiratory tract, dermatological diseases and / or disorders, eye diseases and / or disorders, diseases and / or genitourinary disorders, including, allograft rejection , autoimmune and allergic, cancer, or damaged or aged skin, such as scars and wrinkles.
In another aspect, the invention provides a method for generating or enhancing an immune response in a subject in need thereof, such as a mammal, comprising administering an effective amount of a composition as disclosed herein. The immune response is preferably protective and preferably involves antibodies and / or cellular immunity. The method can be used to induce a primary immune response and / or to increase an immune response.
In certain embodiments, the compositions described herein can be used as a medicament, for example, for use in enhancing or improving an immune response in a subject in need thereof, such as a mammal.
In certain embodiments, the compositions described herein can be used in the manufacture of a drug to generate or enhance an immune response in a subject in need of it, such as a mammal.
The invention also provides a delivery device pre-filled with a composition or vaccine described herein.
The mammal is preferably a human, but it can be, for example, a cow, a pig, a chicken, a cat or a dog, since the pathogens covered in this document can be problematic in a wide variety of species. Whenever the vaccine is for prophylactic use, the human is preferably a child (for example, a baby or infant), a teenager or an adult, where the vaccine is for therapeutic use, the human is preferably a teenager or an adult. A vaccine for children can also be administered to adults, for example, to assess safety, dosage, immunogenicity, etc.
One way of verifying the effectiveness of therapeutic treatment involves monitoring the pathogenic infection, after the administration of the compositions or vaccines described here. One way to verify the effectiveness of prophylactic treatment involves monitoring immune responses, systemic (for example, monitoring the level of production of IgGl and IgG2a) and / or in the mucous membranes (for example, monitoring the level of production IgA), against the antigen. Typically, serum antibody and antigen responses are determined post-immunization, but pre-challenge whereas antibody responses in antigen-specific mucosa are determined post-immunization and post-challenge.
Another way of assessing the immunogenicity of the compositions or vaccines disclosed herein where the nucleic acid molecule (for example, RNA) encodes an antigenic protein is to express the protein antigen recombinately to screen the patient's mucous secretions or serum by immunoblot and / or micro-matrices. A positive reaction between the protein and the patient's sample indicates that the patient has mounted an immune response to the protein in question. This method can also be used to identify immunodominant antigens and / or epitopes within protein antigens.
The effectiveness of the compositions can also be determined in vivo by challenging the appropriate animal models of the pathogen of the infection of interest.
Dosing can be done by a single dose schedule or a multiple dose schedule. Multiple doses can be used in a primary immunization schedule and / or in a booster immunization schedule. In a multiple dose schedule, the various doses can be administered by the same or different routes, for example, a parenteral start and a mucosal boost, a mucosal start and a parenteral boost, etc. Multiple doses will typically be administered with at least 1 week apart (for example, about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc. .).
The compositions described herein that include one or more antigens or are used in conjunction with one or more antigens can be used to treat children and adults. Thus, a human subject can be less than 1 year old, 1-5 years old, 5-15 years old, 15-55 years old, or at least 55 years old. The preferred subjects for receiving the compositions are the elderly (for example,> 50 years old,> 60 years old, and preferably> 65 years old), young people (for example, <5 years old), hospitalized patients, health workers, armed service and armed forces personnel, 15 pregnant women, chronically ill, or immunodeficient.
The compositions are not only suitable for these groups, however, and can be used more generally in a population.
The compositions disclosed here that include one or more 20 antigens or are used in conjunction with one or more antigens can be administered to patients at substantially the same time (for example, during the same consultation or medical visit to a health professional or a hundred vaccination.) other vaccines, for example, 25 at the same time as a measles vaccine, a mumps vaccine, rubella vaccine, MMR vaccine, a chickenpox vaccine, MMRV vaccine, a diphtheria vaccine, a tetanus vaccine, pertussis vaccine, DTP vaccine, H. influenza type b vaccine, 30 an inactivated poliovirus vaccine, a hepatitis B virus vaccine, a meningococcal conjugate vaccine (such as a tetravalent AC vaccine W135 Y), a respiratory syncytial virus vaccine, etc.
In certain embodiments, the compositions provided herein 5 include or, optionally, include one or more immunoregulating agents, such as adjuvants. Exempt Cf'4 captive adjuvants include, but are not limited to, a TH1 adjuvant and / or a TH2 adjuvant, discussed below. In certain embodiments, adjuvants used in the immunogenic compositions of the present invention include, but are not limited to: 1. Compositions Containing Minerals; 2. Oil emulsions; 3. Saponin formulations; 4. Virosomes and virus-like particles; 5. Bacterial or microbial derivatives; 6. Bioadhesives and mucoadhesives; 7. Liposomes; 8. Formulations of polyoxyethylene ether and polyoxyethylene esters; 9. Polyphosphazene (PCPP); 10. Muramyl peptides; 11.. Imidazoquinolone compounds; 12. Thiosemicarbazone compounds; 13. Triptantrin Compounds; 14. Human immunorodulators; 15. L 1 p o p e p t d e s; 16. B e n z o n a f t i r i d i n a s; 17. M i. c r o p a r 11 c u 1 a s 18. Fo l.i nuc I immunostimulatory eotldehyde (such as RNA or DNA; for example, CpG-containing oligonucleotides) EXEMPLIFICATION
The invention now being generally described, will be more easily understood by reference to the following examples, which are included only for the purpose of illustrating certain aspects and modalities of the present invention, and are not intended to limit the invention. EXAMPLE 1: DEVELOPMENT OF OIL EMULSIONS IN CATIONIC WATER
Three types of cationic nanoemulsions (CNES) have been developed for the distribution of self-replicating RNA. Type 1 emulsions are emulsions similar to "MF59". These emulsions were made from the same components as MN59 with the exception that cationic lipids are added. Type 2 emulsions are emulsions that replace Span 85 and Tween 80 in MF59 with phospholipids. Type 3 emulsions are hybrid emulsions that are stabilized by means of lipids or other surfactants and may have additional polymers or surfactants in the aqueous phase of the emulsion.
Three different lipids were used for the preparation of type 1 emulsions: 1,2-dioleoyl-3- c.r.i met, i! ammonium-propane (chloride salt) (DOTAP), 33-ii hydrochloride: - (N ', N' -di methylaminoethane) -carbamoyl] cholesterol (Cholesterol DC) and Dimethyldioctadecylammonium (Bromide salt) (DDA) . DOTAP was used in the preparation of Type 2 and Type 3 emulsions.
The N / P ratio refers to the amount of nitrogen in the cationic lipid in relation to the amount of phosphate in the RNA. nitrogen is the load-bearing element within the tested cationic lipids. Phosphate can be found in the RNA skeleton. A N / P charge ratio of 10/1 indicates that there are 10 positively charged nitrogens from the cationic lipid present for each negatively charged phosphate in the RNA. CNFls type 1:
The ratio of Tween 80, Span 85, squalene, and citrate buffer was not changed for this class of emulsions. These emulsions were prepared with the same concentrations of Mt'5 9. The total amount of cationic lipid given per dose remains constant, regardless of the concentration of lipids. For example, a dose of 10 μg of RNA distributed in an emulsion with 0.8 mg / ml of DOTAP at an N / P ratio of 10/1 would require a 2x dilution. Therefore, the amount of squalene distributed would be 1/2 of that which is normally administered during immunization with MF59. Alternatively, a 10 μg dose of RNA distributed in an emulsion with 1.6 mg / ml DOTAP with a N / P ratio of 10/1 would require a 4x dilution.
In this example, 17 different type 1 emulsion formulations were prepared. The ranges of cationic lipids that were able to be made into emulsions are listed below: Table 1

All formulations with concentrations of 0.8 mg / ml of DOTAP to 1.6 mg / ml produced stable emulsions. All formulations with DC cholesterol concentrations from 0.62 mg / ml to 2.46 mg / ml produced stable emulsions. All formulations with concentrations from 0.73 mg / ml DDA to 1.64 mg / ml produced stable emulsions. Type 2 CNEs:
The percentage of squalene varied with CNEs type 2. Another difference is that from MF59 these emulsions were made in water not in citrate buffer. These emulsions were made with 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and phosphatidylcholine (egg PC), as lipid stabilizers. The emulsions were made ('.or DOPE and egg PC or with DOTAP cholesterol DC, or DDA in the optimized concentrations from the Type 1 emulsion studies.
A separate series of emulsions was made using DOTAP as the only stabilizer. These emulsions contained various amounts of squalene (from 0.43% w / w to MF59 concentration of 4.3% w / w). Type 3 CNEs:
The addition of Pluronic® F127 (poloxomer) to the RNA prior to complexation with an egg PC / DOTAP emulsion led to greater stability when compared to RNase from a sample that did not have the polaxamer added to it. This indicates the role of this polymer to allow a better complexation of RN7 with the drop of oil.
The addition of a small amount of Tween 80 (0.08% w / w) during the emulsification stage of the DOTAP emulsions only led to a smaller droplet size.
Methods for preparing cationic emulsions:
Squalene, sorbitan trioleate (Span 85), polyoxyethylene-sorbitan monoeleate (Tween 80) were obtained from Sigma (St. Louis, MO, USA). Dimethyldioctadecylammonium (DDA), 1,2-dioleoyl-sn-glycero-3-phosphoeoanolamine (DOPE), 3β- [N- (N ', N'-dimethylam; noethane) -carbamoyl] Cholesterol (DC-Cholesterol HCL ), were purchased from Lipideos Avanti. L-α- lysophosratidileolino- (egg, chicken) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) were purchased from Lipoid (Ludwigshafen Germany).
Cationic nanoemulsions (CNEs) were prepared similar to MF59 loaded as described earlier with minor modifications (Ott, Singh et al. 2002). Briefly, the oil-soluble components (ie Squalene, span 85, cationic lipids, lipidic surfactants) were combined in a beaker, lipid components were dissolved in chloroform (CHCI3) or dichloromethane (DCM). The resulting lipid solution was added directly to the oil with Span 85. For a subset of emulsions (CNE01, 02, 17), the solvent was allowed to evaporate at room temperature for 2 hours in a smoke hood before combining the aqueous phase and homogenize the sample. For the remaining emulsions (CNE 12, 13, 27, 32, 35), the oil phase was combined with the aqueous phase or immediately homogenized for 2 minutes using an IKA T2 5 homogenizer at 24K RPM in order to provide a homogeneous raw material . CNE05 was prepared by preparing a liposome stock solution. The liposomes were prepared by evaporating at 10mg / m1 of the chloroform solution DOTAP in a rotary evaporator (model Buchi number R200) at a pressure of 300 milliTorr, for 30 minutes at a temperature of 50 ° C. Evaporation of the residual chloroform was maintained by placing the samples overnight in a Labccrco freeze dryer. The lipid film was hydrated and dispersed by adding 1.0 ml of distilled, deionized water, filtered and placed at 50 ° C to ensure complete suspension of the lipid. The resulting lipomas were added directly to the squalene and were immediately emulsified for 2 min, using an IKA T25 homogenizer at 24K RPM. The emulsions were then left to stand at room temperature on a shaking plate for 2-3 hours after primary homogenization in a hood. The primary emulsions were passed three to five times through a Microfluidity MHOS homogenizer with an ice bath cooling coil, at a homogenization pressure of about 15k - 20k PSI (Microfluidics, Newton, MA). Samples from the 20 ml batch were removed from the unit and stored at 4 ° C. Table 2 describes the components of the emulsions. Table 2


One method of adding lipids to the oil phase of the emulsions was adding dichloromethane (DCM or methylene chloride) to the oil phase. Once added, DCM can be allowed to evaporate completely. After evaporation, the emulsion was then passed through the microfluidizer. Alternatively, in cases where lipid solubility was a problem, the primary emulsion can be made with DCM while still in the organic phase. In that case, the DCM would be allowed to evaporate directly from the emulsion before secondary homogenization.
An alternative method for emulsions that contained lipids as stabilizers was to make a lipid film and hydrate the film, so that the lipids formed liposomes. The liposomes were then added to the oil phase and processed as the standard MF59 was processed. EXAMPLE 2: PREPARATION OF RNA-PARTICLE COMPLEXES 1. Materials and Methods. RNA synthesis
Plasmid DNA encoding an alphavirus replicon (self-replicating RNA) has been used as a template for RNA synthesis in vitro. Each replicon contains the genetic elements necessary for RNA replication, but lacks the sequences encoding the products of genes that are needed for particle assembly. The alphavirus structural genes of the genome have been replaced by sequences that encode a heterologous protein (whose expression is driven by the subgenomic alphavirus promoter). After the distribution of replicons to eukaryotic cells, positive strand RNA is translated to produce any non-structural proteins which, in conjunction, replicate the genomic RNA and transcribe abundant subgenomic mRNAs that encode the heterologous protein. Due to the lack of expression of the alphavirus structural proteins, replicons are unable to generate infectious particles. A bacteriophage T7 promoter is located upstream of the alpavirus cDNA to facilitate synthesis of the RNA replicon in vitro, and the hepatitis delta virus (HDV) ribozyme located immediately downstream of the poly (A) tail generates the 3 'end correct through its autocleaving activity. The sequences of the four plasmids used in the examples are shown in Figures 7A-7B.
After the linearization of the plasmid DNA downstream of the HDV ribozyme with a suitable restriction endonuclease, the performed transcripts were synthesized in vitro using bacterial-dependent T7 or SP6 DNA-dependent RNA polymerase. Transcriptions were performed for 2 hours at 37 ° C in the presence of 7.5 mM (T7 RNA polymerase) or 5 mM (SP6 RNA polymerase) of final concentration of each of the triphosphates provided by the manufacturer (Ambion, Austin, TX). After transcription, the DNA template was digested with TURBO DNase (Ambion, Austin, TX). The RNA replicon was precipitated with LiCl and reconstituted in nuclease-free water. Non-leveled RNA was leveled post-transcriptionally with Vaccinia Leveling Enzyme (VCE), using the ScriptCap m7G leveling system (Epicenter Biotechnologies, Madison, WI), as described in the user manual. The post-transcriptionally leveled RNA was precipitated with LiCl and reconstituted in nuclease-free water. Alternatively, replicons can be leveled by supplementing the transcription reactions with 6 mM (for T7 RNA polymerase) or 4 mM (for SP6 RNA polymerase) of m7G (5 ') ppp (5') G, a structure analog non-reversible leveling (New England Biolabs, Beverly, MA) and the decrease in the concentration of 1.5 mM guanosine triphosphate (for T7 RNA polymerase) or 1 mM (for SP6 RNA polymerase). The transcripts can then be purified by digestion in TURBO DNase (Ambion, Austin, TX) followed by precipitation in LiCl and washing with 75% ethanol.
The concentration of the RNA samples was determined by measuring the optical density at 260 nm. The integrity of the in vitrified transcripts was confirmed by denaturing agarose gel electrophoresis for the presence of the total meat construct. . RNA extension
The number of nitrogen atoms in the solution was calculated from the cationic lipid concentration, DOTAP, for example, has 1 nitrogen that can be protonated per molecule. The concentration of RNA was used to calculate the amount of phosphate in solution using an estimate of 3 nmoles of phosphate per microgram of RNA. By varying the amount of RNA: Lipideo, the N / P ratio can be modified. The RNA was complexed for CNEs in a range of nitrogen / phosphate ratios (N / P). The N / P ratio was calculated by calculating the number of moles of protonable nitrogen atoms in the emulsion per milliliter. To calculate the number of phosphates, a constant of 3 nmoles of phosphate per microgram of RNA was used. After the values were determined, the appropriate emulsion ratio was added to the RNA. Using these values, the RNA was diluted to the appropriate concentration and added directly to an equal volume of emulsion while vortexing slightly. The solution was left to stand at room temperature for approximately 2 hours. Once complexed, the resulting solution was diluted to the appropriate concentration and used within 1 hour. Gel electrophoresis
Gel electrophoresis denaturation was performed to assess RNA binding, with the cationic formulations and stability in the presence of RNase A. The gel was expressed as follows: 2 g of agarose (Bio-Rad, Hercules, CA) were added to 180 ml of water and heated in a microwave oven until it dissolves and then cooled to 60 ° C. 20 rnl. 10 x denaturing gel buffer (Ambion, Austin, TX) was then added to the agarose solution. The gel was poured and left to stand for at least 45 minutes at room temperature. The gel was then placed in a gel tank, and 1x MOPS execution buffer (Ambion, Austin, TX) was added to cover the gel for 1 g beforehand. RNase Protection Assay
Digestion with RNase was achieved by incubation with 6.4 mAU of RNase A per microgram of RNA (Ambion, Hercules, CA) lasted 30 minutes at room temperature. RNase was inactivated with Proteinase K (Novagen, Darmstadt, Germany), by incubating the sample at 55 ° C for 10 minutes. The post-RNase inactivation samples were decomplexed with a 1: 1 to 25: 24: 1 sample mixture of phenol: chloroform: isoamyl alcohol. The samples were inverted several times to mix and then placed in a centrifuge for 15 minutes at 12k RPM. The aqueous phase was removed from the organic phase and used to analyze the RNA. Before loading (460 ng per well), all samples were incubated with formaldehyde filler, denatured for 10 minutes at 65 ° C and cooled to room temperature. Ambion Millennium markers were used for the approximate molecular weight of the RNA construct. The gel was run at 130 V. The gel was stained with 0.1% gold SYBR according to the manufacturer's guidelines (Invitrogen, Carlsbad, CA) in water with stirring at room temperature for 1 hour. The gel images were taken in a Bio-Rad Chemddoc XRS imaging system (Hercules, CA). All studies used RNA from the Clonetech mouse thymus (Mountain View, CA). Heparin binding assay
The RNA was. complexed, as described above. The RNA / CNE complex was incubated with various concentrations of heparin sulfate (Alfa Aesar, Ward Hill MA) for 30 minutes at room temperature. The resulting solutions were centrifuged for 15-20 minutes. The centrifuge tubes were punctured with a tuberculin syringe and the supernatant was removed. The solution was then tested for RNA concentration using Quarvi-.it Ribogreen RNA Assay Kit (Invitrogen, Carlsbad CA) according to the manufacturer's instructions. The samples were analyzed on a fluorescent plate reader from Biotek Synergy 4 (Winooski, VT). The values of free RNA were calculated using a standard curve. Particle size assay
The emulsion particle size was measured using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK), according to the manufacturer's instructions. Particle sizes are referred to as the Z-mean (ZAve) with the poiid.i spersity index (pdi). All samples were diluted with water before being measured. In addition, the particle size of the emulsion was measured using the Horiba LA-930 particle sizer (Horiba Scientific, USA). The samples were diluted with water before being measured. The zeta potential was measured using Zetasizer Nano ZS using diluted samples according to the manufacturer's instructions. Secreted alkaline phosphatase assay (SEAP)
To evaluate the production kinetics and the amount of antigen, an RNA replicon that encodes SEAP was administered with and without formulation for mice, intramuscularly. Groups of 3 or 5 female Balb / C mice with. age 8-10 weeks and weighing approximately 20 g were immunized with CNEs complexed with RNA replicon encoding SEAP at the indicated N / P ratios. The naked RNA was formulated in free RNase IX PBS. A dose of 100μl was administered to each mouse (50 μl per site) in the quadriceps muscle. Blood samples were taken 1, 3 and 6 days after the injection. The serum was separated from the blood immediately after collection, and stored at -30 ° C until use.
A Phospha-Light SEAP uminescent chemiline system (Applied Biosystems, Bedford, MA) was used to analyze the serum. The mouse sera were diluted 1: 4 in phospha-Light IX dilution buffer. The samples were placed in a water bath sealed with aluminum foil sealing and inactivated by heat for 30 minutes at 65 ° C. After cooling on ice for 3 minutes, and equilibrating to room temperature, 50 μl of phospha-light assay buffer was added to the wells and the samples were left at room temperature for 5 minutes. Then, 50 μL of reaction buffer containing 1:20 of the CSPD® substrate (chemiluminescent alkaline phosphate substrate) was added, and luminescence was measured after 20 minutes of incubation at room temperature. Luminescence was measured on a Berthold LB Centra 960 luminometer (Oak Ridge, TN) with an integration of 1 second per well. SEAP activity in each sample was measured in duplicate, and the average of the two measurements is shown. Ele1roporation
E.l. etroporation was a very effective method for delivering plasmid DNA vaccines and this technique was used for self-replicating RNA delivery. The mice were anesthetized with isofluorane, both hind legs were closely shaved to expose the area of the limb to be treated. The 30 μl dose of vaccine was injected into the quadriceps muscle of the posterior limb using a 1/2 cc insulin syringe. The muscle was electroporated using the Elgen® DNA distribution system (Inovio, San Diego). The instrument parameters are as follows: 60V, two points of each 60ms. Another dose was equally distributed to the second member, followed by electroporation. Viral Replicon Particles (VRP)
To compare RNA vaccines with traditional RNA vector approaches to achieve in vivo expression of reporter genes or antigens, viral replicon particles (VRPs) produced in BHK cells were used with the methods described by Perri et al. In this system, antigen replicons (or reporter gene) consisted of chimeric alphavirus (VCR) replicons derived from the Venezuelan equine encephalitis virus (VEEV) genome designed to contain the 3 '(3'UTR) terminal sequences of the virus from Sindbis and a packaging signal from the Sindbis virus (PS) (see Fig. 2 by Perri S., et al, J Virol 77: 10394-10403 (2003)). These replicons were packaged in VRPs by coeletroporation of them into baby hamster kidney cells (BHK), along with defective helper RNAs encoding the Sindbis virus capsid and glycoprotein genes (see Fig. 2 by Perri I al.) The VRPs were then harvested and titrated by standard methods and inoculated into animals in culture fluid or other isotonic buffers. 2. Particle size analysis of oil-in-water emulsions.
After manufacture, the emulsions were analyzed for particle size and zeta potential. Tables 3 and 4 summarize the particle size data and zeta potential data obtained from pre- and post-complexation with an N / P ratio of 4: 1 and 10: 1. The particle size of the emulsions was less than 160 nm for all tested formulations, when measured in the Nano ZS particle sizer. After complexation, some of the particle sizes increased significantly, especially at the N / P ratio of 4: 1. This is probably due to the aggregation and bridging of RNA between multiple droplets of the emulsion. Horriba data generally matched well with NanoZS measurements except for a few cases (CNE02 and CNE32), where there appears to be a larger particle population that is not able to be analyzed in nanoZS. All CNEs with the exception of CNE02 and CNE32 were less than 190nm in size when measured in the Horiba particle sizer. The low variability in size indicates a robust processing method, regardless of the amount or type of cationic lipid added. It is particularly desirable that the average particle size is less than 200 nm in size to allow for sterile filtration. All samples tested passed this criterion. Table 3: Particle Size Data


The Zeta potential was slightly more variable than the particle size data (Table 4). This is in line with our expectations since a series of differences in these formulations is the change in concentration 5 of cationic lipid. For example, CNE01, CNE02, and CNE17, each containing 0.8, 1.6 and 1.2 mg / ml of DOTAP respectively. The zeta potential for these lots was in line with expectations with CNE01 having the lowest pre-complex zeta potential of 15.9mV, followed by 10 CNE17 with a pre-complex zeta potential of 33.4mV and, finally, CNE02 with a zeta potential of 43mV. The zeta potential of post-complexation is generally not much changed from the pre-complexation of zeta potential, probably due to the overload in the emulsions. Table 4: Zeta potential
3. RNase stability test:
To assess the ability of emulsions to protect from RNase degradation, an in vitro test was developed to track formulations. Figure 1 shows the results of the RNase protection test and of CNE01 and CNE17 at one. N / P ratio of 10: 1 and 4: 1. CNE01 protected RNA better at a 10: 1 ratio compared to a 4: 1 ratio. CNE17 showed good protection at 10: 1 Figure 2 shows that CNE 17 was also able to protect RNA at an N / P ratio of 4: 1. CNE 12 and 13 also protected RNA (similar to CNE17) in both load ratios (Figure 2). Figure 3 shows results similar to those of Figure 1 with CNE01 not protecting very well at an N / P ratio of 4: 1. CNE02 protected against RNases very well in both N / P ratios tested (Figures 3 and 4). CNE04 did not protect RNA from digestion with RNase, but CNE05 was able to protect RNA in both tested load ratios (Figure 5). CNE27 showed very little protection from RNase, while CNE32 showed slightly more protection, but in general, less than the formulations mentioned above. CNE 35 (Figure 6) was able to protect ligand, ramen and RNA from RNase degradation. In general, 5 different formulations were able to prevent degradation of RNA in vitro. 4. SEAP screening in vivo:
The A306 replicon, which expresses secreted alkaline phosphatase (SEAP), was used to determine the level of protein expression in vivo after administration of alphavirus vectors. BALB / c mice, 5 animals per group,: were administered with bilateral intramuscular vaccinations (50 μL per leg) on days 0 with SEAP expressing VRP (5x10sUI), naked self-replicating RNA (A306, 1 μg), self-replicating RNA. electroporation (A306 + EP, 1 and 0.1 μg, respectively) and self-replicating RNA formulated with CNE17, CNE05 and CNE35 with a 10: 1 N / P ratio produced as previously described (1 μg or 0.1 μg of A306). The serum levels of SEAP (relative light units, RLU) on days 1, 3 and 6 after intramuscular vaccination on day 0 are shown in Table 5. The data are represented as arithmetic means of the titrations of 5 individual mice per group. Table 5

Table 5 shows that the serum levels of SEAP increased when the RNA was formulated in CNE 17 compared to the control of naked RNA with a similar dose. SEAP expression was increased when RNA was formulated in CNE compared to VRP control, but the expression kinetics was very different. The electroporation distribution resulted in increased EAP expression compared to the naked RNA control, but these levels were lower compared to the SEAP expression level when the RNA was formulated with CNE17. CNE05 and CNE35 reduced the level of protein expression. 5. Effect of N / P ratios on SEAP expression (CNE17)
The A306 replicon, which expresses secret.ala alkaline phosphatase (SEAP), was used to determine the level of protein expression in vivo, after administration of alphavirus vectors. BALB / c mice, 5 animals per group, were administered with bilateral intramuscular vaccines (50μl per paw) on day 0 with self-replicating naked RNA (A306, 1 μg), self-replicating RNA formulated with CNE.17, produced as previously described (A30 6 , 1 μg), streets following N / P ratios of 6: 1, 7: 1, 8: 1, 10: 1, 12: 1, 13: 1, 14: 1, 16: 1.
Serum levels of SEAP (relative light units, RLE) on days 1, 3 and 6 after intramuscular vaccination on day 0 are shown in Table 6. Data are represented as arithmetic means of the titrations of 5 individual mice per group. A correlation of heparin sulfate binding compared to day 6 of SEAP expression is described in Table 7. The percentages of RNA released from the complex in 6x, 8x, and 10x heparin sulfate, respectively, are indicated. Table 6: SEAP serum levels (CNE17)
Table 7: Binding to heparin and expression of SEAP on day 6 (CNE17)

Tables 6 and 7 show that serum levels of SEAP increased when RNA was formulated with a 10: 1 N / P ratio in. control of naked RNA, at a similar dose. A. Another N / P ratio tested expressed smaller amounts of protein expression compared to the JO: 1 N / P ratio, but all showed a higher response than naked RNA. It should be noted that the mean SEAP values of the naked RNA fluctuated considerably, which is exemplified in Tables 5 and 6, with the expression of approximately 35,000 in one experiment, and 5,000 in the other. The level of protein expression on day 6 correlates well with the release of heparin. 6. Effect of N / P ratios on SEAP expression (CNE13)
The A306 replicon, which expresses secreted alkaline phosphatase (SEAP), was. used to determine the level of protein expression in vivo after administration of alphavirus vectors. BALB / c mice, 5 animals per group, were administered with bilateral intramuscular vaccines (50 μl per paw) on day 0 with self-replicating RNA (A306, 1 μg), self-replicating RNA formulated with CNE13, produced as previously described (1 μg 71306), the following P / N 6: 1, 8: 1, 10: 1, 12: 1, 14: 1, 16: 1, 18: 1.
Serum levels of SEAP (relative light units, RLU), rcs days 1, 3 and 6 after intramuscular vaccination on day 5 are shown in Table 8. The data are repiesed as arithmetic means of the titrations of 5 individual mice per group . The correlation of heparin sulfate binding compared to SEAP expression on day 6 is described in Table 9. The percentages of 10 RNA Released from the complex in heparin sulfate at 6x, 8x, and 10x, respectively, are indicated. Table 8: Serum SEAP levels (CNE13)
Table 9: Heparin binding and SEAP expression on day 6 (CNE13)

Tables 8 and 9 show that the serum levels of SEAP increased when the RNA was formulated at all the N / P ratios tested in relation to the naked control RNA, at the similar dose. Protein expression on day 6 correlated well with heparin release. 7. Effect of N / P ratios on SEAP expression (CNE01)
The A306 replicon, which expresses secreted alkaline phosphatase (SEAP), was used to determine the level of protein expression in vivo after administration of alphavirus vectors. BALB / c mice, 5 animals per group, (are administered with bilateral intramuscular vaccines (50 μl per paw) on day 0 with autorrepl: RNA: carn: and nu (A306, 1 μg), self-replicating RNA formulated with CNE01, produced as previously (1 μg, A306) with the following N / P ratios of 4: 1, 10: 1, 12: 1, 14: 1, 16: 1, 18: 1
The serum levels of SEAP (relative light units, RLU) on days 1, 3 and 6 after intramuscular vaccination on day 0 are shown in Table 10. Data are represented as arithmetic mean of the relative light units (RLUs) of 5 individual mice per group. The correlation of heparin sulfate binding compared to SEAP expression on day 6 is described in Table 11. The percentages of RNA released from the complex in 6x, 8x, and 10x heparin sulfate, respectively, are indicated. Table 10: Serum SEAP levels (CNE01)

Table 11: Heparin binding and SEAP expression on day 6 of CNE01

Tables 10 and 1.1 show that the serum levels of SEAP increased when RNA was formulated in all the N / P ratios tested in relation to the naked RNA control, at the same dose. EXAMPLE 3: ASSESSMENT OF PROTEIN EXPRESSION LEVELS USING DIFFERENT OILS
A series of emulsions was produced using different oils, but within the base formulation of CNE17, that is, 5% oil, 0.5% Tween 80, 0.5% Span 85 and 1.4 mg / ml DOTAP. Table 12 below shows the changes in oils for each of the groups. The oil classifications are also listed in Table 12.
The emulsions were tested at a 10: 1 N / P ratio mixture and were complexed as previously described. BALB / c mice, 5 animals per group, were administered with bilateral intramuscular vaccinations (50 μl, leg oer) on day 0 with SEAP expressing VRP (5xl05 Ui), naked self-replicating RNA (A306, 1 μg), autorrepJ.J carn RNAs .distributed using electroporation (A306 + EP, 1 and 0.1 μg) and self-replicating RNA formulated with CNE36, CNE37, CNR38 and CNE41 produced as previously described (1 μg, A306). Serum levels of SEAP (relative light units, RLU) on days 1, 3 and 6 after intramuscular vaccination on day 0 are shown in Table 13. Data are represented as arithmetic mean of RLUs of 5 individual mice per group. Table 12
Table 13


As shown in Table 13, CNE17 shows the highest level of expression throughout the studies. All other emulsions were less than an Iμg dose of naked RNA. CNE36) resulted in greater expression of the new oils, followed by CNE41 and CNE38. An Iμg dose of RNA added directly to MF5 9 changed the response. EXAMPLE 4: IMPROVED IMMUNOGENICITY OF CNE17 OF THE ANTIGEN RSV-F IN A MICE MODEL 1. Methods Murine immunogenicity studies
The A317 replicon expressing the syncytial virus surface fusion glycoprotein (RSV-F) was used for this purpose. BALB / c mice, aged 8-10 weeks and weighing about 20 g, 10 animals per group, were administered with bilateral intramuscular vaccines. All animals were injected in the quadriceps in the two hind legs of each one to obtain an equivalent volume (50 μl per paw) on days 0 and 21 with VRP of expressing RSV-F (IxlO6 Ui), naked self-replicating RNA (A317, 1 μg), AutorrepJ RNA i.canie distributed using electroporation (10 μg or A317 -r ElP), or self-replicating RNA formulated in CNE17 (0.1 μg or I ug of A317). The serum was collected for antibody analysis on days 14 (2wpl), 35 (2wp2) and 49 (4wp2). When measurement of T cell response was necessary, spleens were harvested from 5 mice per group on day 35 or 49 for T cell analysis. fnsaios da. mouse T-cell function: intracellular cytokine immunofluorescence assay
Two to five spleens of identical vaccinated BALB / c mice were pooled and isolated cell suspensions were prepared for culture. Two antigens-stimulated cultures and two unstimulated cultures were established for each splenocyte pool. Antigen-stimulated cultures contained Ix106 splenocytes, RSV F peptide 85-93 (1x10sM), RSV F peptide 249-258 (Ix106 M), RSV F peptide 51-66 (Ix106 M), m.7 b ant ..i-CD28 (1 mcg / ml), and Brefeldin A (1: 1000). Unstimulated cultures did not contain RSV F peptides, and were identical to the stimulated cultures. After culture for 6 hours at 37 ° C, cultures were processed by immunofluorescence. The cells were washed and then stained with fluorescently labeled anti-CD4 and anti-CD 8 monoclonal antibodies (mAh). The cells were washed again and then fixed with Cytofix / cytoperm for 20 minutes. The fixed cells were then washed with Perm wash buffer and then stained with fluorescently labeled mAbs specific for IFN-g, TNF-a, 11, -2 and IL-5. The stained cells were washed and then analyzed on an LSR II flow cytometer. The itowJo software was used to analyze the acquired data. The subpopulations of CD4 + 8 T-cells and CD-i 8-4 T-cells were analyzed separately. For each subset of a given sample, the% of cytokine positive cells was determined. The% of RSV F antigen-specific T-cells was calculated as the difference between the% of cytokine-positive cells in antigen-stimulated cultures and the% of cytokine-positive cells in unstimulated cultures. The 95% confidence limits for the% of antigen-specific cells were determined using standard methods (Isometric Methods, 7th Edition, G.W. Snedecor and W.G. Cochran). Llnsa ios of mouse cell function: secreted cytokine assay
Cultures for the secreted cytokine assay were similar to those shown for the intracellular cytokine immunofluorescence assay except that Brefeidin A was omitted. Culture supernatants were collected after culture overnight at 37 ° C, and were analyzed for multiple cytokines using mouse Thl / Th2 cytokine kits from Meso Scale Discovery. The amount of each cytokine per culture was determined from standard curves produced using purified recow.binant cytokines provided by the manufacturer. 2. Enhanced immunogenicity of CNE17 of RSV-F antigen in a mouse model
Titrations of F-specific serum IgG on days 14, 35 and 49 are shown in Tables 14, 15 and 16. RSV serum neutralization titers on days 35 and 49 are shown in Table 17 and T cell responses on day 4 9 are shown in Table 18 and 19. Table 14: T-specific serum IgG titers of mice on day 14


The serum was collected for antibody analysis on days 14 (2wpl). The data are represented as individual animals and the o i. geometric meanings of 10 individual mice per group. If an individual animal had a titration of <25 (detection limit) it was assigned a titration of 5. Table 15: Serum IgG titers specific for F of mice on day 35

The serum was collected for antibody analysis on days 35 (2wp2). The data are represented as individual animals and the geometric mean titers of 10 individual mice per group. If an individual animal had a titer of <25 (limit of detection) it was assigned 15 with a titer of 5. Table 16: Serum IgG titers specific for F of mice on day 49

Serum was collected for antibody analysis on day 4 9 (4wp2). The data are represented as individual animals and geometric mean estimates of 10 individual mice per group. If an animal had a titration of <25 (detection limit) it was assigned a titration of 5. Table 17: Serum RSV neutralization titrations

Roi serum collected for analysis on day 35 (2wp2) and 4 9 (4wp2). The data are represented as 60% of plaque reduction neutralization titrations of individual mice and geometric mean titration of 10 individual mice per group. If an animal had a titration of <40 (detection limit) it was assigned a titration of 20. NA = not analyzed. Table 18: Frequencies of RSV F specific CD4 + splenic T cells on day 49 (4wp2)

The net positive frequencies for cytokine (%) (antigen-specific) ± 95% confidence interval are shown. The net frequencies shown in bold indicate stimulated responses that were statistically significant> 0. Table 19: RSV F specific CD8 + splenic T-cell frequencies on day 49 (4wp2)

Net positive frequencies for cytokines (%) (antigen-specific) ± 95% confidence interval are shown. The net frequencies shown in bold indicate stimulated responses that were statistically significant> 0.
As shown in Tables 14-19, the CNE formulation] 7 improved: i munogenicity, as determined by the increase in F-specific IgG titrations (5-fold increase of 4wp2), neutralization titrations, cell responses T CD4 and CD8, in relation to naked RNA control. Electroporation improved immunogenicity of RNA compared to naked RNA control, but was less than CNE17 distribution. Importantly, the immune responses elicited in the CNE17 groups fluctuated much less compared to those of naked RNA. For example, day 14 samples from 1 µg of the nude self-replicating RNA group generated antibody titers between 529 and 5110, whereas RNA samples formulated with CNE17 in a 1 µg dose generated antibody titers between 1927 and 5731. In addition, all animals in the CNE17 group responded with a robust response and reinforced very well. In contrast, some of the animals in the nude RNA group did not significantly reinforce. EXAMPLE 5: IMMUNOGENICITY OF RNA-PARTICULAR COMPLEXES IN A MICE MODEL 1. Methods RSV-F trimer subunit vaccine
The trimeric RSV F is a recombinant protein that comprises the ectodomain of RSV F, with a deletion of the region or the fusion peptide that prevents the association of other trimers. The resulting construct forms a homogeneous trimer, as seen by size exclusion chromatography, and has an expected phenotype according to a post-fusion F conformation as seen by electron microscopy. The protein was expressed in insect cells and purified by virtue of an HIS-tag in the fusion with the C-terminal of the construct followed by size exclusion chromatography using conventional techniques. The resulting protein sample is more than 95% pure. For the in vivo evaluation of the F subunit vaccine, 100 μg / ml of trimer protein was adsorbed to 2 mg / ml of alum using 10 mM histidine buffer, pH 6.3 and the isotonicity adjusted with 150 mM sodium chloride . The F subunit protein was adsorbed on alum, with gentle agitation overnight at 2-8 ° C. • Vaccination and challenge of cotton rats
The rays of the female cotton (Sigmodon hispidis) were obtained from Harlan Laboratories. All studies were approved and carried out in accordance with Novartis Animal Care and the Use Committee. Groups of animals were immunized intramuscularly (i.m., 100 μl) with the vaccines indicated on days 0 and 21. Serum samples were collected 3 weeks after the first immunization and 2 weeks after the second immunization. The immunized or unvaccinated control animals were challenged intranasally (i.n.) with 1x105 PFU RSV 4 weeks after the final immunization. Blood collection and RSV challenge was performed in anesthesia with 3% isoflurane using a precision vaporizer. Specific ELISA for RSV F
Individual serum samples were analyzed for the presence of 1 gG specific for RSV-F by enzyme binding absorption assay (ELISA). ELISA plates (96 wells from MaxiSorp, Nunc) were coated overnight at 4 ° C with 1. μg / ml of purified RSV F (delp23-furdel-trunc not cleaved) in PBS. After washing (PBS with 0.1% Tween-20), the plates were blocked with Superb Lock blocking buffer in PBS (Thermo Scientific) for at least 1.5 hours at 37 ° C. The plates were then washed, serial dilutions of serum in assay diluent (PBS with 0.1% Tween-20 and 5% goat serum) from experimental or control cotton mice were added, and the plates were incubated for 2 hours at 37 ° C. After washing, the plates were incubated with horseradish peroxidase-conjugated chicken anti-cottonseed IgG (HRP) (Immunology Consultants Laboratory, Inc, diluted 1: 5000 in assay diluent) for 1 hr at 37 ° C. Finally, the plates were washed and 100 μl of the TMB peroxidase substrate solution (Kirkegaard & Perry Laboratories, Inc) was added to each well. The reactions were stopped by adding 100 μl of H3PO4 IM, and the absorbance was read at 450 nm using a plate reader. For each serum sample, a graph of the optical density (OD) versus logarithm of the reciprocal serum dilution was generated using non-linear regression (GraphPad Prism). Titrations were defined as the dilution of reciprocal serum to an OD of approximately 0.5 (normalized to a standard pooi serum from RSV-infected cotton rats with a defined titre of 1: 2500, which was included in each plate ). Microneutralization fnsaío
Serum samples were tested for the presence of neutralizing antibodies by a plaque reduction neutralization test (PRNT). Two serial dilutions of serum-Hi '(in PBS with 5% HI-FBS) were added to an equal volume of long titrated RSV previously generated to generate approximately 115 PFU / 25 μl. Serum / virus mixtures were incubated for 2 hours at 37 ° C and 5% CO2 to allow neutralization of the virus to occur, and then 25 μl of this mixture (containing approximately 115 PFU) was inoculated into wells in duplicate of HEp-2 cells in 96-well plates. After 2 hours, at 370C and 5% CO2, the cells were covered with 0.75% Methyl Cellulose / EMEM 5% HI-FBS and incubated for 42 hours. The number of infectious virus particles was determined by detecting the formation of syncytia by immunostaining followed by automated counting. The neutralization titration is defined as the reciprocal of the dilution of the serum that produces at least a 60% reduction in the number of syncytia per well, in relation to the controls (without serum). Dog rga 1
The viral load in the lung was determined by a plaque assay. Specifically, the lungs were removed 5 days after RSV infection and a right lobe was placed in 2.5 ml of Dulbecco's Modified Eagle medium (DMEM, Invitrogen) with 25% sucrose and disrupted with a tissue homogenizer. The cell-free supernatants from these samples were stored at -80 ° C. To test for the infectious virus, dilutions of the clarified lung homogenate (in PBS with 5% heat-inactivated fetal bovine serum, HI-FBS) were inoculated into confluent HEp-2 cell monolayers in a volume of 200 μl / well of a 12-well plate. After 2 hours with gentle periodic shaking (37 ° C, 5% CO2), the inoculum was removed and the cells were covered with 1.5 ml of 1.25% SeaPlaque agarose (Lonza) in Eagle's Minimum Essential Medium ( EMEM, Eoriza), supplemented with 5% HI-FBS, glutamine and antibiotics. After 3-4 days of incubation, the cells were again covered with 1 ml of 1.25% agarose in EMEM (Sigma) containing 0.1% neutral red (Sigma). The plates are counted a day later with the help of a light box. Pathology, pulmonary of cotton rat
Five days after RSV challenge, the lungs were harvested and four lobes from each animal were collected and fixed with 10% neutral buffered formalin (NBF) by gentle intratracheal instillation followed by immersion fixation. The tissues were processed routinely to prepare stained sections of hematoxylin & eosin for microscopic examination. The results were evaluated using a modification of previously published criteria [Prince GA, et al, 2001] for the following parameters: peribronchiolitis, alveolitis, bronchitis, perivascular cell infiltrates and interstitial pneumonitis. The lesions were classified on a 4-point semi-quantitative scale. The minimal change (+) contained one or a few small foci, the slight change (++) was composed of small to medium sized foci; the moderate change (+++) contained frequent and / or moderate size foci, and the sharp change (++++) showed extensive foci to confluences affecting more / all tissues. 2. RSV challenge study of cotton rat
The A317 replicon, which expresses the syncytial virus surface fusion glycoprotein (RSV-F) was used for this study. Cotton rats (Sigmodon hispidus), 8 animals per group, were administered with int.ramuscu.1 vaccines at bilateral rcs (50 μl per paw) on days 0 and 21 with naked self-replicating RNA (A317, 1 μg or 10 μg), Self-replicating RNA formulated with CNE17 (A317, 0.1 μg or 1 μg), VRPs (5x106 IU) expressing RSV-F, F-trimer / alum subunit (10 μg), or formalin inactivated RSV vaccine (5200 Fl- pfu). The serum was collected by antibody analysis on days 14 (2wpl) and 35 (2wp2). All animals were challenged with RSV Ix105pfu intrinsically on day 49 and lungs were harvested on day 54 (5dpc) for the determination of viral load and pulmonary pathology.
The titers of F-specific serum IgG at day 14 and 35 are shown in Table 20; individual antibody titers for 8 animals in the selected groups of 2wp2 are shown in Table 21; serum RSV neutralization titrations on days 14 and 35 are shown in Table 22; viral lung titrations 5 days after RSV challenge are shown in Table 23, and lung alveolitis scores 5 days after RSV challenge are shown in Table 24. Table 20: F-specific serum IgG titrations of cotton rats {Sigiaodon hispidus)

8 animals per group, after intramuscular vaccinations on days 0 and 21. Serum was collected for antibody analysis on days 14 (2wpl) and 35 (2wp2), all animals were challenged with Ix105de RSV pfu intranasally on day 5 49. The lungs were collected on day 54 (5dpc) for the determination of viral load and pulmonary pathology. The data are represented as the geometric mean titrations of 8 individual cotton rats per group. If an animal had a titration of <25 (detection limit) it was assigned a 10 with a titre of 5. Table 21: The individual antibody titers in 2wp2
Individual antibody titers for 8 animals in the selected groups (naked RNA and RNA formulated with CNE). Table 22: RSV neutralization titrations of serum from cotton rats (Sigmodon hispidus)

8 animals per group, after intramuscular vaccinations on days 0 and 21. The serum was collected for analysis on days 14 (2wpl) and 35 (2wp2). The data are represented as 60% of plate reduction neutralization titrations. Average geometric titration of 2 pools of 4 cotton rats per group. If an animal had a titer of <25 (limit of detection) it was assigned a titer of 5. Table 23: Lung viral titers 5 days after RSV challenge in cotton rats (Sigmodon hispidus)
8 animals per group, after intramuscular vaccinations on days 0 and 21. The serum was collected for analysis on day 14 (2wpl) and 35 (2wp2). The data are represented as 60% of plate reduction neutralization titrations. Average geometric titration of 2 pools of 4 cotton rats per group. If an animal had a titer of <25 (limit of detection) it was assigned a titer of 5. Table 24: Pulmonary alveoli 5 days after challenge with RSV of cotton rats (Sigmodon hispidus)

8 animals per group, after intramuscular vaccinations on days 0 to 21. All animals were challenged with Ix105 RSV pfu intranasally on day 49. Lungs were collected on day 54 (5dpc) for the determination of viral load and pathology of the lung. The lesions were classified on a 4-point semi-quantitative scale. Minimal change (1) contained one or a few small foci; slight change (2) was made up of small to medium sized foci; moderate change (3) contained foci of moderate and / or frequent size; and the marked changes (4) showed extensive and confluent foci that affect most / all tissues. This shield shows the immunogenicity and protective ability of RNA replicon in the RSV model of the cotton rat. The unformulated RNA replicon induced serum F-specific RSV and IgG neutralizing antibodies after a vaccination, and these responses were reinforced by a second vaccination. CNE was effective in this model, reinforcing F-specific IgG titrations to 1 μg of RNA replicon approximately 9 times and neutralization titrations 4 times after the second vaccination. In addition, CNE1'7 reduced the considerable variations in immune responses that were observed when naked RNA was used, regardless of doses (0.1 or 1 μg), and all animals responded to vaccination. All RNA replicon vaccines provided protection against a nasal RSV challenge, reducing the lung viral load 5 days after the RSV challenge by more than 3 orders of magnitude. The magnitude and protective capacity of the immune response generated by 1 μg of RNA replicon formulated with CNE was within 2 times the response induced by 5x106 VRPs. EXAMPLE 6: EFFECT OF PARTICLE SIZE ON IMMUNOGENICITY
This example shows that particle size affects the immunogenicity of CNE / RNA formulations.
The protocols for the particle size assay and the SEAP Jn live assay are described in Example 2. The protocols for the murine immunogenicity studies are described in Example 3. Figure 8A shows the results (arithmetic mean) of the SEAP assay in vivo . Figure 8B shows the total IgG ritulations of individual animals in the BALB / c mice at 2wpl and 2wp2 time points.
The complexation of RNA with CNE17 increased the particle size from about 220 nm to about 300 nm (data not shown). As shown in Figures 8A and 8B, as the particle size increased, the levels of SEAP expression were reduced, and the responses of the host immune system were also decreased. EXAMPLE 7: EVALUATION OF THE EFFECTS OF ALTERNATIVE CATIONIC LIPIDS ON IMMUNOGENICITY 1. Materials and Methods. Preparation of CNEs
A series of emulsions was produced using the following cationic lipids: DLinDMA, DOTMA, DOEPC, DSTAP, DODAC, and DODAP. Table 25 describes the components of the emulsions.
CNEs were prepared according to the protocols described in Example 1. The RNA / CNE complex was prepared according to the protocols described in Example 2. Table 25
Immunogenicity studies in mice
The emulsions were tested at 10: 1 N / P, 12: 1 N / P. or 18: 1 N / P (see Table 26). Then, the RNA replicator: and the emulsions were complexed as described below in Example 2. BALB / c mice, 5-10 animals per group, were administered with bilateral intramuscular vaccines (50 μl per paw) on days 0 with Naked self-replicating RNA (A317, 1 μg), RV01 (15) (1 μg of A317 formulated in a liposome that contained 40% DlinDMA, 10% DSPC, 48% Choi, 2% PEG DMG 2000), RNA 10 self-replicating (A317, lμg) formulated with CNE13, CNE17, CMF37, CMF38 or CMF42. 2. Enhanced immunogenicity of RNA formulated with CNE of the RSV-F antigen in a mouse model
Total igG titrations (geometric mean titrations 15) from groups of BALB / c mice on day 14 and 35 are shown in Table 26 (groups 1-8). RNA formulated with CMF37 (DOTMA) improved the host's immune response as well, and the IgG titers were comparable to those of CNE17 (DOTAP). RNA formulated with CMF38 (DOEPC) 20 caused a slightly greater use of IgG than with CNE17, but the improvement was not statistically significant. RNA formulated with DSTAP did not significantly improve the host's immune response, and the low IgG concentrations were probably due to the low solubility of the DSTAP in squalene. RNA formulated with CNE13 improved IgG titrations to about 1.5 times more: than RNA formulated with liposomes (DDA). Total antibody titers induced by RNA formulated with CMF43 (DODAC) - were lower than those of CNE17 (Table 30 28, Groups 7 and 8). Table 26
Groups 1-8 had 5 animals / group, and groups 9-12 had 10 animals / group EXAMPLE 8: EVALUATION OF THE EFFECTS OF 5-BUY COMPOSITIONS ON IMMUNOGENICITY
In this example, several emulsions based on CNE17, but with different components of the buffer were prepared. Table 27 shows the compositions of buffer-modified emulsions. Table 27


The in vitro binding assay showed that lowering the concentration of citrate buffer caused the RNA to bind more strongly (data not shown).
The results of murine immunogenicity studies showed that the addition of sugars to CNE17 did not significantly impact the immunogenicity of RNA formulated with. CNF, 17 (Table 26, groups 9-12). Slight increases in IgG titrations were observed with the addition of sorbitol and dextrose.
Table 28 summarizes the results of murine immunogenicity studies when RNAs formulated with CNE17 were prepared using different buffer systems. Table 28

* VA375 replicon, ** vA317 replicon. The replicons were transcribed by Ambion in HEPES buffer, then (i) precipitated with LiCl, (ii) leveled in Tris buffer, and (iii) precipitated with LiCl. All groups had 8 anima: is / g rapo.
The different buffer compositions also affected the particle size. As shown in Figure 9, the addition of sugar (sucrose) decreased the particle size of the RNA / CNE complex (Figure 9A); addition of low concentrations of NaCl (in 10 mM) also decreased the particle size of the RNA / CNE complex (Figure 9A). The i taw buffer did not affect the particle size of the RNA / CN complex (F1 g u r to 9B).
The particle sizes of polymers are shown in Figure 9C. In particular, the addition of 0.5% pluronic F127 to RNA buffer reduced the particle size of the RNA / CNE complex to the size of pre-complexation (CNE particles without RNA).
Total antibody titers and CNE17 neutralizing antibody titers in preferred buffer systems, 80 mM sucrose, 10 mM NaCl and 1 mM citrate, or 2.80 mM sucrose, 10 mM NaCl, 1 mM citrate, and 0.5% (w / v) from Pluronic Kl 27, are shown in Table 28 (groups 4 and 5). EXAMPLE 9: EVALUATION OF THE EFFECTS OF PEG-LIPIDS ON IMMUNOGENICITY
In this example, a series of emulsions were produced using PEG-ipldeids. Table 29 shows the compositions of these PEG-based lipid emulsions. Table 29

For all emulsions, a 10 mg / ml stock solution of DOTAP in DCM was used, and the solvent was evaporated after homogenization. Murine immunogenicity studies were performed as described above in Example 7.
Table 30 shows the titers of pool antibodies at time points 2wpl and 4wp2. For the CNE13 group, the mean of the individual animal titrations, and the geometric mean titrations are shown. As shown in Table 30, the emulsions made with 'PEG-lipids were effective in inducing an immune response against the RSV-F antigen, but the Ululations of total antibodies were at a lower level compared to the RNA formulated with CNE17. In addition, 5 the increase in the concentration of PEG-lipids led to a reduction in antibody titers. Table 30
* vA317 replicon, Groups 1-10 had 5 animals / group and group 11 had 10 animals / group
The report readily recognizes that many other modalities are covered by the invention. All publications and patents cited in this disclosure are incorporated by reference in their entirety. Insofar as the material incorporated by reference 5 contradicts or does not consist of this specification, the specification will replace any such material. The mention of any reference here is not an admission that such references are state of the art in relation to the present invention.
Those skilled in the art will recognize, or be able to determine, using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following 15 modalities.

权利要求:
Claims (17)
[0001]
1. Composition characterized by the fact that it comprises an RNA molecule complexed with a particle of an oil emulsion in cationic water, in which the particle comprises: (a) an oily core that is in liquid phase at 25 ° C selected from from the group consisting of: soybean oil, sunflower oil, olive oil, squalene, squalane or a combination thereof, and (b) a cationic lipid selected from the group consisting of: 1,2-dioleoyloxy- 3- (trimethylammonium) propane (DOTAP), 3β- [N- (N ', N'- dimethylaminoethane) -carbamoyl] cholesterol (Cholesterol DC), dimethyldioctadecylammonium (DDA), 1,2-dimyristoyl-3-Trimethyl Ammonium Propane ( DMTAP), dipalmitoyl (C16: 0) trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N- [1- (2,3-dioleyloxy) propyl] -N, N, N-trimethylammonium (DOTMA) chloride, N, N-dioleoyl-N, N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethyl-ammonium-propane (DODAP) , 1,2-dilinoleyloxy-3-dime tilaminopropane (DLinDMA); so that the total net charge of the emulsion particle before RNA complexation is positive and in which said RNA molecule is a self-replicating RNA encoding a protein antigen and said RNA is anchored to the surface of said particle by interactions non-covalent.
[0002]
2. Composition, according to claim 1, characterized by the fact that the particle further comprises a surfactant among Sorbitan Trioleate, polysorbate 80 or a combination thereof.
[0003]
3. Composition according to claim 1 or 2, characterized by the fact that the oil emulsion in cationic water comprises from 0.01% to 2.5% (v / v) of non-ionic surfactant.
[0004]
4. Composition according to claim 3, characterized by the fact that the surfactant is in an aqueous phase of the oil-in-water emulsion.
[0005]
Composition according to any one of claims 1 to 4, characterized in that the composition comprises from 0.2% to 9% (v / v) of oil.
[0006]
6. Composition according to claim 1, characterized by the fact that the cationic lipid is DOTAP and the oil emulsion in cationic water comprises from 0.5 mg / ml to 5 mg / ml of DOTAP.
[0007]
7. Composition according to claim 1, characterized by the fact that the cationic lipid is Cholesterol DC and the composition comprises from 0.1 mg / ml to 5 mg / ml of cholesterol DC.
[0008]
8. Composition according to claim 1, characterized by the fact that the cationic lipid is DDA and the composition comprises from 0.1 mg / ml to 5 mg / ml DDA.
[0009]
9. Composition according to claim 1, characterized by the fact that the cationic lipid is DOTMA and the composition comprises from 0.5 mg / ml to 5 mg / ml of DOTMA.
[0010]
10. Composition according to claim 1, characterized by the fact that the cationic lipid is DOEPC and the composition comprises from 0.5 mg / ml to 5 mg / ml DOEPC.
[0011]
11. Composition according to claim 1, characterized by the fact that the cationic lipid is DODAC and the composition comprises from 0.5 mg / ml to 5 mg / ml DODAC.
[0012]
12. Composition according to any one of claims 1 to 11, characterized in that the RNA molecule is a self-replicating RNA molecule that encodes an antigen.
[0013]
13. Composition according to any one of claims 1 to 12, characterized in that the average diameter of the emulsion particles is not greater than 200 nm.
[0014]
14. Composition according to any one of claims 1 to 13, characterized in that the N / P ratio of the emulsion is 4: 1 to 14: 1.
[0015]
Composition according to any one of claims 1 to 14, characterized in that the average diameter of the emulsion particles is 80 nm to 180 nm, and the N / P ratio of the emulsion is at least 4: 1 .
[0016]
16. Composition according to any one of claims 1 to 15, characterized in that the composition further comprises a sucrose, mannitol, trehalose sorbitol or dextrose toning agent.
[0017]
17. Use of a composition, as defined in any of claims 1 to 16, characterized by the fact that it is for the manufacture of a medicament to generate an immune response.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US11135287B2|2021-10-05|Method for preparing composition comprising a cationic oil-in-water emulsion

---

US11026890B2|2021-06-08|Oil-in-water emulsions that contain nucleic acids

---

US11167028B2|2021-11-09|Cationic oil-in-water emulsions

同族专利:

---

公开号 | 公开日

---

JP2013531680A|2013-08-08|

---

EP2590625A2|2013-05-15|

---

EP2590625B1|2017-09-20|

---

WO2012006380A3|2012-07-05|

---

US20160256541A1|2016-09-08|

---

CA2804591C|2019-01-22|

---

RU2625546C2|2017-07-14|

---

AU2011276236B2|2016-03-10|

---

US9295646B2|2016-03-29|

---

MX2013000171A|2013-03-05|

---

WO2012006380A2|2012-01-12|

---

JP6025721B2|2016-11-16|

---

ES2649896T3|2018-01-16|

---

US10238733B2|2019-03-26|

---

US11135287B2|2021-10-05|

---

AU2011276236A1|2013-02-21|

---

JP2016204389A|2016-12-08|

---

BR112013000391A2|2016-06-07|

---

US20120156251A1|2012-06-21|

---

RU2013104870A|2014-08-20|

---

EP3449910A1|2019-03-06|

---

CA2804591A1|2012-01-12|

---

MX343410B|2016-11-04|

---

US20190262448A1|2019-08-29|

---

NZ606591A|2015-02-27|

---

CN103327963A|2013-09-25|

---

CN108042799A|2018-05-18|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

CA583561A|1959-09-22|H. Edgerton William|Therapeutically valuable esters and methods for obtaining the same|

---

US367363A|1887-08-02|Joseph f |

---

US3130011A|1958-09-17|1964-04-21|British Titan Products|Production of silicon halides|

---

FR1317586A|1961-03-17|1963-05-08|

---

US4500707A|1980-02-29|1985-02-19|University Patents, Inc.|Nucleosides useful in the preparation of polynucleotides|

---

US5132418A|1980-02-29|1992-07-21|University Patents, Inc.|Process for preparing polynucleotides|

---

US4458066A|1980-02-29|1984-07-03|University Patents, Inc.|Process for preparing polynucleotides|

---

US4668777A|1981-03-27|1987-05-26|University Patents, Inc.|Phosphoramidite nucleoside compounds|

---

US4973679A|1981-03-27|1990-11-27|University Patents, Inc.|Process for oligonucleo tide synthesis using phosphormidite intermediates|

---

US4373071A|1981-04-30|1983-02-08|City Of Hope Research Institute|Solid-phase synthesis of polynucleotides|

---

CA1341423C|1984-10-31|2003-03-04|Paul A. Luciw|Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome|

---

US4689225A|1984-11-02|1987-08-25|Institut Merieux|Vaccine for cytomegalovirus|

---

US5153319A|1986-03-31|1992-10-06|University Patents, Inc.|Process for preparing polynucleotides|

---

DK341386D0|1986-07-18|1986-07-18|Voetman Karin Glassau|PROCEDURE AND APPARATUS FOR ROLLING FLAT DOUBLE PIECES, EX. FOR ROULADES|

---

UA42668C2|1987-11-18|2001-11-15|Чірон Корпорейшн|POLYPEPTIDE, WHICH HAS THE ANTIGENIC PROPERTIES OF THE VIRUS OF HEPATITE S , DIAGNOSTIC REAGENT DL4 To THE VIRUS OF HEPATITE S , COLLECTION FOR THE DEVELOPMENT OF ANTIBODIES To THE VIRUS OF HEPATITE S , METHOD OF THE DEVELOPMENT OF ANTIBODIES To THE VIRUS OF HEPATITE S |

---

WO1989007143A1|1988-01-29|1989-08-10|Chiron Corporation|Recombinant cmv neutralizing proteins|

---

US5047524A|1988-12-21|1991-09-10|Applied Biosystems, Inc.|Automated system for polynucleotide synthesis and purification|

---

US5262530A|1988-12-21|1993-11-16|Applied Biosystems, Inc.|Automated system for polynucleotide synthesis and purification|

---

KR0185373B1|1989-03-17|1999-05-01|로버트 피. 블랙버언|Nanbv diagnostics and vaccines|

---

WO1990014837A1|1989-05-25|1990-12-13|Chiron Corporation|Adjuvant formulation comprising a submicron oil droplet emulsion|

---

US5264618A|1990-04-19|1993-11-23|Vical, Inc.|Cationic lipids for intracellular delivery of biologically active molecules|

---

EP1624068A1|1993-06-01|2006-02-08|Life Technologies Inc.|Genetic immunization with cationic lipids|

---

US6015686A|1993-09-15|2000-01-18|Chiron Viagene, Inc.|Eukaryotic layered vector initiation systems|

---

US5885613A|1994-09-30|1999-03-23|The University Of British Columbia|Bilayer stabilizing components and their use in forming programmable fusogenic liposomes|

---

US5795587A|1995-01-23|1998-08-18|University Of Pittsburgh|Stable lipid-comprising drug delivery complexes and methods for their production|

---

US5700642A|1995-05-22|1997-12-23|Sri International|Oligonucleotide sizing using immobilized cleavable primers|

---

JPH11508231A|1995-05-26|1999-07-21|ソマティックスセラピーコーポレイション|Delivery vehicles containing stable lipid / nucleic acid complexes|

---

US5654452A|1995-06-07|1997-08-05|Molecular Biosystems, Inc.|Lipophilic contrast agents for use in hepatocyte-selective oil-in-water emulsions|

---

US6120794A|1995-09-26|2000-09-19|University Of Pittsburgh|Emulsion and micellar formulations for the delivery of biologically active substances to cells|

---

US6451592B1|1996-04-05|2002-09-17|Chiron Corporation|Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis|

---

WO1997038087A2|1996-04-05|1997-10-16|Chiron Corporation|Alphaviral vector with reduced inhibition of cellular macromolecular synthesis|

---

US6610321B2|1996-07-03|2003-08-26|University Of Pittsburgh|Emulsion formulations for hydrophilic active agents|

---

AT395904T|1996-09-13|2008-06-15|Lipoxen Technologies Ltd|LIPOSOME|

---

US6171586B1|1997-06-13|2001-01-09|Genentech, Inc.|Antibody formulation|

---

EP1006999A2|1997-07-08|2000-06-14|Chiron Corporation|Use of submicron oil-in-water emulsions with dna vaccines|

---

AU6253898A|1997-12-16|1999-07-05|Chiron Corporation|Use of microparticles combined with submicron oil-in-water emulsions|

---

JP2002521423A|1998-07-31|2002-07-16|コリアインスティチュートオブサイエンスアンドテクノロージ|Lipid emulsions and solid lipid microparticles as gene or drug carriers|

---

US6770282B1|1998-10-23|2004-08-03|Heska Corporation|Cationic lipid-mediated enhancement of nucleic acid immunization of cats|

---

ES2242604T3|1999-02-26|2005-11-16|Chiron Corporation|MICROEMULSIONS WITH MACROPARTICLES AND ADSORBID MICROPARTICLES.|

---

GB0012597D0|2000-05-25|2000-07-12|Astrazeneca Ab|Formulation|

---

CN1535140A|2000-09-28|2004-10-06|ϣ|Microparticle compositions and method for manufacture thereof|

---

EP1322287B1|2000-09-28|2006-03-22|Chiron Corporation|Microparticles for delivery of the heterologous nucleic acids|

---

US20030077829A1|2001-04-30|2003-04-24|Protiva Biotherapeutics Inc..|Lipid-based formulations|

---

AR045702A1|2001-10-03|2005-11-09|Chiron Corp|COMPOSITIONS OF ASSISTANTS.|

---

CA2467397A1|2001-11-26|2003-06-05|The University Of Queensland|Flavivirus vaccine delivery system|

---

US6861410B1|2002-03-21|2005-03-01|Chiron Corporation|Immunological adjuvant compositions|

---

US20060189554A1|2002-09-24|2006-08-24|Russell Mumper|Nanoparticle-Based vaccine delivery system containing adjuvant|

---

CA2508228C|2002-12-23|2013-12-17|Vical Incorporated|Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection|

---

NZ543343A|2003-04-25|2008-03-28|Novartis Vaccines & Diagnostic|Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof|

---

NZ581166A|2003-09-15|2011-06-30|Protiva Biotherapeutics Inc|Polyethyleneglycol-modified lipid compounds and uses thereof|

---

US7303881B2|2004-04-30|2007-12-04|Pds Biotechnology Corporation|Antigen delivery compositions and methods of use|

---

WO2005116270A2|2004-05-18|2005-12-08|Vical Incorporated|Influenza virus vaccine composition and method of use|

---

US7807815B2|2004-07-02|2010-10-05|Protiva Biotherapeutics, Inc.|Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA|

---

US7749520B2|2004-07-07|2010-07-06|Statens Serum Institut|Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids|

---

FR2885813B1|2005-05-19|2008-01-11|Oreal|VECTORIZATION OF DSRNA BY CATIONIC PARTICLES AND THEIR USE ON SKIN MODEL.|

---

CN101365485A|2005-11-04|2009-02-11|诺华疫苗和诊断有限公司|Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines|

---

US8877206B2|2007-03-22|2014-11-04|Pds Biotechnology Corporation|Stimulation of an immune response by cationic lipids|

---

US8058069B2|2008-04-15|2011-11-15|Protiva Biotherapeutics, Inc.|Lipid formulations for nucleic acid delivery|

---

RU2530555C2|2008-04-17|2014-10-10|ПиДиЭс БАЙОТЕКНОЛОДЖИ КОРПОРЭЙШН|Stimulation of immune response by enantiomers of cationic lipids|

---

WO2009149418A2|2008-06-06|2009-12-10|Asuragen, Inc.|Novel compositions for the in vivo delivery of rnai agents|

---

WO2010009277A2|2008-07-15|2010-01-21|Novartis Ag|Immunogenic amphipathic peptide compositions|

---

US20110300205A1|2009-07-06|2011-12-08|Novartis Ag|Self replicating rna molecules and uses thereof|

---

WO2011076807A2|2009-12-23|2011-06-30|Novartis Ag|Lipids, lipid compositions, and methods of using them|

---

WO2011111466A1|2010-03-12|2011-09-15|コニカミノルタオプト株式会社|Detection method for intermolecular interaction and detection device therefor|

---

NZ606591A|2010-07-06|2015-02-27|Novartis Ag|Cationic oil-in-water emulsions|

---

US20130195968A1|2010-07-06|2013-08-01|Novartis Ag|Virion-like delivery particles for self-replicating rna molecules|

---

JP6136343B2|2012-06-12|2017-05-31|株式会社リコー|Information processing system, information processing method, program, and recording medium|WO2012006377A2|2010-07-06|2012-01-12|Novartis Ag|Delivery of rna to trigger multiple immune pathways|

---

US9770463B2|2010-07-06|2017-09-26|Glaxosmithkline Biologicals Sa|Delivery of RNA to different cell types|

---

JP5940064B2|2010-07-06|2016-06-29|ノバルティス アーゲー|Immunization of large mammals with low doses of RNA|

---

NZ606591A|2010-07-06|2015-02-27|Novartis Ag|Cationic oil-in-water emulsions|

---

US8822663B2|2010-08-06|2014-09-02|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

---

EP2625189B1|2010-10-01|2018-06-27|ModernaTX, Inc.|Engineered nucleic acids and methods of use thereof|

---

WO2012135805A2|2011-03-31|2012-10-04|modeRNA Therapeutics|Delivery and formulation of engineered nucleic acids|

---

WO2013006834A1|2011-07-06|2013-01-10|Novartis Ag|Oil-in-water emulsions that contain nucleic acids|

---

RU2649133C2|2011-07-06|2018-03-29|Новартис Аг|Cationic oil-in-water emulsions|

---

EP3854413A1|2011-07-06|2021-07-28|GlaxoSmithKline Biologicals SA|Immunogenic combination compositions and uses thereof|

---

US9464124B2|2011-09-12|2016-10-11|Moderna Therapeutics, Inc.|Engineered nucleic acids and methods of use thereof|

---

CN110511939A|2011-10-03|2019-11-29|现代泰克斯公司|Nucleosides, nucleotide and nucleic acid of modification and application thereof|

---

AU2012352180A1|2011-12-16|2014-07-31|Moderna Therapeutics, Inc.|Modified nucleoside, nucleotide, and nucleic acid compositions|

---

US9283287B2|2012-04-02|2016-03-15|Moderna Therapeutics, Inc.|Modified polynucleotides for the production of nuclear proteins|

---

US9878056B2|2012-04-02|2018-01-30|Modernatx, Inc.|Modified polynucleotides for the production of cosmetic proteins and peptides|

---

US9572897B2|2012-04-02|2017-02-21|Modernatx, Inc.|Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins|

---

AU2013243949A1|2012-04-02|2014-10-30|Moderna Therapeutics, Inc.|Modified polynucleotides for the production of biologics and proteins associated with human disease|

---

AU2013243955B2|2012-04-02|2018-02-22|Modernatx, Inc.|Modified polynucleotides for the production of oncology-related proteins and peptides|

---

EP2869842A1|2012-07-06|2015-05-13|Novartis AG|Immunogenic compositions and uses thereof|

---

SG11201408328VA|2012-07-06|2015-02-27|Novartis Ag|Complexes of cytomegalovirus proteins|

---

EP2885419A4|2012-08-14|2016-05-25|Moderna Therapeutics Inc|Enzymes and polymerases for the synthesis of rna|

---

FR2994849B1|2012-08-30|2015-01-02|Commissariat Energie Atomique|FORMULATION FOR THE DELIVERY OF NUCLEOTIDE SEQUENCES LIKELY TO MODULATE ENDOGENOUS MECHANISMS OF INTERFERING RNA|

---

US10253315B2|2012-08-30|2019-04-09|Commissariat A L'energie Atomique Et Aux Energies Alternatives|Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold|

---

EP2922554B1|2012-11-26|2022-02-23|ModernaTX, Inc.|Terminally modified rna|

---

FR2998899B1|2012-11-30|2015-07-17|Commissariat Energie Atomique|HIGH-THROUGH SCREENING METHOD FOR THE IDENTIFICATION OF BIOMARKERS, THERAPEUTIC TARGETS OR THERAPEUTIC AGENTS|

---

EP2943221A1|2013-01-10|2015-11-18|Novartis AG|Influenza virus immunogenic compositions and uses thereof|

---

AU2013374345A1|2013-01-17|2015-08-06|Moderna Therapeutics, Inc.|Signal-sensor polynucleotides for the alteration of cellular phenotypes|

---

WO2014159813A1|2013-03-13|2014-10-02|Moderna Therapeutics, Inc.|Long-lived polynucleotide molecules|

---

US10258698B2|2013-03-14|2019-04-16|Modernatx, Inc.|Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions|

---

US8980864B2|2013-03-15|2015-03-17|Moderna Therapeutics, Inc.|Compositions and methods of altering cholesterol levels|

---

DK2970948T3|2013-03-15|2019-04-08|Glaxosmithkline Biologicals Sa|METHODS OF RNA PURIFICATION|

---

EP3041938A1|2013-09-03|2016-07-13|Moderna Therapeutics, Inc.|Circular polynucleotides|

---

AU2014315287A1|2013-09-03|2015-03-12|Moderna Therapeutics, Inc.|Chimeric polynucleotides|

---

WO2015048744A2|2013-09-30|2015-04-02|Moderna Therapeutics, Inc.|Polynucleotides encoding immune modulating polypeptides|

---

US10323076B2|2013-10-03|2019-06-18|Modernatx, Inc.|Polynucleotides encoding low density lipoprotein receptor|

---

US10842859B2|2014-03-25|2020-11-24|Yale University|Uses of parasite macrophage migration inhibitory factors|

---

BR112016024644A2|2014-04-23|2017-10-10|Modernatx Inc|nucleic acid vaccines|

---

CN111454165A|2014-06-25|2020-07-28|爱康泰生治疗公司|Novel lipid and lipid nanoparticle formulations for delivery of nucleic acids|

---

EP2974739A1|2014-07-15|2016-01-20|Novartis AG|RSVF trimerization domains|

---

EP3171895A1|2014-07-23|2017-05-31|Modernatx, Inc.|Modified polynucleotides for the production of intrabodies|

---

EP3048114A1|2015-01-22|2016-07-27|Novartis AG|Cytomegalovirus antigens and uses thereof|

---

EP3061826A1|2015-02-27|2016-08-31|Novartis AG|Flavivirus replicons|

---

CA2979998A1|2015-03-20|2016-09-29|Protiva Biotherapeutics, Inc.|Compositions and methods for treating hypertriglyceridemia|

---

US10221127B2|2015-06-29|2019-03-05|Acuitas Therapeutics, Inc.|Lipids and lipid nanoparticle formulations for delivery of nucleic acids|

---

WO2017015463A2|2015-07-21|2017-01-26|Modernatx, Inc.|Infectious disease vaccines|

---

US10849920B2|2015-10-05|2020-12-01|Modernatx, Inc.|Methods for therapeutic administration of messenger ribonucleic acid drugs|

---

AU2016342376A1|2015-10-22|2018-06-07|Modernatx, Inc.|Sexually transmitted disease vaccines|

---

EP3364950A4|2015-10-22|2019-10-23|ModernaTX, Inc.|Tropical disease vaccines|

---

CA3005739A1|2015-11-18|2017-05-26|Orbis Health Solutions Llc|T7 alpha viral vector system|

---

EP3394093B1|2015-12-23|2022-01-26|Modernatx, Inc.|Methods of using ox40 ligand encoding polynucleotides|

---

US20190241658A1|2016-01-10|2019-08-08|Modernatx, Inc.|Therapeutic mRNAs encoding anti CTLA-4 antibodies|

---

US20190038555A1|2016-02-26|2019-02-07|The Regents Of The University Of California|Bicontinuous microemulsions and methods of use thereof|

---

WO2017162266A1|2016-03-21|2017-09-28|Biontech Rna Pharmaceuticals Gmbh|Rna replicon for versatile and efficient gene expression|

---

WO2017162265A1|2016-03-21|2017-09-28|Biontech Rna Pharmaceuticals Gmbh|Trans-replicating rna|

---

EP3454891A4|2016-05-10|2019-12-25|The Regents of The University of Michigan|Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration|

---

RU2018142589A3|2016-05-18|2020-09-18|

---

US10967057B2|2016-06-02|2021-04-06|Glaxosmithkline Biologicals S.A.|Zika viral antigen constructs|

---

JP2019519568A|2016-06-30|2019-07-11|アルブータス・バイオファーマー・コーポレイション|Compositions and methods for delivering messenger RNA|

---

WO2018060288A1|2016-09-29|2018-04-05|Glaxosmithkline Biologicals S.A.|Compositions and methods of treatment of persistent hpv infection|

---

GB201616904D0|2016-10-05|2016-11-16|Glaxosmithkline Biologicals Sa|Vaccine|

---

CN112587504A|2016-10-17|2021-04-02|南京绿叶制药有限公司|Lipid nanoparticle of antisense oligonucleotide for inhibiting bcl-2 and preparation method thereof|

---

CN110167587A|2016-11-11|2019-08-23|摩登纳特斯有限公司|Influenza vaccines|

---

WO2018091540A1|2016-11-17|2018-05-24|Glaxosmithkline Biologicals Sa|Zika viral antigen constructs|

---

WO2018104538A1|2016-12-08|2018-06-14|Curevac Ag|Rna for treatment or prophylaxis of a liver disease|

---

US11103578B2|2016-12-08|2021-08-31|Modernatx, Inc.|Respiratory virus nucleic acid vaccines|

---

US20200149026A1|2016-12-08|2020-05-14|Curevac Ag|Rnas for wound healing|

---

WO2018115525A1|2016-12-23|2018-06-28|Curevac Ag|Lassa virus vaccine|

---

EP3558356A2|2016-12-23|2019-10-30|CureVac AG|Mers coronavirus vaccine|

---

US11045540B2|2017-03-15|2021-06-29|Modernatx, Inc.|Varicella zoster virusvaccine|

---

CN110392577A|2017-03-17|2019-10-29|库尔维科公司|For combining the RNA vaccine and immunologic test point inhibitor of anti-cancer therapies|

---

EP3697912A1|2017-10-19|2020-08-26|CureVac AG|Novel artificial nucleic acid molecules|

---

WO2018172556A1|2017-03-24|2018-09-27|Curevac Ag|Nucleic acids encoding crispr-associated proteins and uses thereof|

---

KR101950579B1|2017-05-12|2019-02-20|고려대학교 산학협력단|Absorbent For Carbon Dioxide and Method for Manufacturing The Same|

---

US20200208145A1|2017-05-18|2020-07-02|Modernatx, Inc.|Modified messenger rna comprising functional rna elements|

---

JP2020520640A|2017-05-18|2020-07-16|モデルナティーエックス， インコーポレイテッド|Polynucleotides encoding linked interleukin-12polypeptides and uses thereof|

---

MA49395A|2017-06-14|2020-04-22|Modernatx Inc|POLYNUCLEOTIDES COAGULATION FACTOR VIII CODING|

---

CN111315362A|2017-06-15|2020-06-19|传染病研究所|Nanostructured lipid carriers and stable emulsions and uses thereof|

---

EP3648791A1|2017-07-04|2020-05-13|CureVac AG|Novel nucleic acid molecules|

---

AU2018333530A1|2017-09-13|2020-02-27|Biontech Cell & Gene Therapies Gmbh|RNA replicon for expressing a T cell receptor or an artificial T cell receptor|

---

CN111094549A|2017-09-13|2020-05-01|生物技术Rna制药有限公司|RNA replicons for reprogramming somatic cells|

---

EP3681514A4|2017-09-14|2021-07-14|ModernaTX, Inc.|Zika virus rna vaccines|

---

EP3461497A1|2017-09-27|2019-04-03|GlaxoSmithKline Biologicals S.A.|Viral antigens|

---

MA50803A|2017-11-22|2020-09-30|Modernatx Inc|POLYNUCLEOTIDES CODING ORNITHINE TRANSCARBAMYLASE FOR THE TREATMENT OF UREA CYCLE DISORDERS|

---

JP2021504335A|2017-11-22|2021-02-15|モダーナティエックス・インコーポレイテッドＭｏｄｅｒｎａＴＸ， Ｉｎｃ．|A polynucleotide encoding phenylalanine hydroxylase for the treatment of phenylketonuria|

---

WO2019104195A1|2017-11-22|2019-05-31|Modernatx, Inc.|Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia|

---

CN111447948A|2017-12-04|2020-07-24|英特维特国际股份有限公司|Vaccine with replicon particles and oil adjuvant|

---

WO2019110067A1|2017-12-07|2019-06-13|Aarhus Universitet|Hybrid nanoparticle|

---

MA51523A|2018-01-05|2020-11-11|Modernatx Inc|POLYNUCLEOTIDES CODING ANTI-BODY ANTI-CHIKUNGUNYA VIRUS|

---

CN112088014A|2018-02-28|2020-12-15|华盛顿大学|Self-assembling nanostructured vaccines|

---

EP3773745A1|2018-04-11|2021-02-17|ModernaTX, Inc.|Messenger rna comprising functional rna elements|

---

EP3796893A1|2018-05-23|2021-03-31|Modernatx, Inc.|Delivery of dna|

---

EP3581201A1|2018-06-15|2019-12-18|GlaxoSmithKline Biologicals S.A.|Escherichia coli o157:h7 proteins and uses thereof|

---

WO2020023390A1|2018-07-25|2020-01-30|Modernatx, Inc.|Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders|

---

AU2019321186A1|2018-08-17|2021-02-18|Glaxosmithkline Biologicals Sa|Immunogenic compositions and uses thereof|

---

WO2020047201A1|2018-09-02|2020-03-05|Modernatx, Inc.|Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency|

---

CA3112208A1|2018-09-13|2020-03-19|Modernatx, Inc.|Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease|

---

EP3849594A2|2018-09-13|2021-07-21|Modernatx, Inc.|Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease|

---

WO2020056239A1|2018-09-14|2020-03-19|Modernatx, Inc.|Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome|

---

EP3856233A1|2018-09-27|2021-08-04|Modernatx, Inc.|Polynucleotides encoding arginase 1 for the treatment of arginase deficiency|

---

WO2020097409A2|2018-11-08|2020-05-14|Modernatx, Inc.|Use of mrna encoding ox40l to treat cancer in human patients|

---

EP3908328A1|2019-01-10|2021-11-17|BioNTech RNA Pharmaceuticals GmbH|Localized administration of rna molecules for therapy|

---

CN109771373B|2019-01-23|2021-03-02|浙江工商大学|Liposome-stable oil-in-water Pickering emulsion and preparation method thereof|

---

EP3965797A1|2019-05-08|2022-03-16|AstraZeneca AB|Compositions for skin and wounds and methods of use thereof|

---

AU2020288624A1|2019-06-04|2022-02-03|Cocoon Biotech Inc.|Silk-based products, formulations, and methods of use|

---

WO2020263883A1|2019-06-24|2020-12-30|Modernatx, Inc.|Endonuclease-resistant messenger rna and uses thereof|

---

WO2020263985A1|2019-06-24|2020-12-30|Modernatx, Inc.|Messenger rna comprising functional rna elements and uses thereof|

---

AU2020318680A1|2019-07-21|2022-02-17|Glaxosmithkline Biologicals Sa|Therapeutic viral vaccine|

---

CN110624472A|2019-09-28|2019-12-31|重庆威能钻井助剂有限公司|Emulsifier and preparation method and application thereof|

---

EP3819377A1|2019-11-08|2021-05-12|Justus-Liebig-Universität Gießen|Circular rna and uses thereof for inhibiting rna-binding proteins|

---

WO2021209970A1|2020-04-16|2021-10-21|Glaxosmithkline Biologicals Sa|Sars cov-2 spike protein construct|

---

WO2021247507A1|2020-06-01|2021-12-09|Modernatx, Inc.|Phenylalanine hydroxylase variants and uses thereof|

---

WO2021245090A1|2020-06-04|2021-12-09|BioNTech SE|Rna replicon for versatile and efficient gene expression|

---

WO2021245611A1|2020-06-05|2021-12-09|Glaxosmithkline Biologicals Sa|Modified betacoronavirus spike proteins|

---

WO2022002783A1|2020-06-29|2022-01-06|Glaxosmithkline Biologicals Sa|Adjuvants|

法律状态:
2018-01-23| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-07-02| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-10-01| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-04-07| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2020-09-29| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-12-15| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/07/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US36189210P| true| 2010-07-06|2010-07-06|

---

US61/361,892|2010-07-06|

---

PCT/US2011/043108|WO2012006380A2|2010-07-06|2011-07-06|Cationic oil-in-water emulsions|

---